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SECTION  I 
INTRODUCTION  IRRADIATION  AND  THYROID  CANCER 
J.E.  DUMONT 
The  demonstration of nodules  and  cancers  in the  thyroids of patients 
who  had  been subjected  to  X-ray  therapy for  thymic  enlargement  has  brought 
the  problem of radiation induced  cancers  to  the  forefront  of medical  and 
indeed  public attention.  Inevitably,:the association of  cancers with  a 
previous  treatment has  stirred ·up  public controversy about  the  consequences 
of medical  and  surgical procedures  in general.  Within this controversy 
there is little doubt  that many  would  regard radiation induced  thyroid 
cancer as  the definitive example  of  iatrogenic cancer.  It is also  important 
to  remember  that  the  thyroid is subject  to  another  form  of  iatrogenic 
disease,  hypothyroidism,  which  frequently  follows  radioactive  iodine  therapy 
of  the overactive gland.  While  this has  not  received  the  same  attention 
as  thyroid cancer,it is nevertheless  important  and  the numbers  now  involved 
are very  large. 
The  social  and  political  i'ssues  raised by radiation  induced  thyroid 
disease have wide  ranging  consequences  and must  inevitably involve  the 
community  at large  in determining  and  accepting criteria by which  the 
benefits and  risks associated with  any  procedure  are  seen  to  be  balanced. 
Over  and  above  these  issues,  radiation induced  thyroid cancer  and hypo-
thyroidism are challenging  and  interesting medical  and  scientific problems 
in their own  right.  This monograph  is primarily concerned with thyroid 
cancer,although questions  relating to hypothyroidism are also raised when 
it is appropriate  to  do  so.  With  regard  to  the  cancer, it is of  interest 
that it falls  into  the  category of  carcinoma,  and  although  carcinomas 
represent  90  % of human  cancers  and  share  common  epidemiological properties 
(1,2)  their biology is much  less  studied than of  sarcomas  and  leukemias. 
As  with other carcinomas,  thyroid  tumors  caused  by  irradiation have  a  well 
defined environmental  cause  and  could  thus  be  easily prevented.  However, 
even  though  X-ray  irradiation of  the  thymus  has  been the principal culprit 
leading  to human  thyroid  irradiation,  the latter organ  can be  and  is exposed 
to  a  whole  range of other medical  and  non medical  irradiations  :  fallout 
of  radioiodine after nuclear explosions,  leakage of  such  isotopes  from 
nuclear plants,  industrial radiography,  uptake  of  heavy radioactive elements 
such  as  radium,  radiotherapy,  radiodiagnosis,  radioiodine uptake  tests  and 
other  investigations of  iodine  dynamics  with tracers,  radioiodine  therapy -2-
in hyperthyroidism and  cancer,  etc.  After  irradiation,  thyroid  cancers 
are much  more  frequent  than  spontaneous  carcinomas  or  tumors  induced  by 
other agents  but  their biology and  evolution is similar and  they  constitute 
therefore  the best models  for  such  cancers.  It is interesting in this 
regard  that  a  particularly high  incidence  of  thyroid  cancers has  been 
reported  in China  (3). 
h  h  d  b  131  .  d"  .  "d  Thoug  t  ey  are cause  y  X-ray or  I  1rra 1at1on,  thyro1  tumors 
are  treated by  high doses  irradiation.  This  treatment  requires  the uptake 
of  radioiodine by  the  cancer  tissue  and  its metastases,  which gives  a 
very practical meaning  to  the  concept of  cancer dedifferentiation and 
redifferentiation.  Indeed,  it is the  existence or  recovery  of  iodide 
uptake by  thyroid cancer which provides  the  best opportunity for  treatment 
with I
131
•  Finally,  thyroid  cancers  in general  are  a  very suitable material 
for  the  study of  cancer dedifferentiation;as all  the  individual  steps  of 
specialized metabolism of  the tissue  can be  investigated using  isotopes 
of an  element  which  is only metabolized  in the  thyroid,  iodine.  As  a 
purely radiobiological model,  the  thyroid allows  the  comparison of various 
types  and modes  of delivery of  irradiation either external  (X,  ~ irradiations) 
or internal  (/3 and~ irradiation of  I
131
,  etc  ••• ). 
"The  interest of  good  biological models  for  the  investigation of 
irradiation and  cancer  is obvious.  Whatever  the reasons,  the practical 
questions  that have  to  be  answered  concern estimates  of  the  increase  in 
tumor  incidence  following  relatively low doses  of radiation in much  the 
same  way  that  genetic hazards  have  been evaluated previously. 
Even  in rodents,  we  cannot  hope  to measure directly the  increase  in tumor 
incidence  that  is associated with doses  of  the order  of  1  rad/year or  less, 
so  that extrapolations will have  to be made  from higher dose  levels,  on 
which data are already available or  can be  obtained  in the  foreseeable 
future.  These  extrapolations will of necessity be  performed  over  a  broad 
range,  i.e.,  from doses  of  the order of hundreds  of  rads  per year  down 
to  1  rad/year or even  lower.  Actually,  such extrapolations  should be  termed 
predictions,  and  the only way  by  which  these predictionscan obtain reliability 
is  to  base  them on  a  demonstrated knowledge  of  the mechanisms  involved  in 
the  induction of  tumors  by  ionizing radiation.  Different experimental -3-
systems  and  conditions  seem  to provide us with different  answers,  and, 
from all of  these  seemingly conflicting data,  we  must  derive  the main mecha-
nisms  of  the  carcinogenic process"  {4). 
Because of its scientific and medical  interest,  radiation induced 
thyroid carcinogenesis has  been widely  studied at  the  experimental  and 
clinical level.  However,  neither  the possible specific relations of 
thyroid biochemistry with  the primary radiation lesion nor  the application 
of present day  concepts  of  cancerogenesis  to  the  thyroid have  been explored 
to  any  great extent.  Furthermore  in many  of  the available studies,  the 
dosimetry has of necessity been  inexact  and  consequently  intercomparison 
of  such data or using it to extrapolate.to human  problems  is fraught with 
difficulty.  The  aim of  the present monograph  is to present,  for  the 
clinically oriented reader,  a  short  and  readable  review of  the clinical 
problem of  thyroid  irradiation followed  by more  detailed dosimetric, 
radiobiological  and  experimental  cancerogenesis  fundamentals,  to  outline  and 
define  the physiopathology of its consequences,  the rationale for preven-
tion and  treatment,and  the  important  questions still to be  solved. 
The  clinical problems  of  thyroid irradiation and  cancer have  been 
extensively reviewed  in L.J.  Degroot  "Radiation Associated Thyroid 
Carcinoma"  (5),  origins of human  cancers  in general  in "Origins  of  Human 
Cancer"  (2).  Thyroid  dosimetry  and  radiobiology have been treated by 
J.F.  Malone  (6),  experimental  thyroid  carcinogenesis by K.  Christov and 
R.  Raichev  {7),  thyroid cancer  in general  in "Thyroid Neoplasia"  (8)  and 
in a  full  issue of "Annales  de  Radiologie"  {9).  Our  present  day  knowledge 
on  the clinical aspects  of  irradiation and  cancer have  been  reviewed  in 
a  United Nations  Scientific Committee  on  the Effects of Atomic  Radiation 
(UNSCEAR)  (10)  and  the  experimental  aspects  in another  UNSCEAR  report.  (11). 
The  biology of  radiation is extensively discussed  in"Biology of Radiation 
Carcinogenesis"  (12).  Sources of industrial,  medical  and  environmental 
irradiations are described  in UNSCEAR  reports  (13,14,15). CLINICAL  OVERVIEW -6-
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INTRODUCTION 
The  information available regarding  the relationship 
between  irradiation exposure of the  thyroid gland  and 
ensuing ·  pathologic states is vast and  has  recently infiltrated 
the  lay press  in the  United States.  As  a  result,  the  irradia-
tion effects caused  by  nuclear weapons  and  nuclear plants, 
as well  as  treatment modalities  used  for  thyroid  and  other 
disorders  in man,  are constantly under  scrutiny. 
Experimental  studies of radiation effects on  the thyroid 
gland  and  the  important  issue of dosimetry will  be  discussed 
in separate chapters.  The  present review  emphasizes  the 
incidence and  the clinical aspects of thyroid-induced disease 
following all forms  of irradiation exposure,  and,  where 
possible,  recommendations  are  made for subjects exposed  to 
such irradiation.  The  first section deals with the  functional 
disturbances  induced  by  irradiation. 
I~  Hyperthyroidism and  Ophthalmopathy 
A  transient,  but occasionally severe  form  of  thyra-
toxicosis is  sometimes  seen  in patients with Graves'  disease 
f  11  .  h  .  d  f  d.  .  .  d.  ( 131  )  o  ow1ng  a  t  erapeut1c  ose  o  ra 1oact1ve  10  1ne  I 
(I6,1n.  This  is believed to be  the result of  a  massive  release 
of thyroid  hormone  caused  by  thyroidal  injury following  iso-
topic treatment.  The  state of thyrotoxicosis  following  131I 
administration is rare and  usually temporary  in nature. -8-
A  more  permanent  form  of thyrotoxicosis,  indistinguishable 
from  the hyperfunction described  in Graves'  disease,  has  been 
recently reported  by  Wasnich  and  coworkers  (18).  These  authors 
observed  the occurrence of hyperthyroidism associated with 
ophthalmopathy  in four  patients and  ophthalmopathy alone  in 
three patients following  external irradiation to-the neck 
and  cervical or axillary areas  for  neoplastic diseases.  The 
disorders  in these patients  included breast carcinoma  (2  cases), 
Hodgkin's  disease· (2  cases),  laryngeal carcinoma  (1  case), 
nasopharyngeal  epithelioma  (1  case) ,  and  histocytic  lympho-
cytic  lymphoma  (1  case).  The  hyperthyroid state in the  four 
cases was  most  likely not related to the  involvement of the 
thyroid by  the  primary pathologic  process which  can also 
occasionally lead to  a  thyroid  toxic state  (19) 
In the cases described by Wasnich  and  coworkers  (18),  the 
first  symptoms  of thyrotoxicosis were  observed with  a  mean 
interval of  6  years after the  irradiation therapy,  and  the 
ophthalmopathy developed  between  18  and  84  months  after the 
irradiation therapy.  The  fact that none  of the  five  Caucasian 
pati~nts tested revealed. an  HL-AB  type antigen  (an  antigen 
found  in about half of the  Caucasian patients who  spontaneously 
developed  Graves'  disease  (20~  suggested to these authors  that 
thyroidal  injury by x-ray therapy plays  an  important role in 
the etiology of  a  syndrome  which  is indistinguishable  from 
Graves'  disease,  with the exception of  the above mentioned 
histocompatibility antigens. -9-
II.  Hypothyroidism 
A.  Incidence of  spontaneous  hypothyroidism in  a  normal 
population 
In order to discuss  the  incidence of primary hypo-
thyroidism in patients who  received external and/or  internal 
irradiation therapy,  it is important  to assess first the 
incidence of  spontaneous  primary hypothyroidism  in  a  popula-
tion and its progression with age.  A  recent  survey in the 
North American  population indicated the  incidence  in newborns 
to  be  0.017%  or  1.7 per  100,000  (21).  The  true  incidence of 
hypothyroidism with progressive age  is not  known,  but  a 
recent study by  Turnbridge  and  collaborators  in England  (22) 
indicated it to be  0.8%  in the total  sample  studied and 
0.2%  (females  and males  combined)  in  a  community  studied in 
Finland  (23).  The  mean  age at the  time of the diagnosis  in 
the English  study was  57  years.  An  assumption  is made  that 
the  increments of hypothyroidism are  linear with advancing  age. 
From  the data of these reports  one  can estimate the  rate 
incidence of  spontaneous  hypothyroidism at  0.013%  per year  in 
a  normal  population.  Everything exceeding this rate in  a 
population would  be  in excess of the  spontaneous  incidence 
of hypothyroidism. 
B.  Incidence of hypothyroidism  following  external 
irradiation therapy 
Table  1  summarizes  the  information concerning hypo-
thyroidism following  external  irradiation from  several  studies T
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Analysis  of these data  (excluding data  from 
those patients who  received  a  lymphangiogram)  shows  an 
incidence of  31  in  357  cases  studied,  or  8.6%  In  some  of 
these studies additional factors  besides  irradiation played 
a  role,  such as  the  involvement of the thyroid  glandin  the 
original disorder.  Also,  the  use of  iodinated agents  to 
perform  lymphangiograms  in patients with malignant disorders 
plays  an  important role in the genesis of hypothyroidism. 
One  study  showed  the high  incidence of elevated  serum 
thyroid  stimulating hormone  (TSH)  levels which  supposedly 
reflects decreased  thyroid reserve or  frank  hypothyroidism 
and  is dependent  on  the  amount  or  irradiation 
that was  delivered  and  the extent of the  field which  was 
used  ( 30).  It is likely that the  incidence of hypothyroidism 
in patients whose  thyroid has  been  exposed  to external irradia-
tion is higher  than  can  be  expected  in  a  nonexposed  population  . 
.c  .. 
with  1311 
. Incidence of hypothyroidism in Graves'  disease  treated 
d  1251  an  . 
A  totally separate  issue is the  group of patients in whom 
131
I  therapy has  been applied  in a  therapeutic attempt to 
control hyperthyroidism.  The  treatment of Graves'  disease 
with  isotopes of iodine has  been extensively used  in the manage-
ment  of the disorder.  Follow-up  studies after such therapy 
have  scrutinized the  functional  as well  as  the anatomical 
state of the  thyroid gland  in these patients.  The  high  incidence 
of hypothyroidism occurring after  such  treatment  became  apparent, 
and occasionally  tumor  development was  reported  (35-39) - 12-
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FIGURE  I.  Probability of hypothyroidism with a  single dose of  131I  for 
Graves'  disease.  The  numbers  indicate the dose  of  131
1  administered  in 
microcuries  per  gram  of  thyroid  tissue.  (From Becker,  D.V.,  et al  In  : 
Thyroid  Research  I, 603-609,  1971  , with permission of  the authors  and  editors) (35). - 13-
The  present  study reviews  data dealing with  the  irradiation 
.effects of  131
1  and  125
1  for  therapeutic purposes  in subjects with Graves' 
d.  d.  .  .  d.  (131  )  1sease.  Ra  1oact1ve  10  1ne  I  has  been used  for  many 
years  to control  the hyperthyroid  state of Graves'  disease 
.  h  f  125  .  1n man.  In  recent years  t  e  use  o  I  as  an  1sotope to 
treat this disorder has  been  suggested because of the high 
incidence of hypothyroidism  following  131I  therapy  (35). 
The  results of the cooperative thyrotoxicosis 
follow-up  study are  summarized  in Figure  1.  This  study 
indicates that  the  probability of becoming  hypothyroid  is  the highest 
in the first 2  yea~s after therapy  and  the  cumulative probability increases 
continuously thereafter.  This  Figure also indicates that factors 
other than radiation play a  role in the development of hypo-
thyroidism after 131I  therapy.  Indeed,  the constant  increment 
in the cumulative  incidence of hypothyroidism is observed  even 
following  surgical therapy for  Graves'  disease.  This  is pro-
bably  a  reflection of the further deterioration of the  function 
of the  thyroid remnant  due  to the  underlying  autoimmune  processes. 
The  slope of the  curve  showing  patients treated surgically 
suggests  that a  number  of these patients may  have  become  hypo-
thyroid  due  to these  underlying  factors  alone.  The  latter - 14-
is not a  theoretical concept since the  study by  Wood  and 
Maloof  (40)  demonstrates  the development of hypothyroidism 
as  a  late sequel  in Graves' .disease patients treated with 
anti  thyroid drugs  alone  and  suggests  a  rate of  incidence  of 
spontaneous  hypothyroidism  of  the order of  0.7%  per year. 
This  figure  has  been quoted  by others to  indicate the rate 
of  spontaneous  hypothyroidism in a  population with Graves' 
disease  (41  ) . 
Becker et al  (35  )  clearly indicate in their study 
that a  positive relationship exists between the cumulative 
incidence of hypothyroidism and  the  131r  dose  retained by 
the pathologic Graves'  disease gland  (~Ci/g of estimated 
thyroid weight).  Indeed,  a  linear correlation between  the 
radiation dose of the thyroid  from  131r  and  the probability 
of hypothyroidism above  a  dose of  2500  rem exists.  Extra-
polations  suggest  that a  60,000  rem  thyroid dose  would  render 
all Graves'  disease patients hypothyroid after  5  years.  This 
dose  is in close agreement with the mean  dose of  49,000  rem 
required  to render  euthyroid cardiac patients hypothyroid 
with  131r  therapy  (42 ). 
Very  few  data are available concerning the  lower 
doses  of  131r  (<2500  rem).  Rallison et al  (43)  found  two 
cases of  bona  fide  hypothyroidism  in 1378  children exposed  to 
131r  fallout.  The  average  dose delivered to  the  thyroid gland 
was  18  or  48  rems,  depending  on  the estimate.  When  these data 
were  compared with the  incidence of hypothyroidism in non-
radiated control groups  (4  out of  3801),  the difference was - 15-
not significant.  A  long-term  follow-up  study of the  thera-
peutic  use  of radioactive  iodine  in children with Graves' 
disease,  indicates  the  incidence  to be  46%  (44). 
In order  to  avoid the.high incidence of  hypo-
th  'd'  .  h  131  .  h'ld  d  d  1  .  1  .  h  yro1  1sm w1t  I  1n  c  1  ren an  a  u  ts,  a  tr1a  w1t 
125I  has  been attempted  in patients with Graves'  disease 
(45-48).  The  concept  behind  125I  therapy was  derived  from 
the characteristic features  of the emitted electron irradia-
t .  f  125  1on  o  I.  The  low  penetrating potential in tissue of 
the majority of the electrons  (less  than  0.5  ~m)  and  the 
fact  that  a  small minority of the highest energy electrons 
travel  up  to  30  ~m were  thought to be of special  importance 
in the thyroid gland.  The  125I  located  in the colloid should 
irradiate the  horrnonogenetic  regions  of the  follicular cells 
much  more  than  the nuclei or  stroma.  In contrast  with  131I, 
125I  therapy  should  have  a  primary effect on  the  hormonogenetic 
part of the cell ana  less on  the cell division.  The  nucleus 
would  thus  be  protected  from  radiation sterilization which 
is regarded as  the most  important causal  factor of radiation-
induced  hypothyroidism. 
The  first report by  Greig et al  (45)  was  encouraging, 
but did not definitely settle the  issue of whether or not 
125I  .  d  t  h  131  d'  h  1  1s  more  a  van  ageous  t  an  I  regar  1ng  t  e  ong-term 
hypothyroidism state following  treatment.  Later  studies reporte 
by the  same  group  led  to  the conclusion that using  1251  in 
doses  of  400  ~Ci/g of thyroid weight would  provide better 
results  than conventional doses  of  131I  in the  treatment of - 16-
Graves'  disease  (46,47  ) .  However,  a  recent review of  355 
patients by  the  same  authors  showed  that,  after an  average 
follow-up of  49.4  months,  63.4%  of the total group of 
patients became  euthyroid,  33.5% .became  hypothyroid,  and 
3.1%  were still hyperthyroid  (48).  Therefore,  in most 
published reports with  a  sufficient follow-up  an  unacceptable 
high incidence of persistent hyperthyroidism is found  when 
the dose of  isotope is too  low,  while  a  higher  dose  causes 
an  increased  incidence of hypothyroidism  (see also Section V). 
From  these  finding,  it is concluded that  125I  should 
not  be  used  for  the routine  treament of hyperthyroidism  (48). 
125  131  .  The  theoretical advantage of  I  over  I  as  an  1sotope 
in the  treatment of  hyperthyroidism due  to Graves'  disease  may 
become  less appealing if one  realizes that labelled  1251 
thyroglobulin is eventually introduced  into the  thyroid cell 
as  colloid droplets via the endocytic process.  These colloid 
droplets,  prior to hydrolysis of their content,  travel  towards 
the capillary site of the cell and  consequently deliver 
radiation to the  thyroid nucleus  when  in close proximity of 
the  latter. 
III.  Thyroid  nodules after irradiation of the  thyroid gland 
In order to evaluate the  incidence of thyroid nodules 
in  a  given population exposed  to  irradiation,  the  following 
questions arise. - 17-
1.  What  is the  incidence of thyroid nodules  in  a  non-exposed 
population or in a  population  immediately prior to  a 
planned irradiation  (i.e.,  131
1  therapy  for  Graves' 
disease)? 
2.  What  correlation exists between  the  number  of nodules 
that develop  in a  given population treated with irradia-
tion  (external or internal)  and  the dose  of irradiation 
given to  the patient? 
The  answers  to these  two  questions are discussed  in this  section 
in addition to the  incidence of malignant nodules  in normal  and 
irradiated people. 
A.  Incidence of thyroid nodules  in  a  control population 
Several  studies have  attempted  to provide  figures 
on  the  incidence of  thyroid nodules.  These  figures,  however, 
are variable depending  on  the  ages  of the  subjects  studied 
and whether or not pathologic data  have  been  included. 
Mortensen et al  (49)  found,  in  a  post-mortem study,  an  incidence 
of  20.9%  of palpable  thyroid nodules  (uni- or multinodular).  The 
average  age of this population was  60  years.  Rallison and 
coworkers  (SO)  who  studied  2271  normal  children in Arizona, 
found  an  incidence of 1.5%.  The  age  of these  subjects varied 
from  11  to  18  years.  A  recent  survey by  Trowbridge et al  (51  ) 
of children between  the  ages  of  9  to  16  years  found  the 
incidence of thyroid nodules  to be  0.22%.  The  Framingham 
study reported  an overall  incidence of thyroid nodules  of 
4 • 2%  ( 52) . - 18-
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FIGURE  2.  Prevalence  of  spontaneous  thyroid nodules  in an English 
population.  A positive correlation  (r=0.88)  between  the  incidence  of 
thyroid nodules  and  increasing age  is observed  (From Tunbridge,  W.M.G., 
et al.  Clin.  Endocrinol.  7,  481  ,  1977,  with permission of  the  authors 
and  editors) (22). -19......: 
The  data obtained  in  a  recent study carried out 
in England  by  Turnbridge et al  {22)is  shown  in Figure  2 
and  indicates that a  good  correlation exists between  the 
advancing  age of the participating subjects,  both male  and 
female,  and  the  increased  incidence of thyroid nodularity 
discovered.  These  data may  provide  a  partial explanation 
of the discrepancy between  the  low  incidence of thyroid 
nodules  in a  young  population  {50,51)  and  the higher  incidence 
found  by Mortensen et al  (49).  Also,  the varying methodologies 
used  in studying these  separate groups  certainly contributed 
to the differences. 
The  spontaneous  rate of  incidence of  nodules  ~n the  general 
population was  calculated recently by  Maxon  et al  (41)  on  the 
basis of data  in the  literature and  was  estimated to  be  0.08%  per year; 
t:he  rate of  incidence of thyroid malignancies  was  estimated 
to be  0.01%  per year.  The  latter figure  is higher  than  the 
0.004%  per year  suggested  by  the  Second  and  Third National 
Cancer  survey which  is largely based  on  death certificates 
and  the Cancer  registry data  (53). 
B.  Incidence of thyroid nodules  and  thyroid cancers  in 
Graves'  disease 
For  several decades,  ionizing radiation has  been 
employed  as  a  form  of therapy  for  Graves'  disease.  Thus,  an 
evaluation of  any  thyroid nodule  present  ~s 
indicated prior to  such  therapy. -20-
Dobyns  and  coworkers  (39)  reported that 15.5% 
of the patients with surgically treated Graves'  disease  had 
palpable thyroidal nodules.  The  mean  age of this group was 
40.1 years.  The  incidence of  spontaneous  thyroid nodules  in 
subjects who  were  about  to  be  treated with radioactive iodine 
was  16.4%  in the  same  study,  but the mean  age  was  higher at 
49.7  years.  These  figures  are certainly higher  than  the  2.9% 
incidence report.ed  in the  normal  population  in  a  British 
study with  a  similar mean  age  (22).  The  spontaneous total ·rate of 
incidence of palpable nodularity in patients with Graves' 
disease is estimated to  be  0. 36%  per year,  and  the rate of  incidence 
of malignant palpable nodules  is  0.002%  per year  ~L). 
The  incidence of thyroid nodularity post-treatment 
with 1311  was  also analyzed  by  Dobyns  et al  ( 39)  .  In this 
study 16,042  cases of patients with Graves'  disease were 
analyzed.  The  authors  found  that  86  subjects who  ha.d  no 
palpable nodules at the time of  131
1  therapy had detectable 
nodules  later at surgery.  Of  these  86  patients,  9  had  a  malignan-
cy ,  that is  10.5%  of the operated group.  Since  494 
additional patients had  developed  a  nodule after 1311  therapy, 
but had  not  undergone  surgery yet,  one could  assume  that  an 
equal  incidence of carcinoma  occurred in these nonoperated 
cases with nodules.  An  additional discovery of  52  cases of 
thyroid malignancies  leads one  to estimate the  rate of  incidence of 
thyroid cancer at  0. 05%  per year  and  a  total rate of  incidence of 
nodularity of  0.45%  per year. - 21  -
If the data reported  by  Safa et al  (44)  are combined 
with the cases reported  by  the Cooperative Thyrotoxicosis 
follow-up  study,  a  total of  304  children treated with  131I 
was  analyzed.  In this group  17  cases were  found  with benign 
nodules  and  2  with carcinoma.  Follow-up  time  and  doses 
received in these patients were,  respectively,  11  years  and 
9000  rem.  The  observed rate of  incidence of  cancer  is consequently 
0.06  cases per million persons  per  rem  per year,  a  mean  value that is 
not  different  from  normal  values in  the  adult  population  (0.05 cases)·~  The 
absolute risk of  nodularli..ty  in contrast is 0. 23  cases per million 
persons  per  rem  per  year  which  is slightly higher than the 
adult group  (O.llcases)(4I)~heline et al  (37)  and  Dobyns  et al 
(39~  both called attention to the propensity of young  individuals 
for  the development of nodules after treatment with  131r. 
In adults receivinq  131I  ablation  (32,000  rem  (39)) 
for  cardiac disease  no  nodules  were  found  in  20  patients who 
were  euthyroid before ablation  (54,55  ) .  In  a  group of children 
exposed  to  small  doses  of  131I  from  fallout  (46  rem)  Rallison 
et al  (43)  found  no  difference  in the  prevalence rate of benign 
and  malignant nodules  when  compared with  a  control population 
in a  14-year  follow-up  study. 
The  incidence of death  from  thyroid carcinoma  was 
compared  by  Dobyns  et al  (39)  in patients treated with surgery 
and  those  treated with  131I  for  Graves'  disease.  Their data 
indicate that the risk of death due  to  thyroid neoplasm  in -22-
Graves'  disease is indeed  small  and  does  not differ between 
the modalities of treatment used.  Although the risk of 
development of malignant  tumors  in  a  population is  low, 
the relative high risk of the  young  patients to develop 
nodularity after 131I  therapy  indicates that a  long-term 
follow-up  of these patients  remains  necessary. 
C.  Incidence of nodules  and  tumors  in patients exposed 
to external radiation therapy 
I)  Accidental or  nuclear weapon  exposure 
Since the use of atomic  weapons  in Hiroshima 
and  Nagasaki,  several studies have  shown  that survivors 
have  been  expo_sed  to substantial amounts of irradiation 
and  have  developed  a  number  of malignant  tumors  including 
thyroid carcinoma.  A  study conducted by  Jablon et al  (56) 
found  a  high  incidence of thyroid carcinoma  in a  subsample 
of  the  population. 
In March of 1954,  the Marshall  Islands were 
accidentally exposed  to fallout  radiation  from  the detona-
tion of  a  high yield thermonuclear  device during experi-
ments at Bikini in the Pacific Proving Grounds.  The 
inhabitants of Rongelap  Island received the  largest fall-
out exposure  (  175  rads of whole  body  gamma  irradiation) 
(57  ) .  In addition to  the gannna  rays,  these  subjects 
were  exposed  to iodine  isotopes  as  the result of the 
f.: ssion process.  The  average  thyroid  dose  received for  an  adult 
in the  island of Rongelap,including  the  gamma  dose,is 
calculated to  have  been  335  rads.  The  thyroid dose -23-
delivered to  a  3-year old child on  the  island was  calculated 
to be  in the  range  700  to  1400  rads.  The  first effect 
observed after this exposure of radiation was  stunted 
growth  in  two  boys  who  had  developed  symptoms  of 
myxedema,  and  demonstrated  low  serum  thyroxine  levels. 
Nine  years after the  exposure,  the first thyroid nodules 
were  found  in  a  12-year-old girl.  Subsequently,  thyroid 
nodules  developed  in subjects of other less exposed 
islands.  At  present,  40  of the  243  exposed Marshallese 
or  16.5%  are affected.  Recent  studies  have  shown  that, 
in addition to the nodularity,  the  incidence of hypo-
thyroidism is high  (50%)  in  the  Rongelap  group. 
The  latency of  tumor  occurrence appears  to 
be  dose  related with  a  period  from  11  to  22  years. 
Analysis  indicates that thyroids  receiving  lower  doses 
developed  tumors  later than  those  receiving higher doses. 
This  inverse relationship between  thyroid  dose  and  latency 
had  not  been  observed  in x-ray treated children  (58). 
Since  the latent period  for  the development of thyroid  tumors 
may  be  as  long  as  30  years,  long  term  follow-up  studies 
will probably disclose further  abnormalities of thyroidal 
function  and  structure. 
2)  External  irradiation in man  for  therapeutic 
purposes 
Since  the early decades  of this century,  external 
radiation was  delivered to anatomical  sites such as  the -24-
thymus  (59)  and  the tonsils  (6o),  to treat the  so-
called "status lymphaticus"and chronic tonsillitis 
or pharyngitis.  Later,  dermatologic conditions,  such 
as  hemangiomas  and  acne vulgaris,  were  added  to the 
list of therapeutic indications.  In  1950  Duffy  and 
Fitzgerald  (6I)  suggested the  existence of an etiologic 
link between  a  previous history of childhood  irradia-
tion to the  thymus  and  the occurrence of thyroid carcinoma. 
Since that report,  a  number  of investigators studied sub-
jects who  had  received irradiation for  thymic  hyperplasia 
and other benign conditions  (58,62-68 ).  Factors,  such as  sex, 
irradiation dose,  and  age at treatment,  are  important 
variables  in the evaluation of subjects affected by  this 
treatment. 
The  mean  dose of irradiation delivered is 
variable.  Hempelmann et al  <sa)  studied  a  group of  sub-
jects who  received x-ray treatment during childhood and 
reported in his  fourth  survey  in 1975  on  2872  subjects  who 
received  an  average air dose of  225  R  and  an  average  thyroid 
dose of  119  R.  In  subgroup  C,  reported in this  same  survey, 
a  substantially higher air dose  was  used  (461  R)  with an 
average  thyroid dose of  399  rads.  A  higher  amount  of 
irradiation was  delivered to the  261  patients in this sub-
group via  larger anterior and  posterior ports.  A  smaller 
study published the  same  year  by Refetoff et al  (66 ) 
disclosed an  exposure  to  a  mean  dose of  388  rads  in  30 -25-
subjects who  were  treated for  thymic  hyperplasia. 
Patients  in this study were  irradiated to  the tonsils or 
to the  face  for  acne  and received  a  substantially larger 
mean  dose  ranging  from  860  rads  (tonsils)  to  1500  rads 
(tonsils and  adenoids).  Finally,  a  large study con-
ducted  by  Favus et al  (67)  on  1056  patients who  received 
irradiation for  various  inflammatory diseases of the 
upper  respiratory tract disclosed that a  mean  total dose 
of 807  rads was used  in the  subjects  who  were  irradiated to 
the tonsil  and  pharyngeal  site.  These  studies  indicate 
the possibility of  a  wide variability in the  irradiation 
dose  to which  the  thyroid was  exposed.  Of  interest 
is the  study of  Madan  and collaborators  ~8 )  where  irradia-
tion was  administered to the scalp for  tinea capitis and 
where  doses  to  the  thyroid were  estimated to be  only  6.5 
rem  (  68).  Of  note is that thyroid carcinoma  has  been 
reported  in subjects  who  have  been  irradiated for other 
benign skin conditions  such  as  hemangiomas  (66  1 69)  and 
acne of the  face  (70). 
If the various  studies mentioned  above  are 
analyzed  ( 58,62 , 65-68 )  it is possible to observe that the 
indidence of thyroid nodules  and  thyroid cancer is increased, 
when  compared with  a  control population.  Recently,  the 
data of Colman  et al  (71),  Madan et al  (72),  Albert et al 
( 73) ,  and  Hemplemann .et al  (58 )  were  combined  and  analyzed 
by  regression analysis  ( 41).  This  analysis revealed that -26-
there was  a  good  correlation between  the  incidence of 
thyroid nodules  and  thyroid cancer  on  the  one  hand  and 
the total dose  in rem  received by  the thyroid gland on  the 
other·  Absolute  risk for  the thyroid cancer  and 
total nodules  appeared  to be  4.2  and  12.3 cases per million/ 
rem/year,  respectively. 
It is also clear that the  33%  incidence of 
thyroid cancer  in subjects who  received irradiation and 
underwent  surgery because of the presence of  a  detectable 
lesion  (67)  is higher  than that reported  in the American 
autopsy series  (13%)  accumulated  by  Nishiyama et al  (74). 
The  incidence,  however,  is lower  than that  found  by  Sampson 
et al  (75)  (28.4%)  in  a  Japanese  population and  Fukunaga 
et al  (76)  in Hawaii  (24%).  From  studies previously 
reported  (77- 79),  it is apparent that the  incidence of 
thyroid cancer is low when  the  irradiation dose  administered 
exceeds  2000  rem.  To  explain this phenomenon,  one  must 
assume  that the protective mechanism is based  on  complete 
destruction of  the mitotic capability of  thyroid cells. 
The  type of histologic  lesions  encoun~ered in 
radiated subjects who  subsequently underwent  surgery are 
shown  by  the data  in Table  2  (67  ).  Of  interest is the 
fact that in this study  49  of the  60  cases  who  were 
operated on  had  a  thyroid  tumor  smaller than  15  mm  which 
was  consequently considered as occult thyroid carcinoma or -27-
Table 2.  Histologic Diagnoses  in Subjects Operated on. 
Diagnosis  No.  of Cases 
Carcinoma  60 
Papillary  23 
Papillary-follicular  34 
Follicular  3 
Benign  120 
Multiple adenomas  86(4o)t 
Single adenoma  18(6) 
Hiirthle-cell  tumor  3(3) 
Colloid cyst  10(2) 
Thyroiditis  3(15) 
Other*  2 
Hyperplastic  lymph  node 
Schwannoma  of  recurrent  1 
laryngeal nerve  1 
Totals  182 
*Associated with normal  thyroid histology 
tFigures  in parentheses  indicate secondary diagnoses  in subjects 
with  >1  histologic diagnosis. 
(From  Favus,  M.J.,  et al.  N Engl  J  Med  294:1019,  1976.  Reproduced 
with permission of  the authors  and  editors)  (67). -28-
"minimal  carcinoma."  Twenty-one of the carcinomas 
found  were  smaller than  0.6  mm  and  were  discovered neither 
by  palpation nor  by  scan.  Of  additional interest is 
that in this study by  Favus  (77)  72%  of the thyroid 
carcinomas  were  actually associated with benign  adenomas. 
Distant metastases were  not observed,  but  lymph  node 
involvement was  present in  28%  of the patients who  under-
went  surgery  (table  3). 
The  average  latency of the malignant  tumors  is 
variable.  In the  study of Hempelmann  et al  (58)  the 
minimum  latent period was  5  years  for  thyroid cancer  and 
10  years  for  benign lesions.  The  data reported by  these 
authors also suggest that with smaller doses  of irradia-
tion there was  a  longer  latency period before benign 
lesions developed.  In the  study by  Favus et al  (67)  the 
mean  latency in the  examined  group was  27.5  years 
year.  They  define  latency as  the  length between  the 
time of therapy  and  the year of  1974  when  their  survey was 
conducted.  The  latency in the  study of Refetoff et al 
( 66)  was  comparable,  namely  24.4  ± 5.2 years. 
It is apparent  from  the studies of  Hempelmann 
et al  (58)  that the  incidence of  thyroid nodules  pre-
dominates  in females.  The  female:male  ratio was  1.9:1 
... 
for malignant thyroid lesions  and  2.3:1  for  benign  lesions 
in that study.  In  subgroup  C  a  higher  incidence of thyroid 
cancer was  found  in the Jewish population  (7.2%)  than  in -29-
Table 3.  Characteristics of Thyroid  Carcinomas  in Irradiated Subjects 
Mixed 
papillary 
Papillary  follicular 
Characteristics  Totals  tumors  tumors 
All cases  60  23  34 
Size of  largest tumor: 
Microscopic  15  10  4', 
3f  1-5 mm  6  3 
6-15  mm  28  6  20t 
)15  mm  11  4  7) 
Coexisting  benign  tumors  43  21  22* 
Centricity: 
Unicentric  32  19  10 
Multicentric  28  4  24-r 
Lobes  involved 
1  45  20  22 
Both  15  3  12 
Thyroid-capsule  invasion  12  1  10* 
Blood-vessel  invasion  5  0  4 
Lymph-node  involvement  17  2  15* 
*P<  0.05  by  chi-square analysis  (papillary vs mixed) 
tp<  0.01  by  chi-square analysis  (papillary vs mixed) 
* 
* 
& 
Follicular 
tumors 
3 
1 
0 
2 
0 
2 
3 
0 
3 
0 
1 
1 
0 
(From  Favus,  M.J.,  et al  N Engl  J  Med  294:1019,  1976.  Reproduced with 
permission of  the authors and  editors) (67). -30-
the  non-Jewish  populatio~  (2.9%).  The  fact that the 
Jews  in subgroup  C  were  1  year older and  had  received 
a  slightly higher dose of irradiation did not explain 
the higher  incidence of thyroid carcinoma  in this popu-
lation. 
IV.  Methods  of Evaluation in Subjects with  a  History of 
Irradiation Exposure 
A.  Necessity of evaluation 
A  number  of screening programs  have  been established 
in the United States to recall subjects who  had received 
external irradiation in the past  (66, 67).  Since the  number 
is large,  this represents  a  serious  problem.  The 
proceedings of a  recent Conference  in Chicago  ( 5  )  devoted 
to the  subject clearly stated that the· screening programs 
are  justified,  and  recommendations  were  made  concerning the 
diagnostic techniques  to be utilized to analyze the subjects 
at risk.  These methodologies  are  summarized hereafter. 
B.  Clinical evaluation 
The  physical  examination of the neck  area with 
special attention to  the  thyroid is considered of primary 
importance.  However,  one must  bear  in mind  that up one-
third of the  small  thyroid cancers  (  <  6  mm)  reported by 
Favus et al  (67)  were  undetectable  by  the thyroid  scan  and 
by  physical examination.  In addition,  non-thyroidal  tumors 
of  importance developed,  such as  salivary gland  tumors  ~I 
and  parathyroid  adenomas  ( 82,83).  Whether or not  thyroid - 31  -
scans  should be  used  in addition to physical  examina-
tion,  to detect lesions  in exposed patients was  exten-
sively discussed at the  previously mentioned  symposium 
(So).  It is certainly true that a  certain percentage of 
thyroidal lesions,  which could not  be  uncovered  by physical 
examination alone,  is picked  up  by  such techniques. 
Discrete regions of  increased or decreased 
radionuclide uptake were  identified in  278  scintigrams 
or  26.3%  in the study of  Favus· et al (67).  The  scintigraphy 
of the thyroid failed,  on  the bther hand,  to demonstrate 
in a  small  percentage of cases an abnormality which was 
found  on physical examination.  The  data  seem to indicate 
that the use of scintigraphy on  a  first visit basis may 
be  a  useful tool to investigate patients exposed  to neck 
or chest irradiation in the past.  Subsequent  follow-up 
evaluations  should  not  include  scintigrams except  in those 
subjects where  new  palpable abnormalities  became  apparent 
Th  .  t  f  h  .  . 
0  f  h  d.  123  d  e  ~so opes o  c  o~ce  w1.th  wh1.ch  to per orm  t  ese stu  1.es  are  I  an 
99mtechnetium  ( 80). 
Physical  examination is required on  a  yearly 
basis or when  lesions develop  because of the  latency  shown 
by  these  tumors.  As  far  as other tests are concerned,  no 
specific markers  for  thyroid  tumor  jifferentiation are 
available.  The  measurement of  serum  thyroglobulin  (Tg)  has 
been extensively investigated in the patients who  had  been 
exposed  to  irradiation previously  (84  ).  The  conclusion 
reached  by  these authors  indicate that there is a  difference -32-
COINCIDENCE  OF  PALPATORY  THYROID  ABNORMALITIES 
AND  ABNORMAL  TESTS  (SCAN  AND  SERUM  HTg  nglml) 
IN 30  SUBJECTS  PREVIOUSLY  EXPOSED  TO  EXTERNAL  X-RAY THERAPY 
n=13 or 
43.3% 
E] Thyroid 
abnormality 
on palpation 
~Abnormal 
thyroid scan 
.Elevated 
serum 
HTglevel 
n=17 
or 
56.7% 
••  Malignant 
lesion 
•Benign 
lesion 
FIGURE  3.  Incidence of  abnormal  tests in patients who  received external 
x-ray  therapy  in the past.  White  areas  represent normal  findings  or tests. 
Note  that  56.7%  of  this  small  population had  one  or another  abnormal  finding. -33-
in plasma  thyroglobulin levels when  subjects with 
nodules  in.the thyroid gland are  compared with  those 
without  such  lesions  in the  thyroid gland.  However,  the 
measurement of Tg  does  not  allow  a  distinction between 
those patients who  have  a  benign or  a  malignant  tumor  of 
the gland.  Consequently,  the assay provides  no  informa-
tion regarding the histologic classification of the lesions. 
Of  importance,  however,  is the  fact that a  subgroup of 
subjects was  found  representing  13%  of the population 
analyzed  in which  an  elevated plasma  thyroglobulin is found 
in subjects with otherwise  normal  thyroid glands.  Whether 
or not these patients represent  a  high risk subgroup  among 
the  irradiated population is not  known  and will only  become 
apparent after prolonged  follow-up  studies. 
Additional  studies performed  in our  own  institute 
concerning testing procedures  concur  with  the findings  of 
Schneider et al  (84).  Indeed  each  individual test, 
including  a  palpation of the thyroid gland,  when  applied 
to subjects  who  have  received irradiation in the past, 
will reveal abnormalities  in certain subjects that will  Ag~t be 
revealed  by other tests  (Fig.  3)  (85). 
v.  Treatment 
A.  Surgery 
Once  a  lesion is detected in the  thyroid of  a 
patient who  has  received external  irradiation,  most  experts 
would  agree  that surgery is mandatory.  The  final  conclusions -~-
of the conference in Chicago  (80  j  can  be  summarized  as 
follows: 
1.  A  nodule greater than  1  em  or  a  dominant  nodule  in a 
multinodular goiter  should be  considered for  surgery. 
2.  Pre-operative suppressive  therapy is not necessarily 
recommended  but may  be  selected by  the  surgeon to render 
the operation technically easier. 
3.  Total  lobectomy  and  isthmectomy of the affected lobe with 
subtotal thyroidectomy  on  the contralateral lobe is considered 
a  minimal  operation for  a  benign or malignant nodule. 
4.  Total  thyroidectomy is recommended  if obvious metastatic 
disease or bilateral disease is present. 
5.  Modified  neck dissection should  be  used if involvement 
of  the lateral  lymph  node  chain is present. 
6.  Thyroidectomies  should only be  performed  by  experienced 
surgeons  in the field. 
7.  Postoperative thyroid ablation with 131r  depends  on  the 
individual  and  should  be  used:  a)  when  obvious  residual 
tissue is present in the neck,  or  b)  when  suspicious 
disease is present in the neck or metastases are present in 
the  neck  or elsewhere. 
Since patients will have  permanent  hypothyroidism after 
surgery,  the administration of  thyroxine is indicated. -35-
B.  Thyroid  hormone  therapy 
Three possible indications  for administering 
thyroid hormone  to suppress thyroid  function after irradia-
tion  can  be  summarized  as  follows  :  1)  to prevent 
the development of  new  nodules or neoplasma,  2)  to  shrink 
existing nodules,  and  3) to prevent further  growth or neoplastic 
transformation of such  nodules. 
The  experimental evidence obtained in animals 
indicates that radiation-induced  thyroid  tumors  are pre-
vented  by  TSH  suppression.  On  the basis of these experi-
mental data,  the  following  recommendations  were  made  by the 
panel at the Chicago  Conference (5,80 ) • 
1)  Patients with normal  thyroid glands who  had 
been  exposed  to sufficient amount of irradiation during 
childhood or adolescence  be  considered  for  the prophy-
lactic administration of thyroid  hormone. 
2) In patients in whom  thyroid abnormalities  have 
developed  and who  are considered for  surgery,  a  trial with 
hormone  administration to shrink the  nodule  may  be  con-
sidered.  Usually this therapy  should  not  exceed  6  months. 
3)  All patients with radiation-related abnormal 
thyroid glands,  who  for  some  definite reasons  cannot  undergo 
surgical excision,  should receive  suppressive  therapy with 
thyroid hormone. 
4)  All patients who  have  been  thyroidectomized 
should receive  thyroid hormone  therapy. -36-
5)  Therapy with any  form  of  thyroid  hormone  is 
acceptable,  and  a  full  replacement is the goal. 
These  recommendations  also obviously apply 
largely to the patient who  has  been  exposed  to other  forms 
of irradiation in whom  a  nodule develops. 
CONCLUSIONS 
From  the analysis presented in the present chapter,  it is 
clear that  in  any  form  of irradiation therapy used  in man,  be 
it internal or external or administered therapeutically or 
accidentally,  long-term sequelae must  be  expected.  The  develop-
ment of nodules  (benign or malignant)  is of great concern,  and 
a  physician should definitely request  information with respect 
to previous  exposure to irradiation  when  &  patient 
presents with this clinical problem.  Such  information is some-
times difficult to obtain since the irradiation often occurred 
in early childhood and  many  of  the patient records are not 
available  for  scrutiny.  One  impor~ant rationale for  evaluating 
these patients is that the irradiation can  lead to functional, 
' 
as well  as  structural  abnormalities of the thyroid gland which 
are  likely to occur with  a  great latency. 
At  the present time,  it is not'known whether  these 
lesions continue to occur with  a  certain frequency  beyond  25 
and  30  years after irradiation.  However,  it must  be 
assumed  that continuous  development of tumors  occurs  in these 
patients and  that a  careful physical  examination to evaluate 
T~irmetabolic status as well  as  the structures in the neck  is -37-
required  to detect any  structural or  functional  abnormalities. 
Therapy must  ensue  in cases where  definite structural or 
functional  abnormalities are present. 
In view of the significant  incidence of radiation-
induced  thyroidal disorders,  careful exclusion of  the  thyroid 
from  radiation fields, is indicated whenever  feasible. BASIC  SCIENTIFIC  CONSIDERATIONS -40-
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1.  INTRODUCTION. 
The  thyroid  is probably  the  internal  organ  that  is most  frequently 
subjected  to  significant doses  of  ionizing radiations.  This  has  already been 
illustrated by  other  contributions  to  this volume  and  is reinforced  by 
Table  1,  which highlights  the glands'susceptibility to  irradiation by  nuclides 
of  iodine.  The  circumstances  in which  exposure  can  occur  range  from 
occupational  exposure  and  nuclear  accidents (86.,87lthrough  a  wide  range  of 
diagnostic medical  procedures  that may  or  may  not  involve  the  gland  itself 
(88,89to  therapy of  hyperthyroidism and  thyroid  carcinoma  (90,91). 
Despite  the widespread  irradiation of  the  gland  in medical  procedures 
and  its high  susceptibility to accidental  irradiation,  the dosimetry  of 
nuclides  of  iodine  in it and  its radiobiological  response  have  not  been 
exhaustivel~ studi~d( 6).  The  reasons  for  this are difficult  to assess,  but 
probably relate  to  the feeling  that  thyroid  dosimetry  is  technically difficult, 
if not  impossible.  Furthermore,  many  workers  have  been  of  the  opinion that 
the  radiobiological  response  of  the  gland  is  inherently unstable  and 
unpredictable  (92).  Hence  the value  of  good  dosimetry,  even  if it were 
achievable  ,  has  been  regarded  as  questionable.  This  line of  reasoning 
eventually  led  to both  thyroid  dosimetry  and  radiobiology  becoming  trapped 
in a  closed  loop.  The  radiobiology  could  not  be  explored  quantitatively as 
the dosimetry was  poor,  and  the dosimetry was  not  refined  and  developed 
because  the  available radiobiology did  not  suggest well  defined patterns  of 
response.  This  loop  has  recently been broken,  as  there are  now  reasons  to 
believe  that  the radiobiological  response  of  the  gland  is relatively well 
defined (6,93-96,99).  In view of  this,  and  the  substantial radiation 
burden  to  which  the  gland  is  exposed,  the  case  for  attempting  to refine  thyroid 
dosimetry  by  applying modern  te~hniques and  knowledge  to it, is  a  strong  one. 
This  chapter  attempts  ~o bring developments  in  the  basic  physics  of 
dosimetry  and  the  techniques  of measurement  that are particular  to  the 
thyroid  together. -42-
NATURE  OF  PROCEDURE 
Therapeutic 
Medical 
Diagnostic 
Medical 
Occupational 
Exposure 
and 
Nuclear  Incidents 
Treatment  of  thyroid  carcinoma 
Treatment  of  Hyperthyroidism 
Partial or  Complete  inclusion 
in Radiotherapy Fields 
Radionuclide  Scanning 
Uptake Tests 
Iodine Kinetics 
Uptake  of Nuclides  used  to 
investigate other  organs 
Partial or  Complete  Inclusion 
in Diagnostic Radiology  Fields 
Ingestion of Materials 
External  Irradiation 
RADIATION  TYPE 
X and  y  Rays 
99Tcm,  131I,  123I 
131I,  125I,  9~c, 123I 
1311 ,  1251 ,  9~c, 1231 
Multiple 
X-Ray. 
Multiple\ Principally 
nuclides  of  I  and  Tc 
Multiple 
TABLE  1:  Circumstances  in which Thyroid  is  irradiated. -~-
Initially  the basic physical  considerations  that 
are  important  in good  dosimetry are  outlined,  paying particular attention  to 
the  scheme  followed  by  the Medical  Internal Radiation Dose  (MIRD)  Committee 
in  the  U.S.A.  (97,98).  This  is  followed  by  a  discussion of  the measurements 
which must  be  performed  to  apply  the  scheme  to  the  thyroid,  including  some 
novel  approaches  to determining  the  integral under  the activity - time  curve. 
The  complex distribution of  iodide  in  the  thyroid  requires  that  the microscopic 
distribution of  dose  be  studied,  and  this  is outlined  in Sectiom III,IV. 
Finally the  sizes of  doses  encountered  in practice are  reviewed.  The  conse-
quences  of  these doses  including radiation induced neoplasia and  broader 
aspects of  the gland's radiation response  are discussed  in Sections II and  V. -44-
II.  PHYSICAL  ASPECTS  OF  DOSIMETRY. 
The  physical aspects  of  dosimetry  outlined  in this  section relate  to  how 
absorbed  dose  calculations are performed  for  a  nuclide distributed  through  a 
thyroid  assuming  that  both its mass  and  radionuclide  kinetics 
are  known.  The  methods  used  to determine  the  latter parameters  in practice 
are discussed  in  the  next  section.  The  approaches  available for  determining 
the dose  due  to  internally distributed radionuclides may  be  broadly divided 
into  two  categories.  (Table  2).  They  are  the  traditional approach due  to 
Marinelli (100,101~nd the  Revised  Schema  due  to  the Medical  Internal 
Radiation Dose  (MIRD)  Committee  of  the  Society of Nuclear  Medicine  in  the 
U.S.A.  (97,98). 
.  (  +  The  traditional method  separates  the dos1metry  of  electrons  S ,  S  etc.) 
f  h  f  h  (  d  )  h  b  . d  1  d  .  h  131  .  rom  t  at  o  p  otons  X an  y-rays  •  It  as  een  w1  e  y  use  w1t  I  1n 
the  thyroid,  (102-104)-Although  in many  cases  the data available  to  support 
it are not  extensive,  it is still popular  and  is frequently  cited  in  the 
thyroid  literature (102,1d5).The MIRD  scheme  unifies  the dosimetry  of  photons 
and  electrons  in a  conceptually  s.imple  way  (17 ,98).  Furthermore,  extensive 
documentation has  been produced  to  support application of  this  system in 
humans  (106-114). Both methods  are  outlined  below,  together  with details  of 
nuclear disintegration data  appropriate  for  use  in dosimetry  and  a  brief 
discussion  of  the  new  S.I.  Radiation Units,in  so  far  as  they are relevant 
to  the material  in hand.  It is  important  to note  that both methods  assume 
that  the  activity giving rise to  the  dose  is uniformly distributed  through 
the  volume  of  interest.  Frequently  this will  only  be  approximately  true  in 
the  thyroid.  The  consequences  of  non-uniform distribution of  activity will 
be  discussed  in IV. 
A.  _ The  Traditional Method. 
In  the  traditional method  the dosimetry  of  electrons  and  photons  is 
considered  separately. 
+  -
Electrons  (S  ,  S  ,  etc)  emitted  by most  commonly 
used  nuclides  have  such  a  short range  in tissue  that  they may  be  assumed  to -45-
METHOD  * FORMULAE  DOSE  FROM  1311 
for  1 rci/g 
- Traditional  8 Dose  =  73.8  c  Teff  E  8 
100.9 rad  - (Marinelli)  y  Dos·e  =  0.0332  C Teff  I~g 
Dose  =  A  D.  4>  MIRD  106.2 rad 
or  =  Q  t' s 
* The  formulae  are discussed  in detail  in  the  text. 
TABLE  2  :  The  Traditional  and  MIRD  approaches  to dosimetry with a 
typical  thyroid dose  calculated  by  each method. -46-
be  totally absorbed  in adult human  organs  in which  they  are  emitted  (101,103, 
115).  Hence  it is  commonly  assumed  that  an  organ containing  a  a-emitter  absorbs 
all ·the  energy associated with  the  emitted  a particles. Using  this  assumption 
the  absorbed  dose  from  a  nuclide  completely decaying  in an  organ is  (Tables 
2  and  3): 
Dose  =  73.8 c Teff  Ea  rad 
where  the  symbols  in  the  equation are defined  as  follows: 
C:  Concentration of  radionuclide  in  the  organ,in  ~Ci/g. 
Teff:  Effective Half-Life  of  the nuclide  in  the  organ of  interest,in days. 
(This  is  a  composite  of  the  physical half-life Tp  and  the biological 
half-life Tb,  and  is  equal  to Tp  Tb  /(Tp  +  Tb)). 
Ea  Hean  B energy  emitted  per  nuclear· disintegration,  in MeV 
The  definition of  these parameters,  and  numerical values associated with  them 
f  131r  .  h  h  "d  .  d  .  T  bl  3  or  1n  t  e  t  yro1  ,  are  summar1ze  1n  a  e  . 
Photons  of X and  y-radiation are much  more  difficult  to  absorb  than 
a-particles.  They  are rarely completely  absorbed  even  in  large  oreans.  To 
allow for  this  in dosimetry calculations a  factor  ~ is defined  and  used  to 
account  for  the proportion of  the  photon  energy  that will be  absorbed  in a 
given organ  of  specified  composition and  geometry(I03, 116).  The  quantity g is 
frequently referred  to  as  the "geometrical factor",  since it will obviously 
depend  on  the  size and  shape  of  an  organ.  It is difficult  to  compute  accurately, 
as  it is  a  volume  integral containing  terms  to  account  for  the effects  of 
absorption and  the  inverse  square  law(6,103 ).  However,  it has  been 
evaluated  for  idealized  shapes  such  as  cylinders,  and  tables  of values  are 
available  that may  be  used  with nuclides  emitting photons  whose  energy  is  in 
the  range  60  keV  to  2  MeV.(103,116,117).  Outside  this  range  special 
calculations must  be  made  for  each particular case  as  no  general  approach 
has  be7n developed. 
Using g  the  absorbed  dose  from  photons  emitted  by  a  radionuclide  in organ 
is  (Table  2  &  3): SYMBOL 
c 
I y 
g 
-47-
SHORT  DESCRIPTION 
Initial Activity/Unit Gland 
Mass 
Effective Half-life 
Mean  8 energy per  nuclear 
disintegration 
Specific y-ray Constant, 
i.e.  Dose  Rate  at unit 
distance  from  unit activity. 
Geometrical Factor  to 
account  for  absorption of 
y-rays  in gland 
UNIT  TYPICAL  VALUE 
JJCi/g  Depends  on  Administered 
Dose 
days  6-7  * 
MeV  0 0  180  t 0  0 • 18  8  * 
-1  -1  -2  RmCi  hr  em  *  2.18 
2  em  15.7 
I  ------~------------------------------~--------~------------------------~ 
131  * for  I  only. 
TABLE  3:  Parameters  associated with  the  traditional method  of 
calculating dose  from  radionuclides. -~-
Dose  =  0.0332 C Teff  I  g  rad.  y 
where  C,  Teff'  g  are defined  as  above  and  I  is defined  as  follows: 
y 
Iy  :  Specific Gamma  Ray  Constant,  that is  the  exposure dose rate at unit 
distance  from  unit activity.  In  this  case it is specified  in Roentgens 
per  mCi- h  at  1  em. 
These  parameters  and  numerical  values  associated with  them  for  1311  in 
the  thyroid  are  summarized  in Table  3.  The  value 0.0332  for  the  constant  in 
the  above  equation is slightly less  than  the value 0.0346  sometimes  quoted. 
The  difference  is  accounted  for  by  a  factor  0.96  used  to convert Roentgens 
in which  I~  is  specified  to rads,in which  absorbed  dose  is quoted  (lib). 
y 
The  combined  dose  from  a  8-y  emitting  nuclide  in the  thyroid  is  therefore 
given by 
Dose  = 73.8  C Teff £8  + 0.0332  C Teff  IY  g  rads 
131  Inserting  the values  for  the  parameters quoted  for  I  in Table  3,  and 
assuming  that  the  initial concentration of  activity is  1  ~Ci/g and  that  the 
effective half-life is  7  days,gives  a  8-dose  of  92.98  rad  and  a  y-dose  of 
7.95  rad.  Thus  the  total dose  is  100.9  rad  (Table  2).  The  fact  that  the 
absorbed  dose  in the  gland  is about  100  rads  for  an activity of  131r  of 
1  ~Ci/g may  be  used  as  a  useful  aide  memoire~3).  In many  respects  the 
traditional method  of  dosimetry outlined here  has  been  superseded  by  the MIRD 
approach.  Nevertheless,  it is still necessary  to  be  aware  of it for  a 
number  of  reasons.  For  example,  it is still used  and  most  of  the  thyroid 
dosimetry presented during  the  last  30  years  is based  on  it (6,105). 
Furthermore,  the fact  that  the  results it gives  are slightly different  from 
those  obtained with  the MIRD  scheme  is of  importance when  surveying earlier 
literature. 
B.  The  Revised  MIRD  Scheme. 
In  1968  the MIRD  Committee  published  the first in a  series  of  pamphlets 
that outlined  a  revised  scheme  for  calculating  ~he absorbed  dose  from 
biologically distributed  radionuclides  (97).  The  original publication has 
been  followed  by  comprehensive  support  literature on  the dosimetry  of  photons -49-
and  electrons,  nuclear disintegration scheme  data,  and  applications  to  a 
particular adult  human  phantom(106,114). The  committee  has  also prepared  a 
series of  reports  on  dose  estimates  from  particular radionuclides,  and  th6se 
on  99Tcm  and  iodine  are particularly relevant  to  the  thyroid  019,120 ). 
Recently  the  scheme  has  been updated  and  improved  to render it easier  to use 
and  to  take  explicit account  of  biological models  in dose  calculations  ( 98,114). 
The  scheme  initially appears  complex  as  it is presented using  a  formal 
mathematical  approach  (~7,98).  For  example  exact definitions of  and  suitable 
synbols  for  about  30  quantities  or  units  are required.  These  define  the 
radiation  type,  the  absorbing material,  the  source  and  target  organs  and  basic 
physical quantities.  In  the  interests of  brevity this discussion will be 
confined  to  the  three central concepts  in the method,  and  two  new  concepts 
recently  introduced  to  simplify usage.  Well  presented  introductions  of  a  more 
detailed nature  have  been published  (122-123),  and  are 
helpful when  approaching  the  primary  literature  (97,9~. 
In  the MIRD  scheme  the absorbed  dose  froma  biologically distributed 
radionuclide is computed  as  the  product  of  three factors  as  follows  (Table  2): 
Dose  ={ Concentration of Radionuclide J 
X Duration of  its Presence 
X 
- Symbol  A 
{
Energy Emitted  by  a  unit concentration} 
Symbol  !:::. 
of  the nuclide present·for unit  time. 
X  Fraction of  the emitted  energy 
absorbed  in a  unit mass  of  the  Symbol  f 
organ being  examined 
Dose  A l:::.f  rad 
The  three  components  in the  dose  equation will  be  briefly discussed  outlining 
their main features. 
. .  ,., . 
The  quant1.ty A  1.s  referred  to  as  the  "Cumulated  Activity".  In essence -50-
it is  the  integral under  the activity-time curve for  the  organ and  nuclide 
in question,  and  is  specified  in units of microcurie-hours  (  ~Ci-h).  One 
~Ci-h of  cumulated  activity could  be  the  consequence  of,  for  example,  a 
mean  activity of  1  ~Ci being present  in an  organ for  1  hour,  or  a  mean 
activity of 0.1  ~Ci,  being  present  for  10  hours.  In an  organ which 
instantaneously  takes  up  a  single bolus  of Q yci  and  eliminates it with an 
effective half  life of Teff  hours  the  cumulated  activity is 
""  A  =  1.44 Q Teff  ~Ci-h. 
The  second  term  8  in  the  dose  equation above  is  the  total  energy emitted 
by  the nuclide for  1  ~Ci-h of  cumulated  activity.  This  is  sometimes  referred 
to  as  the  "equilibrium dose rate constant"  (97,98).  Obviously  8  will be 
the  sum  of  the  energies  of  the  individual  photons  and  particles emitted  by 
the  nuclide during  transformation.  As  such it is frequently written as 
=  81  +  82--+---8i- - +- - 8n 
!:8. 
•  1 
= 
'  where  8.  is the  energy 
1  associated with  the  i  th photon/particle emitted. 
The  individual values  of  8i must  take  account  of  both  the  energy  (Ei)  of  the 
emission  involved  and  its relative abundance  (ni)  in  the disintegration 
process.  When  due  account  is  taken of  the  change  in units~ can be written 
as  A·  2.134  E.  n·  1  1  1 
and  hence 
A  =  2.134  L  n·  E· 
L 
r  1 
Extensive  tables  of values  for 4.,  n.  and  E.  have  been  compiled  ( 1  12) • 
"' 
1  1  . 
The  units  in  which~ is  expressed  are  rather~unusual  (Tables  4  and  10). 
Its basic definition is as  energy  emitted  per  fCi-h.  However,  the unit  of 
energy  used  is not  one  of  the  conventional  ones  such as  the Joule  or MeV. 
Instead  a  unit based  on  the definition of  radiation dose  is applied.  This  is 
the  gram-rad  (g.rad)  and  is  the  amount  of  energy  deposited  by  a  dose  of  1  rad 
in a  mass  of  1  g.  Therefore,  the unit  in which  i1  is specified is g.rad per 
rei-h.  When  the  S.I.  System  of  Units  is adopted  in radiation studies SYMBOL 
A 
s 
t' 
Q 
-51 -
SHORT  DESCRIPTION 
Cumulated  Activity = Integral  under Activity 
- Time  curve 
Equilibrium Dose  Rate  Constant  - Energy 
Emitted  per  ~Ci-hr. 
Specific Absorbed  Fraction =  Fraction of 
Emitted  energy  abosrbed  per  g  of  absorber 
Absorbed  Dose  per  unit Cumulated  Activity 
Residence Time  (see  text) 
Administered Activity 
UNITS 
~Ci-hr 
g  - rad 
~Ci-hr 
-1 
g 
rad/  uci-hr 
hr 
~Ci 
TABLE  4:  Parameters  associated with  the MIRD  method  of  calculating 
dose  from  radionuclides. ENERGY 
MeV 
0.179  to 
0.180 
0.188 
0.192 
0.193  to 
0.194 
-52-
ORIGIN 
Mean  Energy  of  a  particles per 
Disintegration 
Mean  Energy  of Principal  a  Particle 
Emitted during disintegration. 
Mean  Energy  of  a  particles,  internal 
conversion and  Auger  Electrons,  per 
disintegration. 
Mean  Energy  of  a  particles,  internal 
conversion and  Auger  Electrons  per 
disintegration plus  allowance  for 
radioactive dqughter  product. 
TABLE  lO:Values  of Mean  Ea  which  have  been  used  for  131I 
and  their  probable origin. -53-
the  need  for  this  anomalous  unit will disappear  (Table  10). 
The  final  term  in the MIRD  dose  equation is f'  which  is called  the 
Specific Absorbed  Fraction.  It is defined  as .the  energy deposited,  per unit 
mass,  in  the  organ  of  interest divided  by  the  energy  emitted  by  the radionuclide 
The  total energy  absorbed  in the ·organ is its mass  (m)  multiplied  by f. 
This  is designated  + and  referred  to as  the Absorbed  Fraction.  Thus 
+  =  m  ~ 
The  absorbed  fraction must  be  assessed  separately for  photons  and  particles 
of  differing energies,  as  the extent  to which  they are absorbed  is energy 
dependent.  Hence  an  individual  absorbed  fraction  term  ;i is associated 
with each  em1ssion of  energy E .•  Thus  the  total  energy  absorbed  from  a 
1 
radionuclide will be 
2.134L,n.  E.+.  =  .  1  1  1 
L. 
~  ll. +  . 
(  1  1  g.rad/  ~ti-h. 
To  convert  this  to absorbed  dose  it must  be divided  by  m,  the mass  of  the 
organ giving 
~  ll.  1 
i. 
ct>  i 
=  m  2:  ll. A;  • 
1  '1:  1 
rad 
~Ci-h 
Extensive  tables  of +  are available for  photons  and  particles of various 
energies  ( 106-110).  However,  for  simplicity  the  absorbed  fraction 
for  particles and  non  penetrating photons  ( <  11.3  keV)  is usually  taken as 
unity  (  96,10~.  This  approximation  is  true  to within a  few  per  cent in adult 
organs.  However, as will be  pointed  out  in  IV,  in the  thyroids  of  small 
children,  in  the  foetus,  or  in experimental  animals  it is unlikely  to  be 
sufficiently true  to  provide useful results. 
Using  the  three quantities A,  A  and  tf,  it is possible  to  compute  the 
dose  from  any nuclide  to  any  organ for  which  the  support  documentation has 
been prepared.  The  calculation process  is  tedious  as  the product  of~i and 
.i must  be  determined  separately for  each  type  of  photon and  particle emitted. 
·  ·  d ·  d  9  9T m  ·  1 ·  d  ·  The  number  of  such  emissions  for  nucl1des  of  10  1ne  an  c  1s  1ste  1n 54-
Table  7.  All  of  these products  must  then be  summed  before  the  dose  can 
finally be  determined.  To  simplify this process  a  new  quantity was  introduced 
This  is designated  "S"  and  is  the  absorbed  dose  per  unit  cumulated  activity 
( 98,113).  It is  evident  that Sis in fact  equal  to  the  sum  of  the  above 
products,  divided  by  the mass  of  the  organ of  interest,  i.e. 
s  =  !  ~~. +. 
m  •  1  1  ... 
rad/  Ci-h. 
Values  of  S  are available for  over  110  radionuclides distributed  through  19 
organs  in a  standard  human  phaPtom(113  ). Those  for  some  nuclides  of  iodine  and 
99T  m  ·  h  h  .d  .  d  .  T bl  5  c  1n  t  e  t  yro1  are  surnrnar1ze  1n  a  e  .  From  the  above  it is clear 
that  the  equation for  dose  may  now  be  reduced  to 
""  Dose  A  .  S  rad 
A  second  refinement recently  introd~ced to  the MIRD  schema  is concerned 
t 
~ 
with  A,  the  cumulated activity  ( 98,114). The  new  concept  is defined  as  the 
cumulated  activity per unit administered  dose,  and  is referred  to as  the 
residence  time  (~).  The  unit for  ~ is hours.  From  the definition 
,_ 
A  Q •  ~ 
where  Q is  the  activity administered  to  the  subject  in rei.  Residence  time 
takes  account  of  both  the  duration of  nuclide  stay  in an  organ  and  the 
proportion of  a  given dose  that enters  the  organ.  Values  for  ~for some 
l .d  .f  .  d.  99  rn  nuc  1  es  o  10  1ne  and  Tc  in the  thyroid  are  given  in Table  6.  It should 
be  noted  that  these values were  computed  on  the  basis  of  a  particular biological 
model,  and  may  not  be  suitable for  general  application  Q14  ). Values 
for  the  thyroid  are also plotted  in Fig.l,  as  a  function  of  the  physical half 
life of  those  in Table  6.  The  resulting  curve  is  smooth. 
From  the  figure  it is  evident  that  once  the  shape  of  the  residence  time  curve 
has  been determined it allows values  of  ~  for  nuclides  with  intermediate 
physical mlf life to be  interpolated reasonably  accurately.,  This  indicates 
the major  advantage  of  the  concept  of  residence  time,  in that it allows  for 
easy  transferability between nuclides  in dosimetric calculations when  there -56-
Fig.  I  :  Residence  time  (~)  for nuclides of  iodine plotted as  a  function of  their 
physical half-life,  using  a  particular model  of  iodine kinetics.  The  curves 
correspond  to  uptake values of  about  5  percent  (lower)  and  25  percent  (upper). 
The  form of presentation is based  on an original by  Berman  (114). -56-
NUCLIDE  PHYSICAL  *  RESIDENCE  TIMES  (HOURS) 
Half-Life  Uptake  5%  Uptake  25% 
123I  13.0  h  0.6°  3.3° 
124I  4.2  d  6.7°  33° 
125I  + 
263°  60.2  d  52.1 
126I  13.0 d  17.8°  88.9° 
129I  6  15.7xl0 y  98°  490° 
130I  12.5  h  0.58 
+  3.1° 
131I  8.06 d  12.52  ...  59.1° 
132I  2.38  h  0.04 
+  0.22° 
133I  20.8  h  l.:J.o  6.1° 
99Tcm  6.03  h  0.06° 
*Values  from  MIRD  Pamphlet No.  10.  (112) 
+Values  from  MIRD  Pamphlet  No.  12.  (114) 
o  Values  Calculated  by  Authors. 
TABLE  6:  Physical Half-Lives  of various  nuclides  and 
residence  times  (1:)  in  thyroid  assuming 
uptake values  of  5  and  25  percent. -57-
NUCLIDE  POSSIBLE  EMISSION  TYPES  ~NERGY EMITTED  AS  X-RAY 
NUCLEAR  NUCLEAR  X-RAY,  I.e.  I.C.and  AUGER  ELECTRONS 
& AUGER  ELECTRONS  (%  of Total) 
99mTc  3  16  13.1 
123I  14  27  28.6 
1241  70  85  1.7° 
1251  1  14  96.2 
1261  13  32  3.3° 
1291  2  15  41.2 
1301  31  48  0.4 
1311  20  37  1.8* 
132,I  116  144  0.5 
1331  39  44  0.4* 
* Contribution from  radioactive daughter  products  neglected. 
o  Not  including annihlation radiation. 
TABLE  7:  Possible Types  of  Emission  including X-rays,  Internal 
Conversion  and  Auger  Electrons,  and  percentage  of  total 
emitted  energy associated with  the  latter. -58-
is no  change  in  the  chemical-biochemical  nature  of  the material  being  used. 
Using  the  concept  of  residence  time  gives  the  final  equation for 
absorbed  dose within the  MIRD  schema: 
Dose  Q '  s  rad. 
Values  of  the  thyroid  dose  computed  for  nuclides  of  iodine  and  99Tcm  are 
listed in Table  5,_  assuming  the activity in the  gland  is  1 fCi/g. 
The  concepts,  units  and  equations  discussed  above  are  summarized  in 
Tables  2  and  4.  However  it is likely that all dosimetric  systems will  soon 
be  adapted to take into account the newly  formulated  S. I.  Radiation Units. 
These  units  and  their present equivalents  are  listed in Table  8.  Fortunately 
the present  revision of  the  MIRD  schema  is relatively  independent  of  the 
system of  units  in which it is  formulated,  and  hence  the  impending  transition 
should  be relatively painless  (98). 
C.  Nuclear Disintegration Data. 
Both  the  traditional and  MIRD  Systems  of  dose  calculation are dependent 
on  the accuracy  and  appropriateness  of  the  nuclear disintegration data used 
in the  dose  formula  outlined  above.  One  would  expect  that  the  standard 
decay  schemes  in sources  such as  "Nuclear Data"  or  "Tables  of  Isotopes"  would 
be  adequate  (124,125).  Indeed  much  of  the published dosimetry_of  131I  in the 
thyroid relies  on  such data  ( 1"02, 103).  However,  in sources  of  this  type details 
are  only  given  of  the  X  ,  S and  y  rays,emitted during  nuclear  transformation 
They  do  not  include  the multiple X-rays,  internal conversion and  Auger  electrons 
that may  be  ejected  from  the  atom due  to  the perturbations it experiences 
during disintegration  (126).  Table  7,  indicates  the  number  of different  types 
of  nuclear  emission associated with  the decay  of various  nuclides  of  iodine 
99  m  and  Tc  .  It also  indicates  the  total number  of  emissions  when  X-rays, 
internal  conversion and  Auger  electrons are accounted  for.  Clearly  the  latter 
are  important,  and  in many  cases  account  for  a  significant portion of  the 
emitted  energy.  This  is particularly true when  disintegration is by  electron 
capture.  For  example  with  125I  and  129r,  the  non-nuclear  emissions  account -59-
NUCLIDE  S*  . I  +  DOSE  FROM  1  ~C1 g 
(Rad/  ~Ci-hr)  INITIAL  ACTIVITY  (rad) 
123I  4.0  X  10-3  1.0 
124I  2.7  X  10-2 
69 
125I  3.0  X  10-3  59 
126I  1.8  X  10-2  126 
1291  7.1  X  10-3  273 
130I  3.9  X  10-2  8.9 
131I  2.2  X  10-2  105 
132I  6.0  X  10-2  0.9 
133I  4.6  X  10-2  21 
99m  -3  Tc  2.3  X  10  0.017 
*Values  from  MIRD  Pamphlet  No.  11  (113) 
+  Depends  on  iodide kinetics. 
TABLE  5:  S,  the Absorbed  Dose  per  ~Ci-hr,  and  dose  from  a  single 
administration  assuming  the  initial  (and  maximum)  activity 
is  1  ~Ci/g. Q
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 - 61  -
for  96  per  cent  and  42  per  cent  of  the  radiated  energy respectively .•  Table  9 
lists  the  basic decay  scheme  for  both  of  these nuclides  together with  the 
full  scheme  necessary for  dosimetry purposes.  The  difference between  the 
two  is dramatic. 
As  well  as  revising  the  basic  schema  for  dose  calculations  the  MIRD 
Committee  have  undertaken  a  detailed  study  of  relevant  events  associated with 
nuclear  disintegration.  As  a  result  comprehensive  documentation  has  now 
been published  on  over  120  nuclei  including  those  listed  in Table  7  ( 112). 
This  does  not  include all  the radionuclides  of  iodine,  but  those  not  listed 
are rarely encountered  in practice. 
Another  example  of  value  of  comprehensive  and  appropriate nuclear  decay 
data  is  given  in Table  10.  This  lists various  values  of  the mean  energy 
of  131r  that  have  been quoted  in dosimetry  calculations,  and  the  probable 
origin of  each value.  Clearly figures  such as  .180  and  .188,  which  have  been 
widely used,  are  significantly  lower  than  they  should  be.  This  in part at 
least,  accounts  for  the difference  between  the  results  obtained  for  the 
traditional  and  the  MIRD  dose  calculations  in Table  2. 1
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III. DETERMINATION  OF  THYROID  PARAMETERS. 
As  outlined  in  the  previous  section the  thyroidal parameters  that 
influence  the macroscopic  ~ose to  the  gland  are its mass  and  the  cumulated 
activity or  the  integral under  the  activity-time curve.  In  this  section the 
procedures  that may  be  followed  to measure  these properties  are  reviewed with 
respect  to  their applicability and  usefulness  •  Gland  mass  may  be  estimated 
by  palpation,  scintiscanning or ultrasonar methods.  Surprisingly,  as will be 
demonstrated  in il!I,A,  the  three approaches  appear  to be about  equally 
accurate.  The  cumulated activity has  traditionally been derived  from 
measurements  of  the  uptake  and  effective half  life of  radionuclides  in  the 
gland.  There  are many  pit~alls in uptake measurements,  and  estimation of 
the effective half  life can be  greatly simplified using  a  thermoluminescent 
techniques.  The  main features  of both of  these  parameters are discussed  in 
B.  Using  the uptake  and  effective half life represents at best  an 
approximate  approach  to determining  cumulated activity.  More  direct approaches 
to  this problem which  are potentially more  powerful  and  accurate exist and 
are briefly reviewed  in  C.  Any  physiochemical  factor  that  ~odifies 
iodine kinetics  in  the  thyroid will also obviously interfere with  the 
cumulated activity,  and  hence  the  absorbed  dose.  The  influence  of  such factors 
are  discussed  elsewhere  in this volume  (see Section  III,  IV). 
A.  Thyroid Mass 
Traditionally it has  been felt that one  of  the  limiting factors  in 
thyroid  dosimetry  is  the  accuracy  of  gland  mass  estimation (92}  ijowever,  some 
reports  in the  literature indicate  that surprisingly good  mass  determinations 
can be made  using relatively crude  techniques(I27-130.}. The  methods  on  which 
objective studies,  have  been performed  are palpation,  scintiscanning  and 
ultrasound  B scanning.  In each case  the validity of  the method  has  been 
assessed  by  comparing  the measured  mass  with  the  actual mass  of  thyroids 
subsequently  removed  at surgery.  Consequently  there  is an  inherent bias  in -64-
the  populations  studied  towards  subjects  with  larger  glands,  as  this  is  a 
feature  of  patients referred for  thyroid  surgery. 
The  potential  of  palpation may  be  assessed  from  studies  by  Soley  ( 127)and 
Smith  et al.  ( 129).  Results  from  the  latter are  summarized. in Table  11.  It 
is  evident  that  almost  70  per  cent  of  the mass  estimates  lie wiihin  25  to  30 
per  cent  of  the  surgical value,  and  that  over  90  per  cent  of  the  cases  are 
within 50  per  cent  of  the  true value.  However  it is  clear  that  agreement with 
the  surgical  estimate  is reduced  significantly when  only  those with  a  gland 
mass  of  less  than  40  g  are  considered. 
The  use  of  scintiscans  to  provide  thyroid  mass  estimates  gave  results 
that  were  generally regarded  as  unsatisfactory during  the  1950's  and  1960's 
(92,131,132).  A recent  study reviewed  19  formulae  used  for  this purpose,  and 
re-evaluated  the  potential  of  the method  (128).  The  formula  finally  selected 
to  calculate mass  was  relatively simple,  being: 
M  0.86  Al.26 
where  M is  the  mass  of  the  thyroid  in grams  and  A  is  its area  on  a  scintiscan 
in  cm2.  The  results  obtained  using  this  relationship are  surprisingly good 
and  are  summarized  ~n Table  11.  The  overall accuracy  is  about  equal  to 
that  obtained with palpation,  and  may  be  slightly better  for  glands  of  40  g 
or  less.  It is entirely possible  that  scintigraphic mass  estimates  can be 
significantly  improved  using  specially designed  collimators  (133,134).  Fig.  2, 
indicates  that  thecros·sectional  area  of -sources  can  be  measured  with  these 
collimators  to  a  high degree  of  precision when  large  sources  approximating 
the  size  of  the  spleen are  used.  The  right side  of  the  figure  indicates  that 
a  correlation which  is  not  quite as  good,  but  is nevertheless useful,is 
obtained  even with very  small  sources.  Application of  these  techniques  to 
the  thyroid  should  improve  mass  estimation. 
Although  the  accuracy  to date  of  the  scintigraphic method  is only  equal 
to  that  of  palpation,  the  technique  has  three  significant  advantages  to 
recommend  it.  First,it is  independent  of  the  experience  of  the  observer. -65-
ALL  CASES 
Deviation from  Cases  within Deviation  (%) 
Surgical Estimate  Palpation  Scintigraphy  Ultrasound 
% 
25  67  69  68 
50  91  95  91 
75  96  99  96 
100  99  99  96 
Total No.  of  Cases  104  74  22 
Cases  with  thyroids  less  than  40  g. 
Deviation from  Cases within Deviation  (%) 
Surgical Estimate  Palpation  Scintigraphy  Ultrasound 
25  47  64  62 
50  8.0  71  92 
75  90  93  92 
100  9.7  93  92 
Total No.  of  Cases  30  14  13 
TABLE  11:  Accuracy  of  Thyroid Mass  Estimates  by  various  techniques.  The 
percentage  of  the  cases  examined  that lie within specific 
deviations  from  the  surgical value  is presented (128-130). 
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Second  it is reproducible  from  day  to day  and  from  place  to place.  Finally 
it is relevant  to note  that scintigraphic mass  estimate refers only  to  tissue 
through which activity is  distributed and  this_from a  dosimetric p0int  of 
view is all that is required.  The  disadvantages  of  the method  obviously 
relate to its cost  and  inconvenience. 
Gland  mass  estimates using  ultrasound  B-scanning  were  evaluated  by 
Rasmussen- and  coworkers  C  130.).  They  used  serial tomographic  sections  of 
the  thyroid  to determine its volume  and  hence  its mass  (Fig.3)  Their results, 
illustrated  in  T~ble 11,  are  approximately  the  same  as  those reported  for 
palpation and  scintigraphy,  and  may  be  slightly better for  glands  less  than 
40  g.  However,  there  is probably considerable room  for  improvement  in the 
ultrasonar method.  For  example  in the  above.  study  the  transducer  and  scanning 
arm  used  were primarily designed  for  large  scale  abdominal  work.  A higher 
frequency  transducer  and  a  more  refined  scanning  arm  would  probably give 
significantly better results,  particularly with  smaller glands.  Furthermore 
the  scanning  technique most  appropriate  for  mass  determination is quite 
different from  that used  in conventional  thyroid  ultrasound  examinations,  and 
is still open  to  improvement. 
Figure .4  sununarizes  the results for  mass  determination listed in Table .11. 
The  heavy  line represents  the mean  accuracy  of  the  three  techniques,  as 
there  is little difference between  them.  The  shaded  area represents  the 
accuracy for  glands  less  than  40  g,  with ultrasound  lying  towards  the  top 
and  palpation  toward  the  bottom.  The  most  appropriate method  to  use  in a 
particular case will depend  on  the  accuracy required  and  the  staff and 
facilities available.  However,  in cases  where  a  subject  is suspected  of 
having  ingested  radionuclides  of  iodine  there  is  a  lot  to  be  said  for  using 
a  scintiscan,  which  can be  performed with as  little as  a  few rei in the 
gland  provided  sufficient  time  is  taken.  From  the point of  view of  future 
developments  in gland mass  estimation it is  clear  that ultrasound, 
scintigraphy and  possibly  CAT  Scanning  could  with refinement,  yield -68-
Fig.  3  :  Ultrasound  B scan of  thyroid  showing  a  tomographic  section 
through  the  gland  that clearly outlines  its crossection. -69-
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Fig.  4  :  The  percentage of  gland mass  estimates  that lie within a  fixed 
deviation from  the  surgical value,  for  the  three  techniqaes  :  palpation, 
sc~igraphy and  ultrasound.  The  full  line is for all glands  while  the 
shaded  area is for  glands  less  than  {j.Q  g.  Based  on  the data in 
Table  II,  which was  derived  from  Refs.:I28-13o·. -70-
more  accurate results. 
B.  Cumulated Activity 
Cumulated  activity,  or  the  integral under  the  activity-time  curve,  has 
traditionally been determined  in thyroid  investigations  from measurements  of 
the  24  h  uptake  and  the  effective half  life of  the nuclide  in question.  The 
met~ods used  to measure  these parameters  and  their validity have  recently 
been  subject  to  investigation and will be  reviewed  here. 
1)  Uptake 
The  thyroid  uptake  of  a  radioriuclide  is  commonly  measured using  a  singl~ 
stationary collimated  probe.  The  activity in  the  gland  is determined by 
comparing  the  count  rate obtained  over it with  that obtained  from  an activity 
standard  in a  neck phantom  (135  ). The  uptake  value  calculated from  this  type 
of  measurement will  only be  true  to  the  extent  that  the  phantom actually  , 
represents  the  geometrical  and  attenuation conditions  present  in the  subject's 
neck.  It has  long  been recognized  that differences  in  thyroid  geometry  could 
give rise  to  large errors  in activity determinations with  low  energy nuclides 
such as  125r  (121  ) while it was  f6lt that  such errors would  be  small with 
higher  energy nuclides  such as  99Tcm  or  131r.  However,  Fig.S  indicates  that 
this  is not  the  case  (1.36).  The  figure,  based  on  phantom  studies,  indicates 
the  correction factor  by  which  an  observed  uptake must  be multiplied  to 
compensate  for  variations  in depth  of  the  gland  below to neck  surface.  Over 
the  range  of  depths  studied  the  apparent  uptake  can vary by  a  factor  of  2 
for  131r  and  99Tcm,  and  a  factor  of  4  for  125r.  The  range  of  thyroid  depths 
encountered  in practice is presented  in Table  12,  which  indicates  a  mean 
value  of  about  3  em  and  a  very  large  standard deviation. 
Therefore,  gland  depths  vary  to  such  an  extent  in practice  that  the  ~orrections 
presented  in Fig.S  are essential when  accurate  uptake measurements  are 
required.  The  underlying  causes  for  these  corrections  are  attenuation and 
the  inverse  square  law in about  equal  proportions  (1.36  ) • 
To  apply  the  correction factors  in Fig.S  gland  depth must  be  measured. z 
0 
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GLAND  DEPTH 
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6  2  4 
DEPTH  (em) 
6 
Fig.  5  :  The  correction factor by  which an observed uptake must  be multiplied 
to  give its true value,  as  a  function of gland depth.  A "normal"  thyroid 
was  assumed  to be  3  em  deep.  Adapted  from  O'Connor  and  Malone  (.136)  • -72-
NO.  OF  CASES  THYROID  DEPTH  MEASUREMENT  OF  DEPTH  REFERENCE 
(Mean  ± ls.d.)  to 
92  3.85 ±  1. 60  Centre  of  Gravity  of  thyroid  Schulz  and  Rollo (137) 
100  3  ±  2  Centre  of Gravity  of  thyroid  Vennart  ( 201) 
53  2.6  To  anterior  of  lobe  Wellman  et al  ~02.) 
42  2.1 
+  - 1.1  Centre  of Gravity  of  thyroid  This  study  (probe) 
21  2.2 
+  - 0.9  Centre  of Gravity  of  thyroid  This  study  (TLD) 
fABLE  12:  Thyroid  Depths  from  various  studies. - 73-
This  can be  achieved  in a  number  of  ways.  For  example  the ratio of  the 
counts  obtained  at  2  distances  from  the  neck  surface  is sensitive  to variations. 
in gland  depth  (137).  Fig.6 gives  a  plot of  this  ~atio for  neck-detector 
d .  f  4c  d  4  .  .131  1stances  o  30.  m an  50.  em,  ustng  I,  Determination  of  the  thyroid 
counts at  these distances  from  a  subject allows  its depth be  read  off  from 
the  figure.  The  advantage  of  this method  is  that  no  special  equipment  over 
and  above  an  ordinary uptake  counter  is required.  Its disadvantage  is  that 
relatively  long  counting  times  are  needed  to  give  statistically significant 
results.  Alternative methods  that  could  possibly be  employed  to determine 
gland  depth  include  use  of  the ratio of  Compton  scattered  counts  to  the  counts 
in the  main  peak  (138,139h  use  of  a  lateral radionuclide  scan,  or  an  ultrasound 
scan  (136  ). It is  also possible  to construct both stationary and  moving 
detectors whose  response  is relatively independent  of·depth,  and  there  is  a 
good  case  for  applying  such  instruments  to quantitative uptake measurements 
in the  thyroid  (139-146). 
The  dependence  of  thyroid activity measurements  on  gland  depth is  the 
main  source  of  error  in conventional  uptake methodology.  Smaller  errors  of 
the  order  of  10  per  cent  and  2  per  cent may  arise  from variations  in lobe 
separation and  gland mass  respectively.  In very accurate determinations 
these may  also be  corrected  for  036).  The  level  of  circulating extra  thyroidal 
activity seldom presents  serious  problems  1n practice,  except  shortly after 
a  dose  is  administered  or  when  the  uptake  is very  low  044). 
When  a  very precise value  of  the  thyroid  uptake  is not  required it may 
be  estimated  using  thermoluminescent  discs  fixed  with  BAND  AID  dressings  to 
the  subjects anterior  or  posterior  neck  surface for  a  24  hour  period.  This 
type  of  measurement  is very  easy  to  perform  in remote  situations  in which 
direct access  to  equipment  or  laboratory facilities may  not  be  easily available. 
Th  .  .  bl  .  .  f  .  .  f  125  d  131  .  .  e  m1n1mum  measura  e  quant1t1es  o  act1v1ty  or  I  an  I  us1ng  L1F  or 
Caso4  (Dy)  thermoluminescent discs  are  listed  in Table  13.  Clearly activities 
of  the  order  of  1 rei are well  within  the  range  of  these materials.  The 0
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Thermo luminescent  Discs  Nuclide  and  Activity 
131!  (lJCi)  1251  (lJCi) 
LiF  4.4  8.3 
CaS04(Dg)  0.32  0.13 
Selected  Batch of 
Caso4  (Dy)  0.1  0.04 
TABLE  13:  Minimum  measurable  thyroid activities 
in 1.1Ci  of  125r  and  131r  with 
thermoluminescent discs  placed  for 
24  hours  on  the anterior  neck  surface. 
Values  for  posterior neck surface are 
about  10  times  less. -76-
selected batch of  caso4discs was  chosen  to minimize  the  interdisc variability 
in radiation response  and  background.  Consequently it is more  sensitive as 
the  limiting factor  in sensitivity in these  studies  is  the  standard 
deviation of  the  background  reading  ( 145). 
As  with  the  uptake  probe,  thermoluminescent  disc measurements  of  thyroid 
activity will  depend  on  gland  depth.  Fig.7  shows  the  correction factor 
which must  be  applied  to  the  back  of  neck  TLD  reading  so  that it provides  a 
representative activity estimate.  This  curve neglects errors  that arise 
because  of variations  in gland  mass  and  lobe  separation between  subjects. 
However,  these  errors will  not  be  large  for  gland masses  in  the  range  20-60  g 
and  lobe  separations  up  to  4.5  em.  As  illustrated in Fig.8 very  few  thyroids 
lie outside  these  limits. 
The  requirements  that  gland  depth  be  determined  for  TLD  uptake measurements 
would  destroy  its usefulness  in remote  situations if conventional  high 
technology methods  of  depth determination  had  to  be  used.  Therefore,  a  method 
of  estimating  depth using  the discs  themselves  has  been developed.  Fig.9 
illustrates  the  ratio of  the  reading  from  discs  placed  on  the  front  and 
back  of  a  neck  phantom plotted  against  the  depth  of  the  gland.  These  curves 
allow gland  depth  be  determined  to within about 1.0  ern  (146),  and  hence would 
allow  the  corrections  of Fig. 7 to be applied :in practice without  recourse  to 
more  sophisticated  equipment. 
In Fig.  10  the  uptake  measured  by  the  TLD  technique  is plotted against 
that  obtained  using  a  conventional  probe.  Both measurements  have  been 
corrected  for  gland  depth.  The  correlation between  the methods  is good, 
although  a  best fit  to  the data points  indicates  that  the  TLD  method  gives 
results  that  are· on  average  about  20  per  cent  lower  than  those  from  the 
uptake  probe.  This  is probably,in part at  least,accounted  for  by  the  fact 
that  the  disc  readings  represent  the  average  activity present during  the first 
24  hours  after  a  dose  is administered,  which will  inevitably be  lower  than  the 
point measurement  of  activity made  at  24  hours  by  the  probe.  The  right panel • 
- 77-
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Fig.  7  :  The  correction factor by which  a  back of neck  thermoluminescent 
disc reading must  be multiplied  to  give  a  value  that is representative of 
131  thyroid uptake  of  I.  The  gland depth  in the  phantom is measured  from 
the  front  of  the neck.  Corrections  for  gland mass  and  lobe separation 
are not  included.  A "normal"  thyroid was  assumed  to be  3  em  deep. 
Adapted  from  an original by M.K.  O'Connor,  with his permission,  ( 146 ) • (
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20 
Neck  Phantom 
15 
em 
II 
" 
10 
5 
o~~------~----~----~------~----~----~ 
·2  ·3  ·4 
Fractional  Depth  of  Gland 
Fig.  9  :  The  ratio of  readings  in thermoluminescent discs placed on  the 
front  and  back of a  neck phantom as  a  function of  fractional  gland  depth for 
neck phantoms  of differing diameters.  Courtesy of M.K.  O'Connor,  (146). -80-
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Fig.  10  :  Comparison of uptake values  obtained using  a  conventional  probe  and 
thermoluminescent  discs.  I~ the left panel  the  TLD  discs were  placed  on  the 
back of  the  neck  and  both  the uptake  probe value  and  disc value were  corrected 
for  gland depth.  In  the right panel  the discs were  placed  on  the front  of 
the neck  and  no  corrections were  applied  to disc or probe measurements. 
Adapted  from  originals  by M.K.  O'Connor,  with his permission,  ( 146).. - 81  -
in Fig  .• lO  demonstrates  a  surprisingly good  correlation between  the uncorrected 
TLD  reading  obtained  on  the  front  of  the  neck  and  the uncorrected value  of 
uptake  obtained with  a  probe.  This  correlation simply reflects  the  fact 
that  in this  case,  the magnitude  and  direction of  the  errors  from  both  techniques 
are  similar. 
The  approaches  outlined  to  uptake measurement  indicate that it may  be 
studied  at  a  number  of  levels.  However,  it is absolutely clear  that if 
accurate data are  required  for  dosimetric work  gland depth and  geometry  mus·t 
be  corrected  for.  For  work  demanding  less  accuracy  such  as  diagnostic 
medical  investigations  or  epidemiology  the  same  rigorous  techniques  need  not 
be  applied,  and  in  these  circumstances  there may  be  occasions  when  the 
simplicity and  portability of  thermoluminescent discs  has  much  to  commend  them. 
2)Effective Half  Life 
The  effective half  life of  a  radionuclide  in  the  thyroid may  be 
determined  from  sequential  counts  performed  with an  uptake  probe.  This  method 
is  time  consuming  and  obliges  the  subject  to make  numerous visits  to  the 
laboratory.  Consequently effective half life measurements  have  frequently 
been  omitted  from dosimetry  regimes  on  practical grounds  and  assumed  values 
have  been used.  For  example,  it is  commonly  assumed  that  the  effective half 
life of  131r  in  the  thyroid  is  6-7  days  (92,103). 
An  alternative approach  to  effective half  life estimation,  using 
thermoluminescent  discs  has  been  developed  in recent years  (147-149). 
with uptake measurements  the  technique  involves  fixing  the discs  to  the 
anterior  neck  surface  for  sequential  24  hour  periods.  Effective half  life 
measurements  do  not require  absolute activity determinations.  All  that  is 
necessary  is relative measurements  of  the  activity present  from  day  to day, 
and  this  eliminates  the  need  for  most  of  the  geometrical  corrections  that 
must  be  introduced  when  uptake  is being  estimated.  Furthermore,  while 
positioning  the discs  reproducibly  on  the  neck  surface is  important,  small -82-
variations  from  one  day  to  the  next  are  tol~rable without  substantially 
influencing  the results  obtained  (145).  Therefore,  determination of  effective 
half  life is technically easier  than uptake. 
Fig.  11  illustrates  the results  of  a  comparison between  the effective 
f  'f  f  'd  1  131  d  .  d  .  h  1  .  d'  d  hal  11  e  o  thyro1  a  I  eterm1ne  us1ng  t  ermo  um1nescent  1scs  an 
that  obtained  using  an uptake  probe.  The  correlation is excellent,  ~ndicating 
that for  practical purposes  the  TLD  method  is an  adequate  substitute for 
traditional methodology  (  148~149). The  most  striking feature  of  the  technique 
is  its convenience,  as  after  a  short period  of  instruction most  of  the 
measurements  can  be  made  by  the  subjects  being monitored  in their  own  home. 
The  discs  may  be  returned  to  the  laboratory  in person or by mail 
(  tr4'·9)  This  is clearly a  considerable  advantage  when  monitoring  out patients 
from  a  hospital clinic or  healthy  subjects  who  have  accidentally  ingasted 
radioiodine.  Its benefits for  those  liv'ing  in remote  regions  are also 
evident. 
The  range  of  effective half  lives  encountered  in practice depends  on  the 
iodine kinetics  in  the  subjectsand  the  radionuclide  being  used.  With  131I 
a  range  from  approximately  2  to  8  days  has  been  encountered  ( 149, ISO)  in 
patients  being  investigated  or  treated  for  hyperthyroidism.  In  these patients 
an excellent correlation is  obt~ined between  the effective half  lives  of 
tracer  and  therapy doses,  a  feature which may  be  usefully availed  of  in dose 
prescription  ( 149).  Shorter values  of  effective half  life down  to  12  hours, 
have  been  noted  in patients with  thyroid  .carcinoma  (I51).As  indicated  in 
Table  14  these  changes  give rise  to very  substantial  changes  in  the  dose  the 
thyroid  would  receive  from  a  fixed  initial level  of  radioiodine.  The  table 
also  indicates  that  the  dose  due  to nuclides with  longer  physical  half  lives 
is subject  to greater variation  than  that  from  their  shorter half  life 
counterparts.  This  table highlights  the  need  for  more  extensive data  on  iodine 
kinetics  in normal  human  subjects,  particularly in view of  the possibility 
that  small  relatively stagnant pools  of  iodide  can develop  even  in normal -83-
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Fig.  11  :  Correlation of effective half lives measured with a 
conventional  probe with  those  obtained using  thermoluminescent discs. -84-
BIOLOGICAL  HALF-LIFE  MEAN  GLAND  .+lOSE  (RADS) 
(days)  126I  131I  125I  129! 
2.7  83  29  10  5 
50  100  100  100  100 
104  100  109  139  208 
TABLE  14:  Change  in  thyroid dose  associated with change  in biological 
half-life of  iodide,  assuming  a  dose  of  100  rads  is 
associated with  a  biological half-life of  50  days.  Uptake 
was  assumed  to  be  instantaneous. -85-
thyroids  (IV,, B). 
Determining  cumulated  activity from measurements  of  uptake  and  effective 
half  life as  outlined  above  is at best an  approximate method.  For  example 
the method  takes  no  account  of  the  uptake  phase  or  its duration,  and will  thus 
systemat~cally overestimate  the  cumulated  activity  from  this portion of  the 
activity-time curve.  Furthermore,  iodine 
kinetics  can frequently  be  complex  and  the  curve  indicating  loss  of  radioiodine 
from  the  gland  often has  several  components.  Determining  the  correct method 
of  fitting  such  curves  is difficult and  prone  to  errors.  For  the  above 
reasons  there  is  a  need  to develop  a  more  direct approach  to  the  estimation 
of  cumulated  activity using  concepts  such  as  residence  time,  or  those 
outlined  in  the  next  section  (114,1§2,15~.  In  the mean  time  the results 
obtained using  uptake  and  effective half  life are useful  and will generally 
be  within  20  per  cent  of  the  true value provided.sufficient care  is  taken 
with  the measurements. 
C.·  New  Methods  of  Determining  Cumulated Activity. 
The  cumulated activity,  as  has  already been pointed  out  is essentially 
an  integral of  activity over  time  for  a  particular area  or  volume.  The  most 
common  methods  of  measuring it relies  on  accumulating  single point  counts  in 
time  and  using  the best fit curve  to  these  points  to estimate  a  value  for 
the  integral.  Little attempt  has  been made  to determine  cumulated  activity 
by  applying  the  facts  that  some  radiation detectors  and  many  biological 
systems,  under  appropriate  circumstances,  operate essentially in an  integral 
mode.  This will be  illustrated using  two  examples  which  should  clarify  the 
concept,  and  should  indicate  that  a  more  direct  approach  to measuring 
cumulated  activity is  not  only possible,  but  is also  likely to be  more 
powerful,  convenient  and  accurate  than present methods. 
Thermoluminescent  discs  are  integrating detectors.  During  effective half 
life determinations  as  illustrated in Fig.  12  A,  they are  used  to provide 
point  count measurements  that are  equivalent  to  those  obtained with  an -88-
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Fig.  12  :  Illustration of conventional method  of obtaining data for 
cumulated activity measurements  (top),  and  the possibility of making 
a  direct single measurement  with  thermoluminescent discs  (bottom). -87-
uptake  probe.  However,  each TLD  point actually represents  the  integral of 
the activity in  the  gland  for  the  24  hour  period it is in position.  There 
is  no  reason,  in  theory at least,  why  the discs  could  not  be  left in position 
for  the  entire period  over  which  the  integral is  to  be  determined  as 
illustrated in Fig.  12  B,  If  this were  done  the disc  reading would  be 
directly representative of  the  cumulated  activity during  that period.  To 
convert disc readings  to fCi-h  a  calibration protoc'ol  is necessary.  This  could 
take many  forms,  using  for  example  a  suitable set of  phantoms  or  the 
procedure illustrated in Fig.l3.  In  this  a  second  set of  discs  is placed  on 
the  subjects neck  surface for  24  h  at  the  end  of  the  period  for  which 
cumulated  activity is being  determined.  During  this  time  an  accurate 
measurement  of  the activity in  the  gland  is made  using  an  uptake  probe.  This 
provides  the calibration factor  necessary to  convert  the  reading  in the 
long  term discs  to  }'ci~h. 
In  4  subjects  in whom  the  above  method  was  applied  to  determine 
cumulated  activity the results  obtained were within  about  10  percent  of  those 
calculated  from  the  traditional approach  using  uptake  and  effective half-life. 
However,  a  number  of  technical  problems  must  be  resolved before  the method 
can be  widely applied.  Some  of  these are relatively simple  to  cope with  and 
concern fading  of  the  signal  in  thermoluminescent discs  and  correction for 
the residual activity after  the discs  are  removed  (146,t34).  Others  are more 
practical in character  and  are principally assocfated with finding  a  suitable 
and  acceptable means  of  securing  the discs  to  a  subjec~~neck surface for 
a  period  of  several weeks. 
The  second  direct method  of  determining  cumulated activity is based  on 
continuous  infusion of  a  constant activity per unit time  instead  of  the 
single bolus  normally  injected.  The  method  is based  on  a  principle which 
may  be  stated as  follows  (~~2,153). 
"The  activity remaining in any  organ,  or the whole  body,  after a  period 
of continuous infusion of constant activity per unit time,  is equal  to  the -100 
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Fig.  13  :  Illustration of  a  method  of calibrating a  single  thermolumi-
nescent  disc measurement  of  cumulated activity "A".  A second  set of 
discs  "B"  is positioned for  a  24  hour  period during which  the activity 
in the  gland,  Q)lCi,  is determined with an external probe. -89-
mean  activity that would have  been present over  the  entire period of infusion 
if all the activity were  administered as  a  single bolus at the  commencement 
of the  infusion period" 
The  principle may  not  be  intuitively obvious  though mathematically it is very 
easy  to  prove  (  152). Furthermore,  it has  been validated  in practice using  67Ga 
in rats  (153  .) • 
The  principle  is  illustrated  in  Fig.~.  The  left panel  summarises  data 
on  the  loss  of  a  13.5 rei single bolus  of activity from  experimental  animals 
over  a  13.5  day  (324  hr)  period.  From  the  elimation  curve  the mean  activity 
present  during  the period,  3.1 rei,  can be  calculated.  If  on  the  other  hand 
the  13.5 yei is administered  at  a  uniform rate of  lf~day,  the right panel 
illustrates  that  the activity in  the  animals  builds  up  until at  13.5 days 
their final  activity is  3.1 rei.  This  is equal  to  the mean  activity present  , 
after  the  single bolus,  and  allows  the  cumulated  activity be  calculated  as 
it is  simply equal  to  the mean  activity multiplied  by  the  total  time  period 
involved.  In practice  continuous  infusion is  not  necessary  and  a  semicontinuous 
injection regime  gives  reasonable results although  small  errors  are  introduced 
These  can  be  minimized  if  the  injections are  sufficiently frequent  toward  the 
end  of  the  infusion period  (152,153). 
The  above  methods  provide  a  direct  approach  to measuring  cumulated 
activity.  Both  methods  are  quite  independent  of  the  shape  of  the  activity 
time  curve  and  consequently do  not  require  assumptions  about  the most 
appropriate way  to fit it.  As  a  result  they  are also uninfluenced  by  the 
problems  associated with  the  uptake  phase  of  activity-time curves.  Both 
methods  require  only  a  single measurement  to  be  made,  although ancillary 
calibrations may  be  necessary also(l54)In practice this represents  a  substantial 
reduction  in  the  amount  of  work  involved  in,  for  example,  an.effective half 
life determination.  In human  investigations  the  methods  would  reduce 
laboratory attendances  and  with experimental  animals  they  would  greatly 
reduce  the  numbers  necessary for  a  particular ·investigation.  The  second  method 1
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also has  considerable potential  in microdosimetry  (152).  While  neither 
method  is widely  used  yet,  their  advantages  are  such  that  they  should  in 
their present  form,  or after adaptation for  use  with  concepts  such as 
residence  time,  become  useful  tools  in dosimetric  investigations  of  the 
tpyroid.  It is also evident  that  the  above  concepts  and  methods  could  be 
profitably employed  in physiological  studies. -92-
MICRODOSIMETRIC  CONSIDERATIONS  IN  THE  THYROID. 
In  the discussion  on  physical aspects  of  dosimetry  in II, it 
was  assumed  that activity was  uniformly distributed  through  the  thyroid  and 
that it was  sufficiently large  to  absorb  almost all  the  p radiation emitted. 
It is evident  that if either  of  these  assumptions  is untrue dose  !nhomogeneities 
will arise  in  the  gland.  These arise for  a  number  of  reasons.  For  example 
if  the  range  of  the  emitted  electrons  in tissue  is sufficiently  long  some 
of  them will  escape  through  the  surface  of  the  gland,  thereby,  reducing  the 
surface dose  and  as  a  consequence  the mean  gland  dose.  Alternatively electrons 
with very  short ranges  may  not  be  able  to pass  from  one  follicle  to  the 
next,  or  even  across  a  cell.  Hence  another  form  of  dose  inhomogeneity 
arises.  Finally  iodine kinetics may  vary  from  one  area  of  the gland  to 
another  or  from  follicle  to follicle and  thereby  give rise  to  a  further  dose 
variation  through  the  gland. 
The  microdosimetric  problems  raised  above  have,  with  few  exceptions,  not 
yet been  thoroughly  investigated  (155-157).  However,  sufficient data 
exist  to  gain a  partial insight  into  them,  at  three  levels.  First at  the 
macroscopic  level,  the  loss  of  energy  from  an entire gland,  or  nodule, 
may  be  studied  as  a  function  of  its size.  Second  at  the  level of  an 
individual follicle  the  concentration of  iodide  and  its kinetics  give  a  useful 
insight  into dose distribution.  Finally at  the  level  of  the  individual 
11  d .  f  d  d"  "b  .  f  .  125  .  ce  ,  some  stu  1es  o  ose  1str1 ut1on  or  nucl1des  such  as  I  ex1st  (155-
157)  .. 
A.  Influence  of Mass. 
The  problem of variation of  absorbed  dose with mass  in small  organs  is 
a  difficult  one  which  has  not yet been fully resolved  (113).  Studies  of  the 
dose distribution around  point  sources  of  f  particles are available  and  can 
be  used  to  obtain approximate  solutions  in individual  investigations  ( 109,158). 
In  thyroid  studies  the masses  of  interest range  from  about  100  g  for  a  large -93-
hunan  gland  to  about  1  mg  for  a  mouse  thyroid  or  small  deposit of.thyroid 
carcinoma.  Between  these  extremes  lie  the rat  thyroid,  the  foetal  and 
juvenile human  thyroid,  nodules  in the  adult gland,  well  formed  metastases 
of  thyroid  carcinoma  and  the  normal  human  adult gland. 
Fig.  15  illustr~tes the proportion of  the f  dose  from  131I  that  is 
absorbed  in structures  of  various  sizes.  To  present  the data  in this  form 
it was  assumed  that  the  thyroid  consisted  of  two  spheres.  The  data are drawn 
from  three  sources  that coincide for  glands  larger  than  about  1  g,  but 
diverge  for  smaller  organs  (103,158,159).  The  figure  indicates  that  about  93 
per  cent  of  the  expected  dose will  be  received  in an  infant's  thyroid,  about 
80  per  cent  in  the rat  thyroid  and  50-70  per  cent  in  the mouse  gland.  These 
reductions  are relevant  to radioiodine  treatment  of  thyroid  carcinoma,  which 
presumably  is  intended  to  be  a  syste~ic  form  of  therapy.  Thus  while it 
may  be  easy  to achieve  a  lethal  tumour  dose  in a  10  to  20  g  mass  from  150-Ci 
of  administered activity,  it is much  more  difficult to do  so  in small 
metastases  of  0.1  to  1  mm  radius.  Consequently  there are  sound  dosimetric 
reasons  for  using  such  large doses. 
Fig.  16  illustrates a  more  detailed  experimental  study,  by  Walinder,  of 
the  dose distribution from  131I  across  the mouse  thyroid  (160).  It generally 
supports  the  calculated results  in Fig.  15.  However,  it also illustrates  the 
severe  dose  inhomogeneity  across  the  gland  ranging  from  over  80  per  cent  of 
the  expected  dose  at  the  centre  to  less  than  40  per cent at  the  edges.  While 
the  dose distribution in  large  glands will be  much  more  uniform  there will 
still be  a  peripheral ring  in which  the  dose  is reduced  to  about half  that 
at  the  centre due  to  e~aping p particles  (113).  The  width  of  this ring 
depends  on  the  p energy.  131  .  .  5  For  I  1t 1s  the  order  of 0.  mm  (158). 
The  above  discussion has  concentrated  on variation in f -dose with mass. 
The  photon dose  also varies  but  in a  more  complex  fashion.  For  example  it 
has  been  suggested  that with photons  of  energy greater  than  100  keV  the 
variation is with  m  - 2/3  (113).  In many  practical cases  however  photons M
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Fig.  16  :  The  dose  distribution from  131
1  across  a  lobe of mouse  thyroid. 
On  the  abscissa  the  100  percent value  corresponds  to  total absorption of 
the ~  energy.  Adapted  from  an original by Walinder,  (  160 ) • -96-
d  1  .  hl31  contribute only  a  small  portion of  the  total  ose.  For  examp  e  w1t  I 
it is less  than  10-per  cent  in  the adult human  thyroid.  Hence  variations 
in this  contribution will have  a  relatively small  effect  on  the  overall dose. 
In very  small  glands  such  as  those  in the rat or  the mouse  some  authors 
h  d  f  131  .  1  (  )  neglect  t  e  photon  ose  rom  I  ent1re  y  99  • 
B.  Interfollicular  Inhomogeneity. 
Approximately  90  per  cent  of  the  iodine  in the  thyroid  is concentrated 
in  the  follicular  colloid  (6 ). Therefore,  when  the  gland  contains  radioiodine 
most  of  the  radiation emergesfrom  the  colloid areas.  As  a  result dose 
inhomogeneity will arise if  the  range  of  the r  particles is on  average  less 
than  the  interfollicular  separation.  Another  source  of  dose  inhomogeneity 
lies  in  the  observation that  the  amount  of  radioiodine  taken  up  by  each 
follicle does  not  appear  to  be  constant. f  In early days  after administering 
125r  to rats  the  follicular activity and  size  appea~  to  be  inversely 
related  in studies  performed  by  Lowenstein  and  Wollman  (161-163).  On  the 
other  hand  as  illustrated in Fig.  17,  Riviere  and  co-workers  noted  that 
follicular activity and  surface  area were directly related  (164).  This  implies 
that  the  specific activity per unit volume  will be  less  in large follicles 
than  in smaller  ones,  and  therefore  goes  some  way  toward  explaining  the 
the  results  of  Lowenstein and  co-workers(6,161,163). 
The  above  picture does  not  remain  constant,  and  with  the  passage  of  time 
there  is  some  evidence  to  suggest, _as  illustrated in Fig.l7,  that activity is 
eliminated more  rapidly  from  small  follicles  than  from  large  ones  (161-165). 
Because  of  this,attempts  to  base  estimates  of  dose  inhomogeneity  on  the 
distribution of  activity over  particular follicles  or  areas  at  a  single  time 
are misleading.  The  dose  in a  given area  depends  on  the  integral  of  activity 
over  volume  and  time.  From  the  above  it is evident  that  in  the  thyroid  the 
higher  activity per  unit volume  in small follicles  is  in part  compensated  for 
by  its more  rapid  turnover.  Results  obtained  using  the  second method  of 
estimating  cumulated activity outlined  in III,  C  also  support  this w 
_J 
u 
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_J 
_J 
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LL 
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.......... 
> 
1-f  r- u 
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1-f 
lD 
N  ....... 
10 
-97-
• 
1  2 
FOLLICLE  SURFACE  AREA  (mm 2 ) 
0~----~----~----~----~----~----~ 
0  10  20  30 
TIME  (days) 
Fig.  17  :  Top  :  125r  activity in human  thyroid follicles as  a  function of  their 
surface area.  Redrawn  from  an original by Riviere et al.,  (164 )  Bot tom  : 
uptake  and  loss of activity from  large and  small follicles  in the rat thyroid. 
Redrawn  and  adapted  from  an original by Berjis et al.,  (I 65 ) • -98-
view  ( 152).  These  considerations  apply  to  normal  glands  or  those with diffuse 
disease.  However,  when function  is not  uniformly distributed  as  in single or 
multinodular goitres it is obvious  that larger dose variations will arise. 
C.  Inhomogeneities  at  the Cellular Level. 
Even  if all  the  emitted  p radiation is  totally absorbed  in  the  thyroid 
and  the  activity is uniformly distributed  through  the  colloid,dose  inhomogeneities 
can arise because  the  range  of  some  electron emissions  is such  that  they will 
not  completely  traverse  a  follicular cell  (155-157).  If this  is so,the 
portion of  the  epithelial cell  close  to  the  colloid-cell interface will 
receive  a  larger  dose  than  the  basal portion and  the nucleus.  An  extensive 
study  of  the dosimetry of  125I  in this  regard  has  been performed.  Fig.  18 
illustrates  the  calculated electron dose distribution across  colloid,  a 
follicular  cell and  stroma.  The  cell in this  figure,  which  has  been adapted 
from  the  work  of Gillespie et al.,  is representative of  a  hyperthyroid  rather 
than  a  normal  gland  (157).  Table  15  presents  the mean  gland  dose  and  the  dose 
to  the  nuclei  of  follicular  cells calculated for  all 125I  emissions  on  the 
basis  of  a  normal  human  thyroid model  used  by  Fiege  and  co-workers  (155,156). 
The  calculations  are  in all cases  dependent  on  the  assumptions  made  about 
follicle size,  cell size and  the  fraction of  the  gland  occupied  by  colloid  1n 
the model  thyroid  used.  Al~ering these  assumptions will alter  the  computed 
dose values.  For  example  increasing  the  colloid fraction will  increase  the 
portion  of  energy  absorbed  in it and  thereby  reduce  the  dose  to  the  cell 
nucleus  (6,155,157 ).  Calculations  have  been performed  for  a  number  of  normal 
and  hyperthyroid  human  glands  and  for  a  normal  rat  thyroid  (99  ,155,157). 
The  125I  studies described  above  are  in many  respects  classical.  Little 
detail  of  a  similar character  is available for  other nuclides with  the  possible 
exception of  129I  for  which  some  results are given  in Table  15  (156).  There 
is  scope  for  extending  similar  investigations  to other nuclides  and  for  a 
detailed  study  of  the  relevant structural aspects  of  the  thyroid  in healthy 
a  d  d 1 .  d  t  t  ( f  th  1 .  .  1  f  .  12 5 I  1  3 I I  ·  h  n  sease  s  a  es  or  e  c  1n1ca  aspect  o  us1ng  or  1n  t  erapy 
see II,  II,A  and  V). 100~---=-
(f) 
ww 
>(f) 
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~ 050 
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Fig.  18  :  Dose  distribution from  125r  across  follicular colloid,  elongated 
follicular cell and  stroma.  Redrawn  and  adapted  from  an original by 
Gillepsie et al.,  (157). , 
.·. 
- 100-
NUCLIDE  DOSE  RATE  (m  rad/h) 
Cell Nucleus  Mean 
1251  46.8  73.5 
1291  114.2  147.3 
TABLE  15:  Nuclear  and  Mean  Gland  dose  rates 
from  1  ~Ci/g of  125r  or  129r  in a 
normal  adult  human  thyroid. V.  DOSES  TO  THE  THYROID  IN  PRACTICE 
The  methods  discussed  in  II  allow the dose  to  the  thyroid  to be 
calculated,subject  to  the  qualifications raised  in  IV.  In 
many  circumstances  it is not  possible.or  even desirable,  to  perform all  the 
measurements  detailed  in  III  in each  individual  case,  as  all  that  1s 
required  is  an approximate  dose  estimate.  To  this end,lists  of  doses  to  the 
gland  have  been prepared  based  on  the  assumption  that its mass  is  19.6 g  and 
using  a  particular model  for  iodide kinetics  (113,11~,120).  From  these results 
data  on  thyroid dose  and  whole broy dose  for  a  group  of  nuclides  of  iodine  and 
technetium are  summarized  in Table  18.  The  nuclides  were  assumed  to  be 
administered  as  Sodium  Iodide or  Sodium  Pertechnetate  (119,120). 
F  h  bl  .  .  .d  h  h  d  .  f  129I  .  h  1  rom  t  e  ta  e  1t 1s  ev1  ent  t  at  t  e  ose  per  mC1  o  1s  t  e  argest. 
This  is  in part due  to  its exceedingly  long  physical half  life.  This  is 
closely followed  by  126I  and  131I  and  by  124I  and  125I.  A reduction of  a 
133  factor  of  5  to  10  takes  place for  doses  from  I  d  130I  an  .  A  further 
f  f  1  .  .  .d  .  h  d  f  123  d  132I  d  actor  o  0  reduct1on  1s  ev1  ent  1n  t  e  oses  rom  I  an  ,  accounte 
for,in part at least,by their short physical half  lives.  Finally  the  dose 
from 
99Tcm~ afactor  of  100  down  on  that  from  123I  or  132I.  From  a  radiation 
protection point of  view,the ratio of  thyroid  to whole  body  dose  is of 
interest.  It is clear  that  this  is most  fav~urablefor the  nuclides  giving  the 
highest  thyroid  doses,  and  is  the  order  of  1000:1  in all but  the  short  lived 
nuclides  (16~.  It is also  of  interest that  there  is little difference  in  the 
whole  body  dose  per mCi  from  99Tcm,  123I  and  132I. 
In  individual  cases departures  from  these  estimates may  be  dramatic  due 
to variations  in  iodine kinetics  and  gland mass.  For  example  the variation 
in  the  dose  to  the  thyroid  in a  group  of  patients  receiving  identical 
therapeutic activities  of  131r  has  been  evaluated  and  is greater  than  one 
order  of  magnitude  (14~.  Such  variations  are particularly likely  to  occur 
to  those whose  glands  are diseased,  and  consequently  should  be  borne  in mind 
when  radioiodine  therapy  is  being prescribed. - 102-
Therapeutic medical  procedures  requiring radionuclide  irradiation of  the 
.  f.  d  131I  1  h  h  125I  .  thyro~d are  for  the greater part  con  ~ne  to  ,  a  t  oug  ~s 
occasionally used  (90>91,92,105,169).The  largest activities,  of  the  order 
of  150  mCi,  are admini  stered during  treatment  of  thyroid  carcinoma  and  its 
metastases.  The  data  in Table  16  is of  little value  in estimating  the 
absorbed  dose  from  this procedure,as  the  size of  the mass  being  treated  is 
highly variable  (!II, IV,A),  and  both uptake  and  effective half  life can be 
in  the region  of  an  order  of magnitude  lower  than normal  (6,91,105  ). The 
latter properties may  sometimes  be  favorably  improved  by medical management 
(91, 105).  As  indicated  in Table  17  the  absorbed  doses  achieved  can range  from 
about  1,000  to  about  100,000 rads.  The  limitation on  administered activity 
arises mainly  from  considerations  of  the dose  to  the whole  body  and,  in 
cases with diffuse pulmonary metastases,  the  lungs. 
In  therapy of  hyperthyroidism high activities  of  the  order  of  10  mCi 
were  traditionally administered  ( 192).  In recent  years,however,much  lower 
activities  in the  range  2-4  mCi  are not uncommon  ( 170-172),  although high 
dose  therapy still persists.  To  obtain a  reasonable estimate of  the  absorbed dose 
in rads,  the activity retained  in  the gland  in rci/g and  the  cumulated  activity 
must  be  evaluated  as  outlined  in  II and III. In  the  absence  of  such 
measurements  quoted  doses  represent,at best,mean values  that  in  individual 
cases  can  be  highly misleading  ( 149).  Subject  to  this qualification, 
administered activities  in  the  10  mCi  range  are associated with gland  doses 
of  10,000-20,000 rads,  and  those  in  the  2-4 mCi  range  are associated with doses 
of  2,000- 10,000  rads  (Table  17). 
Diagnostic  investigations  of  the  thyroid,  such as  uptake  tests or  scans 
.  131  .  .  .  d.  .  .  . 
us~ng  I  have  trad~t~onally had  h~gh ra  ~at~on doses  assoc~ated w~th them. 
For  example it was  not  uncommon  to  use  activities up  to 30  rei for  uptake 
estimates  and  up  to  200fCi  for  scans  (  175). The  doses  associated with  these 
activities would  be  in  the  range  40  rads  and  250  rads  respectively  (173- 75). 
These  doses  are  unacceptably high given  the availability of  more  sensitive A
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 PROCEDURE 
Thyroid  Carcinoma 
Therapy 
Hyperthyroidism 
Therapy 
Thyroid  Scan 
Thyroid Uptake 
- 104-
ACTIVITY  ADMINISTERED 
AND  NUCLIDE 
80  - 150  mCi  of  131I 
1-10 mCi  of  131I 
5-50 mCi  of  1251 
2-3  mCi  of  99  Tern 
50-100 rei of  131I 
50-.100 rei of  123I 
5-50 rei of  131I, 
5-50 rei of  123I 
*  .  1  d"  "b  .  f  124  1nc  u  1ng  contr1  ut1ons  rom  I. 
ABSORBED  DOSE  RANGE 
3  5  10  to  10  rads 
1,000  - 15,000 rads 
1,000  - 30,000  rads 
0.2 - 2.0  rads 
30  - 300  rads 
3  - 50  rads* 
3  - 150  rads 
*  0.3 - 25  rads 
TABLE  17:  Typical  Dose  Ranges  for  Medical  Procedures.  Extreme values  are 
not  accounted  for. - 105-
equipment  and  alternative nuclides  ( 173,174).  Consequently,for many  purposes 
these  tests  in their  traditional  forms  can be  regarded  as  hazardous  and 
obsolete  ( 174).  With modern  equipment,uptake  tests may  be  performed  using 
131:·  as  little as  a  few  rei of  I,  which  substantially reduces  the  gland dose. 
·  b  h"  db  ·  .  123  "f  ·  ·  "1  a1  d  A further  reduct1on may  e  ac  1eve  y  us1ng  I  1  1t 1s  ava1  ao  e,  an 
its short half  life does  not  interfere with  the  purpose  of  the  test being 
performed.  In making  dose  estimates  for  123I,it is well  to  re~ember that it 
.  11  .  d  .  h  124  1s  usua  y  contam1nate  w1t  I.  With  commercially available material,this 
will  approximately double  the  thyroid  dose,  and  may  give rise to  some 
h  ·  1  bl  (  )  · d  ·  ·  ·  99  m  · d  11  tee  n1ca  pro  ems  173  •  Thyro1  1mag1ng  us1ng  Tc  prov1  es  exce  ent scans 
with a  greatly  reduced  thyroid dose  although with  the activities commonly 
131  used  the whole  body  dose  is  comparable with  that  from  a  I  scan.  As  99Tcm 
pertechnetate' is not  a  perfect analogue  for  iodine,  special  cases  exist 
where  an  iodine  scan will still be  required  (151,17S).noses  associated with 
typical diagnostic  procedures  are  listed in Table  17. 
Apart  from  the  above  situations,the  thyroid may  also be  irradiated  by 
being  included  in direct  or  scattered radiological  beams  from both  therapeutic 
and  diagnostic  sources.  The  doses  received vary  in their  size  and  consequences 
(6, 72, 17 6-178).  The  gland  is also  sometimes  irradiated  to quite high 
dose  levels,  during radionuclide  investigations primarily aimed  at other 
organs.  These  doses  may  be  minimized  by  using  effective  thyroid  blocking  or 
discharge  procedures  (89, 179). 
AccidentalJor  unintentional  irradiation of  the  thyroid  is most  likely to 
occur  through  in~stion of  nuclides  of  iodine  or  other materials with  similar 
dosimetric  properties.  In practice  such  incidents  are most  likely  to  occur 
in those  handling  such  nuclides  for  medical  and/or  biological applications, 
to  persons  working  in  the  nuclear  industry,  or  following  uncontrolled  release 
of  fission products.  The  most  widespread  procedures  that presently give rise 
.  .  f  .  a  .  d.  .  .  .  d  .  h  125  to  a  ser1ous  r1sk  o  1nJest1ng ra  1010d1ne  are  those  assoc1ate  w1t  I - 106-
protein iodination and  those related  to dispensing  and  administering  therapeutic 
131  doses  of  I.  In many  institution~work of  this nature  is performed  on  a 
regular basis  up  to several  times  per month.  Table  18  lists approximate 
thyroid  doses  that would  result from  ingesting  small  amounts  of  activity 
during  such procedures.  The  amounts  that would  have  to be  ingested  to reach 
the maximum  permissable doses  allowed by various  regulatory agencies  are also 
listed  (168,180-182).  From  the  table it is evident  that  there  should  be 
little practical difficulty in keeping  the  annual  dose  below 5  rads.  Higher 
dose  limits require  sustained activities in the  gland  that  approach  those 
used  for  diagnostic  purposes  (173).  One  of  the most  useful devices  for 
reducing  ingestion is  a  well  designed  fume  cupboard,  which  as  illustrated in 
Fig.  19  is very effective in this regard. 
In  the  aftermath of  nuclear  explosions  or  other  incidents  involving 
release of  fission products,radionuclide& of  iodine may  be  relatively 
abundant.  Since  the  circumstances  of  each  incident are different no,general 
guidelines  on  the  thyroid dose  can be  presented.  However  primary data  on 
particular events  are available  and  of  interest  (87).  With regard 
to  the release of  small  amounts  of fission products  into  the  environrnen~ 
.  1  .  b  .d  129  part1cu ar attent1on must  e  pa1  to  I.  Because  of  its exceedingly  long 
physical half  life,once it is introduced  into the  environment it is difficult 
to eliminate.  Consequently,its  concentration in  stable iodine must  be 
monitored  and  kept  low  ( 156).  Its dosimetry  in  the  thyroid also needs  further 
investigation,particularly in view of  the  existence  of  long  term stagnant 
pools  of  iodine even in normal  glands  (163,167). 
The  figures  presented  above  are  intended  to provide  approximate 
rather  than  accurate  est~ates of  the  dose  in individual cases.  They 
apply only  to  human  thyroids.  Dose  estimates  for  experimental  animals  would 
be  quite different due  to  the gland mass  considerations  outlined  in  IV,A 
and  due  to  substantial differences  in iodine kinetics. - 107-
Radionuclide  Dose  per year  (rad)  Typical  Incident(s)  leading  to dose 
131I  1.5  Ingestion once  of ,.., 1  lJCi 
5.0  Ingestion  20  times  of  ~V0.15 l!Ci 
30.0  Ingestion  20  times  of  'V 1  l!Ci 
50.0  Ingestion 20  times  of  rv 1.5 lJCi 
150.0  Ingestion once  per week  of "'  1 • 5  llCi 
125I  1.0  Ingestion once  of ""'1  llC i 
5.0  Ingestion  20  times  of NO. 25  l!Ci 
30.0  Ingestion  20  times  of""l.5 llCi 
50.0  Ingestion 20  times  of  ~Y2.  5  l!Ci 
150.0  Ingestion once  per weel of .v2 . 5  llCi 
TABLE  18:  Typical  incidents  leading  to annual  thyroid radiation doses 
in  the  range  1.0-150  rads 100 
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50  100  150 
SPEED  (m/min  at  30cm  opening) 
.  125  .  .  .  •  Fig.  19  The  relat1ve  I  act1v1ty present  1n  the  thyro1d  of workers  per-
forrn~ng protein  iodinations  as  a  function  the air speed  in a  fume  cupboard. 
Redrawn  and  adapted  from  an original  by  Birchall,  (86). - 109-
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SECTION  IV 
CONTROL  OF  PHYSIOLOGICAL  FUNCTION  AND  GROWTH 
IN  THE  UNIRL~IATED THYROID 
I.  Cellular Physiology of  the Thyroid Follicular Cell 
II.  Control  of  Thyroid 11etabolism 
A.  The  Action of  TSH 
B.  Intracellular Biochemical  Regulatory Mechanisms 
1)  The  Cyclic  AMP  System 
2)  Regulation by  Iodide of Cyclic  AMP  System 
3)  Role  of  Calcium 
4)  The  Cyclic  GHP  System 
C.  Other Possible Physiological  Controls  Besides  Thyrotropin 
D.  Control  of Human  Thyroid 
E.  Control  of Thyroid  as it affects  Iodine Metabolism 
III.  Control  of Thyroid  Growth 
IV.  Thyroid  Cell Kinetics 
A.  The  Normal  Thyroid  at Rest 
B.  The  Stimulation of Cell Proliferation - 112-
The  thyroid has  two  main  endocrine  functions  :  secretion of 
thyroid hormone_s, thyroxin  (T4)  and  triiodothyronine  (T3),  which  is 
carried out by  the  follicular cells and  the  secretion of calcitonin 
by  the  C cells.  Thyroid hormones  are first synthesized as  a  prohormone, 
thyroglobulin  (Tg),  a  large glycoprotein.  This  prohormone  is released 
with  thyroid  hormone  from  the  thyroid.  In the  present section,  we 
shall  review recent  developments  on  the  function  and  growth of  the 
thyroid  and  on  their control. - 113-
I.  CELLULAR  PHYSIOLOGY  OF  THE  THYROID  FOLLICULAR  CELL 
The  role of  the  thyroid follicular cell is to  trap  iodide  and  to 
use it for  the synthesis  of  the  thyroid hormones.  This metabolism proceeds 
by  several well  defined steps  (Fig.  1)  (221-230). 
- the  trapping of  iodide by  active transport at  the base  of  the 
cell against  an electrical gradient and  its transport  in the follicular 
lumen  where  it is concentrated  (226,227). 
- the oxidation of  iodide by  a  peroxidase,  presumably at the  interface 
of  the cell ant  the  lumen  (i.e.  on  the microvilli),  into  an oxidized 
form of  iodine and  its incorporation in the  tyrosyl  groups  of  thyroglo-
bulin,  forming  mono  (MIT)  and  diiodotyrosine  (DIT)  residues  in the protein. 
The  H2o2  used  by  the peroxidase is supplied by an ill defined H2o2 
generating  system which uses  NADPH+H+  as  coenzyme  (221,223,229). 
- the oxidative coupling in the  thyroglobulin molecule  of already 
formed  iodotyrosines  into  iodothyronines  T4  and  T
3 
and  very  small  amounts 
of  rT3•  This  oxidation seems  to  be  catalyzed by  the  same  peroxidase 
(rT3  is 3-3'-5'  triiodothyronine)  (221,223,229). 
- by diffusion and,  in some  species,  by  the  stirring of ciliae,  thyro-
globulin slowly mixes  in the colloid;  iodination and  oxidative coupling 
take place when  the molecule  encounters  the apex of  the cells;  the 
rapidity of  this process  depends  on  the  level  of activity of  the  gland  (231). 
- secretion seems  to require  the  internalization of  thyroglobulin 
in colloid droplets  for  its digestion by  lysosomal  enzymes.  Ingestion 
may  be carried out by  two  processes  :  micropinocytosis  (232)  or pseudopod 
engulfment  and macropinocytosis i£.phagocytosis  (222,  233  ).  The  latter Fig.  1 
- 114-
EXTRACELLULAR  CELL 
THYROGLOBULIN  SYNTHESIS 
21~~~~~HYP~1s-~I~~~ME~! 
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mechanism accounts  for  thyroid hormone  secretion after acute  TSH 
stimulation,  but  the role of  the  two  processes  in basal  secretion is 
still debated. 
- digestion of  thyroglobulin is carried out  in secondary  lysosomes 
first by  reduction of  SS  bonds  by glutathione  (GSH)  and  then by  proteolysis 
(234). 
- it is assumed  that after proteolysis  the  iodothyronines diffuse 
from  the  secondary  lysosomes  in the cell and  from  the  cell to  the extra-
cellular space  (222,  224)  but an exocytotic process  is not  excluded. 
+ 
- iodotyrosines  are deiodinated  in the cell by  a  NADPH+H  dependent 
deiodinase  and  this  iodide mixes with newly  entered  iodide.  Released 
aminoacids  and  carbohydrates  presumably mix with  the cellular pools 
while  the  lysosomes  recycle  (  222  ).  There  is evidence  that  some 
tyroxine  is deiodinated  to  T3  and  rT3  in the  follicular cell, more  so 
after TSH  stimulation,  which  accounts  for  the  fact  that T
3 
and  rT3  secretion 
are more  important  than their relative concentration in Tg  would  allow 
(235,236). 
The  metabolism of  iodine  in the  thyroid  is geared  for efficient 
utilization of  a  scarce  and  highly discontinuous  supply of  iodide  to  the 
organism  :  the  trapping of  iodide  can achieve  a  gradient of more  than 
100  to  1;  I  is concentrated  in the follicular  lumen  where  iodination 
takes  place.  For physiological  concentrations,  all  the  iodide  taken up 
is  immediately oxidized  and  bound  to  Tg;  the Tg  peroxidase  system is 
able  to  synthesize  iodothyronines with very  few  iodine  atoms  per Tg 
molecule  (  237  ).  Thus  the capacity of  the  thyroid  to  synthesize  thyroid - 116-
hormone  is mostly  in excess  of  the regular  requirements  for  these 
hormones,allowing it to  use  efficiently even transient supplies  of  iodine. 
The  high  storage capacity of  Tg  for  iodine and  of  the  colloid  lumen 
for  Tg  allows  a  normal  thyroid  to  sustain steady secretion of  iodothyro-
nine  for  a  long  time  after a  block of  synthesis. 
II.  CONTROL  OF  THYROID  METABOLISM 
Until very  recently,  it was  accepted  that  the activity and  growth 
of  thyroid tissue was  controlled  by  one  factor  :  the  TSH  plasma  level. 
In such  a  scheme  the  gland  responds  only  to  a  positive signal,  TSH,  which 
itself is controlled by  a  negative  feedback at the  level of hypophysis. 
As  the  only control  is posttive,the  system may  be  called unidirectional  (238). 
However,  it was  later shown  that  the  iodine  supply exerts  a  negative 
control  on  the  gland.  Moreover,  several  other factors  have  been 
shown  to  influence  thyroid metabolism in vivo  or in vitro  :  the  thyroid 
hormones  themselves,  catecholamines  and  cholinergic agents.  The  physiolo-
gical  relevance  of  these  factors  remains  to  be  demonstrated.  TSH,  the main 
regulatory agent,  is secreted discontinuously by  the hypophysis;  its 
concentration exhibiting a  nocturnal rise  (239).  It does  not  appear  to 
be  catabolized by  its target organ  (240). 
A.  The  Action of TSH 
TSH  stimulates all facets  of  thyroid metabolism.  On  the  basis of 
kinetics,  two  types  of effects can be  distinguished  :  rapid effects which 
correspond  to  a  functional  activation  (e.g.,  activation of  secretion, 
iodothyronin~ synthesis  and  of general  met~bolic pathways)  (241)  and 
delayed effects which  correspond  to growth  or to an  increased functional 
capacity of  the tissue  (increased syntheses  and  thus  increased volume  of 
cells,  RNA  and  protein contents of cells and  number  of cells)  (241-245). 
' - 117-
The  stimulation of  secretion mainly bears  on  the first step of  this 
process,  i.e., phagocytosis.  In dogs,  pseudopod  formation  takes  place 
within 2  min.  after TSH  addition to  the  incubation medium  of  thyroid slices 
(  246  ),  intracellular accumulation of colloid droplets  follows  (247, 
248);  thyroid  hormone  release is  increased  10  min.  after 
TSH  injection  (248,249).  The  amplitude  and  the  length of  this effect 
increase with  the  dosage  of hormone.  The  kinetics of  TSH  action on  iodide 
transport  is clearly biphasic  :  it is depressed  early  (up  to  I  to  2  hours) 
and  greatly enhanced  thereafter  (  249,  250  ).  The  former  effect is 
due  to  an  acute  increase  in iodide efflux  rate  from  the  follicular cells 
presumably reflecting a  general  increase  in membrane  permeability  (251). 
The  latter effect is caused by an enhanced unidirectional  clearance  of 
iodide  by  the  ce.lls  presumably reflecting the  induction of  iodide carriers 
(  252  ).  The  activation of  iodide binding  to proteins  and  of  iodothy-
ronine  formation  is also very  rapid.  Two  enzymatic  systems  are  involved 
in this  process  :  the  generation of H2o2  and  the oxidation of  I  by  a 
peroxidase  (221,229,253,254).  As  no  rapid effect of  TSH  on peroxidase activity 
has  been observed  (255)  and  as  H2o2  mimics  the  action of  the  hormone  it is 
probable  that  the  H2o2  generating  system is  the  target of activation  (241,256). 
The  in vivo  stimulation of  thyroid  blood  flow is an early or  a 
delayed effect depending  on  the  species  (248,257,258). 
In general all  the  rapid effects of  TSH  are not  inhibited by  protein 
or  RNA  synthesis  inhibitors while  the  delayed  effects which have  been 
studied  in this regard  are  inhibited by  such agents  (  252,  259,  260  ). 
In the latter case,  it is therefore believed that  the hormone  acts at  the 
transcription  level  (252).  Chronic  stimulation causes both types  of 
effects,  i.e., activation and hyperplasia.  The  hyperplasia is characterized - 118-
by  an  increase  in the  number  and  in the volume  of  thyroid cells and  an 
increase  in the  concentration of  ribosomes  (241,  243,  245). 
The  effects of  any  hormone  may  be  distinguished,  from  a  physiological point 
of  v1ew,  by at least  two  criteria  :  the  delay of  the  action and  the nature 
of  the  action  (Tablet).  The  delays vary  from  seconds  to  days.  The  effect 
may  be  to  stimulate or  inhibit an existing function,  or  to  induce  a  new 
function  (i.e.,  to  differentiate)  in the  target cell.  The  induction of  a 
new  function obviously  implies  the  formation of  selective units,  these units 
being enzymes,  organelles,  etc.  The  stimulation of  a  function may  imply  an 
increase  in the  number  of units  (growth)  or  an activation of  existing units. 
The  primary biochemical  mechanisms  involved  in these actions may  be very 
simple  such  as  changes  of  permeability  (~. to  Ca++)  or  in membrane  transport, 
or  the  formation,  or  the  release of  allosteric effectors  (e.g., cyclic 
nucleotides).  When  new  units are  formed,  the mechanisms  may  operate at the 
translation and/or at the transcription level;  an  induction,  i.e., a  diffe-
rentiating action,  would  presumably  require  an effect at  the  level of  trans-
cription.  A probable point of action of  the  signal  in the cell may  be 
proposed  for  each mechanism  (e.g.,  plasma membrane  for  effect on  permeability, 
nucleus  for  transcriptional events,  etc.).  It is obvious  that an  action 
which requires prior synthesis of  RNA  and  of  protein will  require at least 
an  hour  and  sometimes  days  whereas  an effect  on  the membrane  may  be  quasi 
immediate.  Similarly effects which require  RNA  synthesis will be blocked 
by  inhibitors of  transcription  (e.g.,  actinomycin)  and  translation  (e.g. 
puromycin,  cycloheximide,  etc.).  Thus,from rather  simple  considerations  a 
~seful classification of  hormonal  effects may  be  proposed  (Table 1 ).  Effects 
at one  level could  cause  effects at  the  subsequent  levels,  e.g.,  an 
activation of membrane  transport  could modify  transcription.  If an  action 
at  a  given level  causes  one  of  the  preceding  types  of effect,  e.g.,  activation - 119-
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at  the  transcription level causing a  change  in membrane  permeability,  this 
effect acquires  the characteristics of its cause  (e.g.,  delay,  sensitivity 
to  inhibitors,  etc.).  However,  it is conceivable  that  the  signal may  act 
independently at the different  levels.  In the  case of  TSH,  one  can find 
effects at all the  levels.  Whether  they are all secondary  to  a  unique 
primary biochemical  event  (e.g.,  the activation of  adenylate  cyclase)  is 
doubtful. 
A present working model  of  the regulation of  thyroid cell metabolism 
is outlined in Fig. 2  • 
B.  Intracellular Biochemical  Regulatory Hechanisms. 
Three  types  of regulatory circuits have  been demonstrated 
++  a)  the  cAMP  system;  b)  the  cGMP-Ca  system;  c)  the  iodide  feedback  loop  (XI). 
The  cAMP  and  cG}W  systems  are  located  in follicular cells  (261)  as  is 
presumably  the  iodide  loop.  In  such  a  scheme  continuous  lines represent 
chemical  reactions while  interrupted lines  represent negative (-) or positive 
(+)  controls,  i.e.,  inhibitions or activations.  As  can be  seen,  TSH  acts 
on  the  thyroid cell mainly  through activation of adenylate cyclase;  cyclic 
3'5'-AMP  formed  by  adenylate  cyclase is degraded  by  specific phosphodiesterases; 
it acts  on  the cell metabolism  through activation of  cAMP  dependent  protein 
kinases;  phosphorylation of cellular proteins  by  the  enzymes  activate or 
inactivate  these proteins  thus eliciting the hormonal  effects.  This  scheme 
is  the. direct application to  TSH  and  thyroid of  the general Sutherland concept 
of  hormonal  action  (  262,  263  ).  In  some  species,  adrenergic  agents, 
by  a  /.3  type  of effect,  also activate  thyroid adenylate cyclase.  The  cyclic 
3'5'-JUW  system is negatively controlled by  the  iodide  supply of  the gland, 
this ·control being exerted by  a  postulated oxidized derivative XI.  This 
action probably bears  on adenylate  cyclase.  As  in other tissues,  intracyto-- 121  -
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plasmic  Ca++  also plays  a  regulatory role.  Its level presumably  depends  from 
the balance between passive influx through  the plasma membrane,  or  from 
intracellular stores  (e.g.,  mitochondria),  and  the active outflow by  the 
plasma membrane  and  uptake  by  the mitochondria.  This  level is  increased 
by  acetylcholine.  Ca++  mimics  some  effects of  TSH  (e.g.,  it activates protein 
iodination)  but  antagonizes  some  others  (e.g.,  cAMP  accumulation,  secretion). 
++ 
The  level  of  intracellular Ca  regulates  cGMP  accumulation;  but  the role 
of  cQ1P  is not known. 
The  scheme  presented does  not account  for  some  TSH  effects which are 
clearly not  secondary  to adenylate  cyclase activation  (such as  the accelera-
tion of phosphatidylinositol  turnover)  (264,265). 
It is now  well accepted  that most  effects of  TSH  on  the  thyroid are 
secondary  to  the activation of  thyroid adenylate  cyclase by  the  hormone 
( 241'  266  ).  However,  it should be  pointed out  that  the criteria proposed 
by  Sutherland  to validate this hypothesis  (  262  )  have  only been  fully 
satisfied for  dog  thyroids  in vitro and  for  some  effects of TSH,  namely  the 
activation of  secretion and  of  the binding of  iodide  to proteins. 
Whether  cyclic AMP  is the  secondary messenger  of  TSH  growth  promoting 
action is not yet  proved.  Cyclic ·M1P  or its analogues mimic  several  TSH 
activations of biosyntheses  in intact cells in vitro  :  of proteins  synthesis 
(  267,  268  )  of ornithine decarboxylase  synthesis  (269,270),  of precursors  incor-
poration into  RNA  (241,242,244,267)  of  RNA  polymerase  (267),  the  induction of  an 
iodide  trapping capacity in isolated cells  (252),  etc  ••• ,  but  the relation 
of  these  effects to  growth is not proved.  Cyclic  AMP  as well  as  cyclic  GMP 
promotes  thyroid  growth  and  accelerates protein and  RNA  synthesis when  injected 
in vivo  (271,272).  Inhibitors of  phosphodiesterase  such as  the methylxanthines - 123-
potentiate goiter formation  in vivo  (27~.  However,  they may  raise  c~~ 
as well as  cAMP  levels.  Moreover,  it is difficult to exclude absolutely 
indirect effects  (e.g.,  on  TSH  secretion)  in these  in vivo  experiments  (241). 
The  evidence  therefore suggests  that cyclic AMP,  at least partly,  mediates 
the  growth promoting action of  TSH.  However,  this is far  from  proved  and 
this hypothesis  remains  doubtful  for  two  reasons  : 
the failure  to  induce  true growth by cyclic AMP  or  an analogue  in an  in 
vitro intact cell system(274 ).  This negative evidence itself is of 
doubtful value as  the DBcA}W  concentrations used were  much  less potent 
than  the  TSH  concentrations which elicited cell multiplication(241). 
- the prevailing hypothesis  in the cyclic nucleotide field  that cyclic 
AMP  rise  induces differentiation while cyclic  GMP  or/and  Ca++  rise and 
cyclic JUW  fall  cause  growth  (224,238,275). 
That  TSH  and  cyclic AMP  may  induce differentiation is suggested by  the 
fact  that  in thyroid cell culture both induce  the formation of follicle like 
structure and  the  resumption of  iodide uptake  and  binding  to  proteins,  and 
thyroid hormone  synthesis  (276).  Since differentiation of  thyroid  in the 
fetus  in vivo  occurs  in decapitated embryos,  it is not  sure whether  this 
action of  TSH  has  a  role  in vivo  (277). 
The  scarcity of  iodide  in  food  and  its irregular intake are  compensated 
by  a  very efficient iodide  trapping mechanism  in the thyroid,  by  the availa-
bility of excess  thyroglobulin in the follicular lumen  to bind  iodine and 
by  storage of  this  iodine  in the  thyroglobulin.  All  the biochemistry of  the 
thyroid  is geared  to  retain and  make  the most  efficient use of  iodine.  It 
is therefore  to  be  expected  that  regulatory mechanisms  should exist  to shift - 124-
this pattern in case of  excess  iodine  intake.  Indeed,  iodide at high 
concentrations  inhibits its uptake  (278)  and  its binding  to proteins  in thyroid 
(the WOlff-Chaikoff  effect)  and. decreases  secretion and  blood  flow  in activated 
glands  (278,279).  Moreover,  the  iodide  supply in the  di~t modulates  the 
response· of  the  thyroid  to  TSH,and  iodine deficiency induces  thyroid growth 
in hypophysectomized  animals  (  280,281  ). 
Iodide  in vitro inhibits  the TSH  enhancement  of  cAMP  accumulation. 
Several  indirect arguments  have  suggested  a  model  to explain this action. 
Iodide after its trapping by  the follicular cell is oxidized by  thyroid 
peroxidase  and  bound  to  thyroglobulin  :  part of  the oxidized  iodide is trans-
formed  in a  compound  XI  which negatively controls  cAMP  accumulation by 
inhibiting  adenylat~ cyclase,  activating the phosphodiesterases  or  cM1P 
efflux from  the cells  (  282  ).  This model  accounts  for  several  data obtained 
with dog  thyroids.  XI  may  also affect directly some  steps of  iodine meta-
bolism  (such  as  trapping)  (283)  or  the  action of cyclic 3'5'-AMP  (284). 
The  identity of  XI  and  its mechanism of  action are unknown.  The  XI 
scheme  does  not  account  for all the  inhibitory effects of  iodide which  are 
not  relieved by perchlorate or peroxidase  inhibitors.  It is  therefore proba-
ble that other mechanisms will have  to  be  postulated  to  explain effects, 
such as  the  inhibition by  iodide  of  secretion in hyperthyroid patients with 
antithyroid drugs.  Moreover,  results  showing  that  iodothyronines  inhibit 
directly thyroid  function  (  285  )  suggest  that  thyroid hormones  them-
selves may  constitute negative  feedback  signals if not  XI.  The  rapid 
kinetics of  the  action of methimazole bears  against this hypothesis.  However, 
independently of  iodide,  the  interest of  an  intracellular negative  control 
by  thyroid hormone  is obvious  :  the  iodothyronine  content of  thyroglobulin 
would  modulate the  response  of  the cell  to TSH,  i.e., the  amount  of  thyroglo-
bulin taken up  and  hydrolyzed,  i.e.,  the  secretion of  thyroid hormones. - 125-
3.  Role  of  Calcium 
Tissues  can be  divided  in two  categories.  In unidirectional  systems 
the  tissue  is only  submitted  to positive control,  i.e.,  to  the action of 
one  stimulatory signal.  In bidirectional  systems,  the  tissue is regulated 
both by positive and  negative control,  i.e., by1stimulatory and  inhibitory 
signals  (238,275).  It has  been proposed  that  in unidirectional  systems  cAMP 
++  on  the  one  hand  and  cGMP  and/or Ca  on  the other hand  act in parallel, 
whereas  in bidirectional  systems  both types  of signals would  be  opposite  (238,275). 
The  predominant  role of  Ca++  as  a  signal  for muscle  contraction in  the 
excitation-contraction coupling  and  in the  excitation-secretion coupling 
raises  the  question of  a  possible role of  calcium in thyroid secretion or 
more  generally in the  regulation of  thyroid metabolism  (224,233,241  ). 
1  ++  .  .  .  Extracellu ar  Ca  1s not necessary for  the  pr1mary effect of  TSH  on  thyro1d, 
the  increase of cyclic  3'5'-AJW  accumulation,  nor  for  one  of  its consequences, 
secretion,  but is required for  two  other metabolic effects  induced  by  this 
primary action  the  activation of  iodide binding  to proteins  and  of  glucose 
oxidation  (  233  ).  ++  A rise of  intracellular Ca  per  se  1n  the  thyroid 
++  stimulates very much  these metabolisms  (286);  Ca  is thus  necessary  and 
sufficient to elicit such  activations.  On  the  other hand,  not  only  does 
++  Ca  not  increase cyclic  3'5'-~~ accumulation  and  secretion but it depresses 
h  .  1  h  ++  .  .  .  t  ese var1ab  es •  T us  Ca  appears  to have both  s1m1lar  and  oppos1te 
effects  to  TSH  and  cyclic  3'5'-AJW  (286).  TSH  accelerates  the release  of 
intracellular calcium.  ++  Thus,  TSH  causes  a  translocation of  Ca  in thyroid 
tissue  (287).  This  effect could  correspond  to  an  increased release of 
++  .  .  .  .  Ca  from  an 1ntracellular sequestrat1ng  s1te  to  the cytosol,  w1th  a  subse-
quent  spill-over of  this  Ca++  out  of  the cells,  but it could as  well  reflect 
.  .  d"  ++  an  1ncrease  1n  the  1scharge of  Ca  from  the  cytosol  to  the extracellular 
space.  This  action ·could  correspond  to  an  increase or  a  decrease of  cytosol 126-
++  ++  Ca  level.  The  role of  Ca  in TSH  action thus  remains  to  be elucidated. 
Elements  of  the  cGMP  system have  been  identified in thyroid.  This  tissue 
contains  c~~ (286,288)  and  a  guanylate  cyclase  (289).  In dog  thyroid slices 
in vitro,  cGMP  levels are enhanced  by  carbamylcholine  and  acetylcholine  (286  , 
-6  288  ).  The  action of  carbamylcholine  is inhibited by  atropin  (10  U); 
it corresponds  to  a  muscarinic effect.  Under  various  experimental conditions, 
TSH  failed to  enhance  cGMP  levels  in thyroid. 
In thyroid  slices, whatever  the  stimulatory agent,  no  increase  in cGMP 
.  ++  .  .  ++  .  level  is observed  1n  the absence  of  Ca  1n the med1um.  Thus  Ca  1s 
required  to  increase  cGMP  level in thyroid cells.  In the presence of  iono-
-3  phore A23187,  calcium per se  (10  ~1)  markedly  enhances  cGMP  concentration 
in dog. thyroid slices.  Thus  calcium is necessary and  sufficient to raise 
or even  to maintain intracellular  cGMP  level  (286).  If we  start to understand 
the regulation of  cGMP  concentration in thyroid,  its role 
remains unclear.  According  to  the Yin-Yang  hypothesis  ('238),  cGMP 
could  be  expected  to antagonize  cAMP  action if the  thyroid  is a  bidirectional 
system,  or  to mimic  cAMP  action if the  thyroid  is a  monodirectional  system. 
In fact,  all agents which raise  cGMP  levels  in thyroid cells activate,  as 
TSH,  the binding of  iodide  to proteins  and  the pentose phosphate  pathway, 
but depress  the stimulation of  cAMP  accumulation and  of .thyroid secretion 
induced by TSH.  These effects are abolished in calcium depleted  thyroid slices. 
Thus,  the  thyroid cell behaves neither as  a  unidirectional nor as  a  bidirec-
tional  system,  but rather as  a  system with both  types  of properties  (286). 
The  question may  of  course be raised whether  in vivo  the  thyroid is a 
uni- or bi-directional system.  Classically,  until now,  the  thyroid  as  the 
adrenal  has  been considered  as  a  typically unidirectional  system,  being 
regulated by  one  positive signal  (TSH  or ACTH).  However,  the existence of - 127-
cholinergic sensitive  cGMP  accumulation as well  as  of cholinergic nerve 
terminals  in some  thyroids are compatible with the hypothesis  of  a  negative 
cholinergic regulation,  i.e., with  the  concept  of  a  bidirectional control 
of  this tissue.  It should  be  pointed out  however  that,in vivo,stimulatory 
rather than  inhibitory effects of acetylcholine on  thyroid secretion have 
been found  ( 290). 
All  the agents which  increase  cGMP  concentration in the  thyroid tissue 
thus also elicit certain metabolic effects  :  activation of  the binding of 
iodide  to proteins,  of  the pentose phosphate  pathway,  inhibition of  cAMP 
accumulation and  of  secretion.  There  is good  evidence  that  these effects 
++  are  secondary  to a  rise of  Ca  in the cytosol.  It is however  not clear 
++  whether  they are  caused by  Ca  or by  the rise in cGMP  which  is consequent 
to  enhanced  calcium concentrations;  the question remains whether  the  increased 
cGMP  accumulation is a  necessary link between agents  such as  acetylcholine 
and  their effects or  is a  mere  by  product of this main action.  The  mechanism 
by  which Ca++  or  cGMP  negatively modulates  cAMP  accumulation is not clear. 
C.  Other Possible Physiological Controls besides Thyrotropin 
A neural  control  of  thyroid metabolism has been postulated for  a  long 
time.  Cannon  (291)  already  showed  indirectly that cervical  sympathetic 
stimulation could  induce  thyroid  secretion.  However  because  of  the  demons-
tration of  the central role of  the hypophysis  in the regulation of  thyroid 
function,  and  of  a  normal  physiological  regulation operating in enervated 
or  transplanted glands  these observations were  forgotten.  Old  and  recent work 
suggests  that  the  sympathetic  and  parasympathetic  innervation may  modulate 
thyroid metabolism and  its response  to  TSH  (257,29~ as  in the  case of other 
endocrine  glands  ( 293). - 128-
The  existence of  an adrenergic control  of  thyroid metabolism has  been 
demonstrated  in  some  species  but not  in others  (e.g.,  the  dog) 
(257,292).  In sensitive  species,  adrenergic  terminals,  some  of  them  ending 
up  close  to  follicles,  have  been observed.  The  number  of  these  terminals 
may  decrease with age  (29~.  Catecholamines  stimulate  thyroid  secretion in 
vivo  and/or  in vitro  and  when  this has  been investigated adenylate  cyclase 
of  such  thyroids  responds  to  these effectors  (294,295  ).  The  stimulatory 
effect appears  to  be  cyclic  AMP  mediated  and  of  the ;32type • 
However,  some  effects  inhibited by  0(  type  inhibitors have  been  reported  (29~. 
The  evidence  in favor  of  a  cholinergic control  is much  less  strong at the 
present  time.  It consists mainly  in the  fact  that acetylcholine  in vitro 
has  a  definite action on  thyroid metabolism  (vide  supra)  and  that it may 
influence  secretion in vivo  (  290  ).  Prostaglandins  seem  to  play an 
important  role  in  thyroid metabolism but  the nature of  this role is still 
unclear.  The  thyroid  appears  to  contain prostaglandins  of  the various  types 
and metabolic  studies  suggest  that it synthesizes  them.  Prostaglandins  of 
the  E  type  activate adenylate cyclase,  raise cyclic AMP  levels  in thyroid 
slices and  mimic  several  of  the  cyclic  AJW  dependent  TSH  effects  (23~ 241, 
266,296  ).  Proteins binding specifically prostaglandins of  theE  type 
have  been  iden;:ified  ( 297).  It has  been  reported  that TSH  increases prosta-
glandin formation  in  thyroids  in vitro  (  298  )  and  several mechanisms 
have  been  proposed  for  this action,  however  in our hands  no  such  effect has 
been  found.  The  probably  important  role of prostaglandins  in the  TSH  action 
and  in  the  regulation of  thyroid metabolism remains  an  open field. 
The  thyroid  is undoubtedly  also  regulated  by  other unspecific hormones. 
Insulin and  glucocorticoids are often necessary  for  the  survival  or  growth 
of  follicular cells in culture  (  299,  300  ).  Moreover,  goiter  formation, 
i.e.,  growth in vivo  is enhanced or requires  a  secretion of  growth  hormone - 129 -
(  301  )  and/or  insulin  (302),  and/or glucocorticoids  (30~. 
D.  Control  of Human  Thyroid 
Although  the metabolism of  human  thyroids  and  its regulation has  been 
much  less  studied  than in animal,  the main  regulatory circuits described here 
seem  to  apply  to  this  tissue.  Human  thyroid tissue contains  a  TSH  sensitive 
adenylate  cyclase  and  cyclic nucleotide phosphodiesterases  an~when intact, 
responds  by  an  impressive rise of  cyclic AMP  to  TSH  (  304,  305  ).  TSH 
enhances  several parameters  of  thyroid metabolism in vivo  and  these effects 
are mimicked  by  dibutyryl cyclic  3'5'-AJW  and  by prostaglandin E1  (306,307). 
Catecholamines  by  a ;S  type of effect,also enhance cyclic  AMP  levels  in the 
thyroid  and  mimic  some  TSH  effects  (  305  ).  Adrenergic  innervation of  the 
follicles has  been dembnstrated  (308).  Carbamylcholine by  a  muscarinic 
type  of effect raises  cyclic  GMP  levels  in the  tissue  and  affects  thyroid 
metabolism.  Prostaglandins  stimulate  thyroid  secretion in vivo  (309). 
E.  Control of Thyroid  as  it affects  Iodine Metabolism 
Thyrotropin in vivo  and  in vitro acutely enhances  protein iodination, 
iodothyroninffisynthesis  and  thyroglobulin endocytosis with a  consequent 
release of  thyroid  hormone.  Its effect on  iodide  trapping is biphasic,  with 
decrease  during  the first  two  hours,  followed  by  a  progressive  increase. 
Thus  an  acute  injection of  TSH  induces  an  immediate  release of  thyroid  iodine, 
followed  by  a  delayed  increase of uptake  of exterior  iodide  (241). 
Under  conditions of chronic  stimulation,  all  the  steps  of  iodine metabolism 
are accelerated  :  iodide  trapping,  binding to  proteins as well  as  its 
release as  iodothyronine.  The  net result of  these effects  is  to  increase 
the  immediate  uptake  of  iodine,  but  to accelerate very much  its release.  In 
chronically stimulated  thyroids,  the  uptake  of  iodine is high but its thyroid 
half life is considerably shortened.  This  situation applies  in clinical - 130-
thyroidology to hyperthyroidism  (Graves'  disease or Basedow's  disease)  and 
certain types  of  endemic  goiters.  Similarly under conditions of  chronic local 
activation  (eg.  in chronic  thyroiditis or toxic  adenomas)  the  release of 
iodine is generally rapid even  though  the  total iodine uptake may  not be 
increased. 
The  adaptation to  iodine deficiency classically consists  in greatly 
increased  iodide  trapping  in the  thyroid.  l~ereas this may  be  accompanied 
by  a  faster release of  iodine,  in the established cases of  endemic  goiter, 
as well  as  in many  cases  of  sporadic goiter,  iodine  turnover  in the hyper-
plastic gland  is slow. 
In chronically understimulated  thyroids,  eg.  under  thyroid hormone 
therapy,  all the  steps of  iodine metabolism are  slowed  down;  the  uptake  of 
iodide is  low  and  its half life is prolonged  (310). 
III.  CONTROL  OF  THYROID  GROWTH 
The  best known  and  studied mechanism controlling thyroid growth  is  the 
tonic regulation by  thyrotropin and  the pituitary thyrotrophs.  Howev~r, 
as  reviewed by Doniach  (311),  other processes exist. 
Any  treatment  that decreases  thyroid secretion induces,  by  relieving 
the  feedback  exerted on the pituitary,  a  secretion of thyrotropin which 
itself enhances  thyroid  growth.  That  such  a  mechanism applies may  be  proved 
by demonstrating  a  decrease  in thyroid hormone  level,  an  increase  in TSH 
level and  the  suppression of  growth by  thyroid hormone  administration or 
hypophysectomy.  This  has  been  shown  to be  the case  for  compensatory hypertrophy 
(i.e.  after removal  of  one  lobe of  the  thyroid)  or  in goiters obtained with 
an  iodine free diet or after administration of  goitrqgens  (i.e.  drugs which 
inhibit  iodide  trapping  or oxidation).  The  fact  that,  even in hypophysecto-- 131  -
mized rats,  thyroid  size remains  larger under  condition of  iodine  free  diet 
suggests  that intracellular factors  (eg.  the postulated  XI)(28~ may 
also play a  role in this  type of  growth. 
After successful! grafting, surviving thyroid follicles exhibit mitotic 
proliferation and  formation of  new  follicles.  A similar phenomenon  may 
be  observed  in areas of  the human  thyroid  flanking  hemorrage  or  inflammation. 
This  type  of hyperplasia,  called "reparative growth"  is essentially self 
limited and  independent  of  TSH,  as it is not  inhibited by  thyroxine  or hypo-
physectomy.  Whether  this process  corresponds  to a  relief of local  inhibition 
or  to  the release of  local activators,  such  as prostaglandins,by tissue 
injury is unknown.  There  is no  doubt  that tissue injury induces  a  release 
of prostaglandins,  that prostaglandins enhance  cAMP  accumulation  in thyroid 
cells and  that  cAMP  appears  to  be  a  possible mediator of  thyroid cell multi-
plication  (see  below.).  It has  been  suggested  that infantile thyroid growth 
is similarly independent  of TSHps the  glands  of rats given daily injections 
of  thyroxine  from birth,  grow  from  a  birth weight  of  1 mg  to an adult weight 
of  17  mg  at  the  age  of  4  months  (  312  ).  However,  this evidence 
should  be  reexamined  by  more -modern  methods  (i.e., with  serum TSH  measurements). 
The  biochemical mechanisms  of cell growth control  are still in general 
poorly understood.  The  best data available concern mostly fibroblasts  in 
culture.  In  such systems,  there is a  negative correlation between  cAl1P 
levels and  growth,and  cAJ~ itself and  its analogues  inhibit growth.  However, 
even  in fibroblasts,  there are  cases  in which  cAMP  rises are not  accompanied 
by  decreased  growth  (31~ and  there is evidence  that Ca++  may  be  a  positive 
signal  of  growth  (27~.  In other types  of cells,  (eg.  the  lymphocytes)  cGMP 
has  been proposed  as  a  positive signal of  growth  (31~.  In the  thyroid TSH 
stimulates cell growth  and  multiplication in vivo  and  in culture.  On  the ·basis - 132-
of  experiments  in which  TSH,  but not  DBcAMP,  enhanced  thyroid cell multi-
plication in culture it has  been  suggested  that  this  TSH  effect is not 
mediated  by  cAMP  (274).  However,  the  concentrations  of  TSH  and  DBcAMP  used 
were not  equivalent,  the  DBc~~ concentration being  in other  system equi-
potent with  1/100  of  the  TSH  concentration used  (241).  Moreover,  there are 
now  several  arguments  supporting concept  that in the  thyroid  cAMP  may  be 
one  of  the positive signals of  growth  : 
1)  cAMP  as  TSH  enhances  protein synthesis  in vitro and  increases, 
presumably  by  an action at the  transcription level, iodide  transport  (241,252) 
2)  cAl~ as  TSH  enhances  ornithine decarboxylase  synthesis which  is a 
concomitant  of cell growth  is most  eucaryotic  systems  (269,270) 
3)  cAMP  as  TSH  injected in vivo  induces  thyroid  growth  (271) 
4)  cholera toxin,the only known  action of which  is  to  activate adenylate 
cyclase,  enhances,as  TSH,the  growth of  dog  thyroid cells in culture  (217)  • 
Although  there are  alternative explanations  for all these results,  we  think 
that  they  strongly  suggest  that  cAJW  may  be  a  the mediator of  growth  in 
follicular cells. 
At  the present  time,  nothing is known  on  the  other possible reeulators  of 
thyroid  growth outside  (e.g.  prostaglandins,  acetylcholine,  growth hormone, 
.  .  )  .  .  (  ++  )  ~nsul~n,  etc  or  ~ns~de  Ca  ,  cG11P,  etc.  the cell. 
IV.THYROID  CELL  KINETICS 
A.  The  Normal  Thyroid at Rest 
All  the  functions  of  the  thyroid  in iodine metabolism and  iodothyronine 
secretion are carried out  in the  functional  units of  the  gland,the follicles, 
whose  elements,  the follicular cells,  enclose  the colloid  lumen.  Beside  these - 133 -
cells,  the  thyroid also  contains  from  20  to  30  % stromal cells,  mainly 
fibroblasts  and  endothelial cells,  and  scarce  C cells  (the calcitonin 
secreting cells)(245,315).  The  thyroid cells normally undergo little mitotic 
activity,  but  they  can be  induced  to  do  so  under direct or  indirect 
stimulation  (goitrogen diets,  TSH) 
l{hatever  the  species  in which it has  been measured,  the  renewal  rate of adult 
thyroid follicular cells is very  slow  (Fig.  3).  In young mice  the  3H thymidine 
labelling index  (percent of  S  cells  in the population,  at any  time)  is 
about 0.19%  (316)  and  in adult rat about  0.14%  (  6  ) •. As  gland weight 
and  cell number  are relatively constant,  the proliferative activities indi-
cated  by  the  index simply reflect cell renewal.  In mice,  the  length of 
the  S  phase  (as measured  by double  labelling)  is about  5~2h (316),  which 
is very  similar to  S-phase duration in most  tissues of  the mouse  and  rat. 
In  the rat  thyroi~ it has  been  assumed  to  be at least 6  h  (  6 ). 
Knowing  the  S-phase duration  (ts)  and  the  labeling  index  (L.I.  =  percent 
of  3H thymidine  pulse - labeled cells)  the  turnover  time  (to)  in a  tissue 
can be  calculated using  the  formula  :  t0  ts  :  L.I.  x  100.  This  represents 
the  time  for  the  replacement  of  a  number  of cells equal  to  that present  in 
the  considered population.  The  equation assumes  homogeneous  (rectangular) 
age  distributions of cells along  the  cell cycle  (as  in steady state populations 
with cell loss occurring randomly).  If growth fraction  (G.F.)  is unity 
(that is there is no  quiescent  compartment)  to= Tc  (cell cycle  time).  The 
turnover  time  can  therefore be  estimated at 5.2  x  100/0.19  =  2736  h,  i.e. 
more  than  100  days,  in the rat.  Assuming  a  cell cycle of  50 hrs S6) 
with ts =  6  h,  12  % 0f  the  cells  should  be  labeled if all cells were  in 
the mitotic cycles.  As  the  labeling  index  is of 0.14 %,GF  should  be  of  the 
order of  0•14 % =  1.16  %,  i.e.  in the  thyroid  there would  be at any  g1ven 
12% 
time  1%  of  the  cell-population progressing  through  the 
cell cycle. - 134-
Fig.  3  The  mitotic cycle  in eukaryotic cells. 
M  Mitosis 
S  Phase of  DNA  synthesis 
G 0  Phase of cells not currently engaged  in the mitotic cycle - 135-
It should  be  pointed out  that without knowing  the  growth fraction,  such 
measurements  do  not  allow to  establis:h whether  the  thyroid is a  Go  system 
(i.e.  a  system in which  a  few  cells would  constitute a  germinating pool  and 
most  of  the cells would  not participate in the proliferation pool  {GF  low)) 
or  a  G1  system in which most  of  the cells would  participate in the prolife-
ration  albeit with very  long  G1  phases  (GF  = 1)  or an  intermediary  system. 
In PTU  treated rat Sheline has  estimated  GF  to at least 0.2  (317). 
Data on  labeling  index,  S-phase  and  renewal  rate are not yet available 
in man,  although  the double  labeling  in vitro with  thymidine  could provide 
such data.  The  validity of  this  technique  for various  tissues has  been 
demonstrated  (318).  It is known  that,  even during growth,  cell multipli-
cation must  be  slow in human  thyroid.  Mitoses  are only very rarely seen 
in  the follicular cells.  Moreover,  Doniach has  calculated that  the human 
thyroid ;eighing  1 gat birth and  20  g  by  20  years,  without.much  change  in 
the proportion of follicular cells vs  colloid or other cells,  the cells must 
undergo  about  5  mitoses  in 20  years  (319),  i.e.  about  1  every  3  or  4  years, 
more  if there are cell deaths.  Doniach  suggests  that there may  be  almost 
no  division in the  adult.  In our  laboratory,  preliminary experiments  by 
Galand  show  very  low but definite labeling index  in the follicular cell 
population  (of  the order of  1/10  .• 000)  and  somewhat  higher proliferative acti-
vities in interfollicular cells  (Fig. 4). 
B.  The  Stimulation of  Cell Proliferation 
Acute  administration of  TSH  induces  in the  thyroid  a  wave  of  DNA 
synthesis  and mitoses  (241,320).  Chronic  stimulation by  the hormone 
induces  intense cell proliferation,  resulting in tissue growth.  Such  a 
response  can be  obtained by  direct administration of  the hormone  or by  indirect 
stimulation of  the pituitary by  any  goitrogenic agent.  Such  agents  by - 136-
Fig.  4.  -Radioautograph from  human  thyroid  gland,  following  in vitro 
incubation  in the  presence  of  3H-thymidine  (10  uCi/ml)  for  15  m1n. 
Note  a  heavily labelled follicular cell,  having  incorporated  the  DNA 
precursor,  thus  indicating that  the cell is engaged  into proliferative activity. 
- Slices  +  1  rnm  thick were  incubated at  37°C  in Eagle  Basal  Medium 
(diploid)  supplemented with  10  % fetal  bovine  serum,  and  gassed with 
carbogen. - 137-
decreasing  thyroid hormones  synthesis  and  thus its secretion relieve the 
pituitary thyrotrophs  from  the  tonic  inhibition exerted by  these hormones  and 
consequently activate TSH  synthesis  and  secretion. 
The  kinetics of rat  thyroid  growth  under  chronic goitrogenic  stimulation 
follows  a  classical  sigmoid&  curve  in log weight  vs  time  coordinates  : 
it consists of  a  lag phase,  followed  by  logarithmic  growth  and  a  plateau 
(6,  204,  321).  It mainly reflects cell multiplication as  the  number  of 
cells per light microscopy field does  not  change  and  as  total weight  and 
DNA  increase  in parallel  (6,  204  ).  The  cell multiplication involves  both 
strom&  and  follicular cells,  the  former  earlier and  more  so  than  the  latter 
(321).  The  increase  in thyroid cell number  under  chronic  stimulation  could 
be  due  to  increased multiplication of  a  germ  cells pool, to expansion of  this 
pool  or  (if GF  =  1)  to acceleration of cell division in the whole  cell 
population.  The  fact  that early growth is accompanied  by  a  dramatic  increase 
in the  DNA  labeling index has  been  taken as  argument  in favor  of  the 
latter hypothesis  (  6 ).  Whatever  its mechanism,  the  induced cell multipli-
cation is  similar in young  and  adult rats  (317). 
It is of  interest that  removal  of  the  stimulant  induces  a  rapid 
decrease  in  the  number  of  cells followed  by  a  plateau at a  level higher 
than  the  starting level  as  if 2  populations of cells would  exist  one  stable, 
the  other dying  under  resting conditions  (  245  ). 
Several  arguments  support  the  concept  that  the  thyroid cells have  a 
small  but  definite lifespan,  i.e.  that  they  can undergo  only  a  limited 
number  of divisions  : 
a)  the  growth  curves  reach  a  plateau even  though  the  same  stimulus 
remains  present  (4  to  5  doublings)  (6,204).However,  if the labeling  index 
decreases  it does  not fall  back  to its previous value  (321)  which  suggests - 138-
a  cell turnover at a  higher level. 
b)  after thyroid weight has  reached  a  plateau,  removal  of one  thyroid 
lobe  does  not  induce  further  growth  in the  remaining  lobe  (319). 
c)  assuming  that  the rate of cell multiplication remains  as  high in the 
adult as during growth,  with  a  renewal  time  of  4  years,  the number  of  thyroid 
cell divisions  in man  would  be  about  15  to  20,  in the mice  (renewal  time 
100  days)  12  to  16,  during whole  life. 
d)  in culture our  dog  thyroid cells reach  a  plateau in their growth 
(5  to  6  doublings)  much  before  they  reach  confluence (217). 
Such  a  conclusion has  obvious  implications  in the  interpretation of 
human  thyroid pathology  and  therapy  (eg.  to interpret the  latency of  r 131 
treatment  of hyperthyroidism).  However,  it needs  to be  further substantiated. RADIATION  INDUCED  DAMAGE SECTION  V 
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I.  CHEMICAL  EFFECTS  OF  IONIZING  RADIATION  AND  o2  METABOLISM  IN 
THE  THYROID 
A detailed analysis of  the  chemical  effects of  ionizing radiation 
in cells is out of place  1n this monograph.  Excellent  reviews  on  the 
subject have  been published  (322-334).  However,  the effects of  radiation 
involve  the  generation of  free  radicals,  02- and  H
2o
2
,  whereas  the 
thyroid,  as  the  leukocyte,  is the site of  a  very active oxidative 
metabolism in which H
2o2  and  possibly 02- are  involved  and  processed. 
It is therefore of  some  interest to  review this little considered 
subject briefly to  show  how  the particular metabolism of  the thyroid may 
affect its response  to  radiation and  to  point out areas which  deserve  to 
be  investigated. 
Much  of  the  energy  absorbed  by  irradiated cells goes  into  producing 
excited molecules.  It appears,  however,  that most  of  this  energy  does 
not  produce  chemical  reactions  and  is eventually dissipated as heat. 
It is ionizations  that lead  to most  of  the  immediate  relevant 
changes  and  these  changes  are  subsequently  transferred 
through a  chain of  chemical  reactions,  finally producing irreversible damage 
to critical molecules  of biologic  importance  to  the cell.  Chemical  damage 
may  be  repaired before it is irreversible by radical recombination,  or other 
mechanisms,  and  the energy dissipated as  fluorescence,  phosphorescence or 
vibrational energy. 
The  time  required for  this entire chain of physical  and  chemical  events, 
from  the initial interaction of  the  ionizing wave  or particle until  the 
initial biologic change,is  of  the order ofmilliseconds or  less.  The 
subsequent  devel~pment of  biochemical  and visible physiologic  changes, 
however,  may  take hours  to  days  or even longer. - 142-
P~IATION AND  FREE  RADICALS 
(after Pryor) 
Rad 
~  +  INITIATION  H2o  )  H20  +  e 
H 0+ 
2 
)  H+  +  OH• 
e  + H20  ~  OH  +  He 
PROPAGATION  H•  + 02  ~  HO  • 
_..:.  H+  +  02  presence of o2  2 
....::--
-
02  +  H202  --+OH  +  OH•  +  02  (Haber & Heiss  reaction) 
H•  +  RH  ~  R•  +  H2 
RH  +  H02 •  ----+  R•  +  H202 
OH•  +  RH  ~  R•  +  H2o 
R•  +  RH  +  02  _.,  R•  +  ROOR  presence of o2 
TERMINATION  He  +  He  ~  H2 
OH•  +  HO •  2 
~  H2o  +  02 
He  +  HO  •  2 
~  H202 
OH•  +  OH•  ~  H202 
H•  +  OHe  ~  H2o 
H•  +  R•  ~  RH 
OHe  +  Re  ~  ROH 
HO  •  2  +  HO  •  2  ~  H202.  +  02 
TABLE  I  Radiation and  free  radicals  (324). 
•  :  symbol  of  free  radical. - 143-
The  radiosensitive target or critical macromolecule  in the cell may 
be  inactivated by direct action,  which would,  of  course,  be  the only 
mechanism operative  in molecules  or viruses  irradiated in the  dry state. 
Since  roughly  80  per cent of  the mammalian  cell is water,  however,  it is 
probable that most  cellular radiation damage  is mediated by  aqueous-free 
radicals.  Moreover,  most  of  the products  from  water react with organic 
compounds  to  give organic  free  radicals  similar to  those  formed  directly 
by  absorption of radiation  (323). 
In its simplest  form,  the ejection of an electron and  resultant ioni-
zation of water by radiation leads  to  the  formation of hydrogen  (H•)  and 
hydroxyl  (OH•)  free radicals.  Free radicals  are atoms  or molecules  con-
taining unpaired electrons.  Such entities are usually highly unstable and 
therefore very reactive.  The  free  radicals  produced by  the radiolysis of 
water generally have  a  lifetime of  the order of a  microsecond or less 
before  recombination or reaction with another molecule occurs.  Current  evidence 
·indicates that under  anoxkconditions  the  OH•  radical  is the major oxidizing 
species,  whereas  H• is the  reducing  species at the pH  of cells.  In the 
presence of  oxygen,  no•2  and  H2o2  become  important oxidizing products.  The 
free  radicals  formed  in cellular water may  lead  to  a  wide variety of  chemical 
reactions  in organic molecules  in the cell,  eventually terminating in damage 
to critical macromolecules.  The  energy may  subsequently be  transferred 
within the macromolecule,  causing rupture of a  bond  or other damage  quite 
distant  from  the initial site of attack.  The  radiation chemistry of water 
is schematized  in Table I. 
Cells  irradiated in the  presence of  oxygen are considerably more  susceptible 
to  the  development  of  damage  than those  irradiated anoxically.  It appears 
that oxygen  reacts  strongly during  the  chemical  stages  of  fixation of  radiation 
damage  in a  number  of ways  (336).  The  first is in the - 144-
aqueous  medium  of  the cell, where  the presence of  oxygen leads  to  the 
- formation of  o2  and  HO~ radicals  as well  as H2o2,of which particularly 
Ho•  is much  more  reactive than  the radicals produced  in the  absence of 
2 
oxygen.  In addition,  when  oxygen is present it may  attack organic molecules 
directly.  It does  so  by  combining  rapidly with  the  organic free  radicals 
produced  by radiation leading  to  the  formation of  peroxy radicals  and  thus 
irreversible damage  (R
0  +  o2 ~  RO~),  preventing normal  repair reactions 
(R•  +  H  • --7  RH).  When  the relative radiosensitivity of cells is studied 
as  a  function of  the  oxygen content  of  the  surrounding medium,  it is  found 
that sensitivity rises rapidly  from  the  anox~c state and  becomes  maximal  at 
an  oxygen  tension  (p02)  of about  20  to  30  mm  of mercury.  Most  normal  tissues 
in vivo,  therefore,  are maximally  radiosensitive,  though hypoxic  areas  of 
reduced  sensitivity may  occur  deep within  tumors,  where  the vascular 
supply  is poor.  Apart  from  the  above  effects of oxygen,a  number  of 
others  have  been described  and  are  implicated in physiological  aspects 
of  the repair and  recovery  from  radiation damage  (436-438). 
Free radicals will attack all available organic molecules,  the most 
important  targets  in cells being proteins  and  their  SH  groups,  lipids  and 
nucleic acids.  Alterations of  the latter may  imply  genetic  changes.  The 
principal  lesions observed  in DNA  irradiated in aqueous  media  have  been  shown 
to  be  hydrogen bond  breaks,  single or double  strandbreaks,  and  degradation 
of  purine or pyrimidic bases  (eg.  apurination,  apyrimidination,  i.e.  release 
• 
of  degraded  purines  and  pyrimidines  leaving unsubstituted deoxyribose  residues 
in the  DNA  chain)  (323). 
Oxygen  radicals  are also  produced naturally in aerobic cells.  o
2 
is 
generated  by mitochondria  (326), by  the autooxidations  of .intermediates of  the 
electron transport  chain  (eg.  flavins)  of  hemoglobin,  by oxidases  (eg.  xanthine 
oxidase),  etc.  Leukocytes  and  macrophages  generate o2  during phagocytosis. 
o2  in the  presence of H2o2  and  trace metals  generate highly reactive and - 145-
SPONTAJffiOUS  PRODUCTION  OF  OXYGEN  RADICALS  IN  CELLS 
(after Fridovich{329) 
Reduced  cytochrome P450,  flavine  ,  NADPH  ~  e 
o2  +  e  ~  02 
02  +  e  +  2H+  ~  H202 
02  +  H202  ~  OH  +  OH•  +  02  (Haber  and  Weiss  reaction) 
H202  +  e  +  H+  ---+  H2o  +  OH• 
OHe  +  e  + H  + 
~  H
2
0 
ENZY~~TIC DEFENSES  AGAINST  o2  DERIVATIVES 
Superoxide  dis mutases  02  +  02  +  2H+  ---4»  H202  +  02 
Catalases  H202  +  H202  ~  2H20  +  02 
Peroxidases  H202  +  RH2 
~  2H20  +  R 
(notably  GSH  peroxidase which  generates  GSSG) 
Ascorbate 
NAD(P)H2  Semidehydroascorbate  reductase 
•  symbol  of  free  radical 
TABLE  2 - 146-
toxic OH•  (327-330).  Several mechanisms  have  evolved  t~ protect  the 
cell against these free radicals  (Table II).  The  electron transport chain 
reduces  o2  to H2o  with little release of other intermediates.  Mitochondria 
and  cytosol  contain superoxide dismutases  (329)  and  there is compelling evi-
dence  that  these  enzymes  are  the main  defense
4 system against o2  toxicity in 
bacterial and  eukaryotic cells.  Catalases  and  peroxidases  also efficiently 
dispose of H2o2,  thus  further decreasing  the probability of  OH•  formation. 
If o2  toxicity were  also  due  to electronically excited singlet oxygen 
formation  in the Haber Weiss  reactions  (~31)  the  same  mechanism  of  defense 
would  operate.  Ascorbate  is also  an  effective scavenger  of free radicals 
and  notably of  the  superoxide  02- radical  (332).  Semidehydroascorbate is 
reduced  in cells by  a  still ill defined  semidehydroascorbate reductase with 
NADH2  or  NADPH2  as  coenzyme.  Tissues which  contain much  ascorbate  (adrenal, 
leukocyte,  thyroid)  are also  tissues with a  very active non mitochondrial 
respiration.  This  ascorbate  system could  therefore constitute another 
defense mechanism against  o2  free radicals. 
Systems  which protect against o2  toxicity may  decrease radiation damage. 
It is clear from  Table  1  that  in the  radiochemical  decomposition of H2o  the 
reactions which  require o2  involve Ho2•  and  o2  •  The  removal  of  Ho2 •  and 
its conjugated base  o2  would  obviously decrease  OH•  and  R• generation. 
!~deed, it has  been  shown  that  superoxide dismutase  decreases  radiation 
damage  in cells in culture and  even whole  animals  (329,333).  Similarly, 
radiosensitive tissues  accumulate  the  semidehydroascorbate radical during 
exposure  to  ionizing radiation  (334);  ant it has  been  suggested  that  the 
higher  resistance  to  radiation of  leukocytes  in comparison with  lymphocytes, 
is due  in part to  their higher capacity  to reduce  semidehydroascorbate 
(336).  While  ascorbate itself was  formerly considered  to have  no  radio-
protective ability in vivo  (336),  it has  recently been  shown  that ascorbic 
acid exercises  a  radioprotective effect on mammalian  cell cultures  in vitro 
and  on rats  subjected to whole  body  irradiation in vivo  (431-433). - 147-
In the  leukocyte  and  other macrophages o2  generation appears  to 
be  an  important mechanism for  the killing of bacteria  (328,  337). 
These cells  themselves  are protected against  the  toxic effects of  their 
products  by  their enzyme  defense mechanisms.  Indeed,  they contain 
superoxide dismutase,  catalases,  GSH  peroxidase,  GSSG  reductase  (NADPH2), 
semidehydroascorbate  reductase  (NADPH2)  and  high concentrations  of ascorbate. 
The  intracellular o2- is  transformed  to  H2o2  by  superoxide dismutase,  and 
H
2o2  is reduced  by glutathione peroxidase  and  catalases.  The  reduction of 
GSSG  formed  is carried out  by  GSSG  reductase  (NADPH2)  and  the  pentose phos-
phate pathway with  NADPH2  as  intermediate,  which explains  the  close coupling 
of  the activation of  o2  generation and  of  the  pentose phosphate  pathway 
in the  leukocyte.  Leukocytes  and  macrophages  are also highly radioresistant 
(335,  337). 
Little is known  about  02  metabolism 1n  thyroid.  Iodide is oxidized 
by  a  peroxidase using  presumably H2o2  as  substrate  (228,338).  The  possibi-
lity that lipid peroxides  could  be used  as  the oxidizing agent has  not 
been explored.  The  system which generates H
2o2  has  not  been identified; 
it is known  to use  NADPH
2 
as  coenzyme  (221,339).  It could quite possibly 
be  similar  to  the  leukocyte  system in which o2  is generated by  reduction 
of o
2 
by  a  NADPH2  linked  enzyme,  o
2
- itself being  transformed  in H
2o2  by 
superoxide  dismutase.  In fact xanthine  oxidase,  which  generates o2  ,  has 
been identified in thyroid,  and  has  been proposed  as  an  important  source 
of H2o2  in the  gland  (340).  Hati  and  Degroot  have  also  suggested  a  role 
for o2  in the generation of H2o2  in thyroid  (339). 
Nothing  is known  about  the  existence of defense mechanisms  against o2 
free  radicals  in thyroid,  i.e.  superoxide  dismutase,  catalases,  GSH  peroxidase, 
GSSG  reductase,  semidehydroascorbate reductase,  etc.,  although  the high 
concentration of ascorbate and  the  linkage between activation of  iodination - 148-
and  activation of  the pentose phosphate  pathway  suggest  that  such 
mechanisms  exist.  Knowledge  about  these defense mechanisms  and  their 
regulation would  not  only be of  academic  interest in the  interpretation of  the 
relative radioresistance of  thyroid cells  (Section V,II)  but  it might  open 
new  avenues  of prevention and  protection by  the  physiological or  pharmaco-
logical control of  these mechanisms.  The  successful!  radioprotection 
offered by  superoxide dismutase  in vivo  (333)  is certainly hopeful  in 
this regard.  It is  therefore interesting that Murad  et al.  have  proposed 
the  general hypothesis  that guanylate  cyclase  could  function as  a  monitor 
of 0  free  radicals  1n  the cell and  through cyclic  GMP  regulate their disposal 
2 
(341).  The  thyroid contains  guanylate  cyclase  and  cyclic  G~W and  their role 
in this  tissue is now  actively studied  in our  laboratory. 
II.  EFFECTS  OF  RADIATION  ON  THE  THYROID 
The  biological consequences  of  thyroid  irradiation have  been  subj-ect  to 
investigation for many  years,  particularly since  the  introduction of  radio-
nuclides of  iodine  led  to  its widespread  irradiation during medical  procedures 
(6).  Among  mammalian  systems,  the  gland  is unique  in that it is one  of  the 
few highly differentiated tissues  for  which it is necessary  to  develop  a 
complete  radiobiology.  The  knowledge  that is required  ranges  from  information 
on mutagenic  and  carcinogenic events,  through data on  cell  survival  and its 
relatianshipwith the integrity of  the  gland as  a  whole,  to  the results of 
studies  on  the effect of radiation on hormone  output,  cell function  and 
degree of cellular differentiation. 
Despite  the need  for  extensive radiobiological data on  the  thyroid,  the 
subject has  not  developed  as well  as might  have  been  expected,  with  the possible 
exception of  studies  on radiation induced neoplasia  (5,6,41,183,184,212). - 149-
The  reasons  for  this are  mainfold  and  include,  in relation to cell survival  and 
associated studies,  the absence,  until relatively recently of  a  method  that 
might  be  used  to quantitatively measure  effects in this area.  Studies  on  the 
effects of  radiation  on  gland  function  have  been  equally  hampered  by  the  absence 
of suitable methodology  and  by  the  absence  of  a  good  tradition of  radiobiological 
measurements  of eellfunction.  The  in  vivo  data that are available are difficult 
to interpret,  with  the  exception of  those  on  extreme  effects,  such  as  destruction 
of  the  gland.  Information  on  less drastic consequences  of  thyroid irradiation 
obtained in vivo is confused  by the  presence  of  body  pools  of  hormone  and  the 
response  of  the  gland  to  stimulation via  the  hypothalamic-pituitary-thyroid axis. 
Many  of  these  problems  may  be  reduced  by  the  development  of suitable tissue culture 
methods  for  study of  the  glands  response  (96,  186,  211). 
The  effects of  radiation  on  the  thyroid  have  been  reviewed  recently  by 
Doniach  and  Malone  (6,  183),  and  the  problems  of  dosimetry are  reviewed  in 
Section  III.  As  indicated there internal irradiation is not  easily standardized 
because  of  heterogeneity  of  isotope distribution and  differences in dose  rate  due 
to differences in uptakes  and  effective half life.  Consequently in many  radiobiol-
ogical studies the  dosimetry  has  been either nonexistant  or  very  approximate  in 
character  (6).  Although  exceptions  to this statement exist (99,  160) it is prudent 
to start by  having  serious  reservations about  the  validity of all absorbed  dose 
estimates in in  vivo  radiobiological studies of  the  thyroid  employing  nuclides 
of iodine.  Hence  we  have  used,  in this section,  results  which  for  the  greater 
part were  obtained  using  external  X or  gamma  radiations.  Qualitatively similar 
conclusions  may  be  drawn  from  internal irradiation data. 
If the doses  are large  enough,  acute irradiation may  inhibit many  pathways  of 
thyroid metabolism.  Increasing levels of external  gamma  ray  irradiation will, 
within  a  few  hours,  inhibit purine  biosynthesis  (50%  inhibition for  3500  rads), 
protein synthesis  (75000  rads)  and  the  trapping  (300.000 .rads)  and  organification 
(200.000  rads)  of iodine  but  not  02  consumption  in sheep  and  calf thyroid slices 
in vitro.  Such  rapid effects  obviously - 150-
involve  direct damage  to  enzymes  and  membranes.  The  most  sensitive 
parameters  (purine biosynthesis)  is only affected  by very high doses 
comparable  to  large  in vivo  radiotherapy doses  (342,343). 
In vivo  high  exposures  to X irradiation  (750  to  4500  rads)  of  sheep 
induce,  after nine weeks,  obvious histologic lesions  (fibrosis,  necrosis, 
vascular damage,  inflammation)  without much  apparent  change  in thyroid 
function  (344).  Interphase cell death as  evidenced by  a  disappearance 
of  thymidine H3  labeled DNA  from  irradiated thyroids also  takes  place 
at  such levels  (194,  208,  345).  Other delayed direct effects of radiation 
at  lower  levels  (250  to  1500  rads)  are  the appearance of  chromosomal 
abnormalities  (190,  346)  and  decreased  growth  response  to  goitrogens, 
although  the  DNA  content per cell may  be  increased 
(203-205,  208,  347- 349).  As  the major part of  this  growth response  is a 
direct result of  cellular proliferation,  this effect reflects  inhibition 
of  cell division which may  result  in mitotic death.  This  effect 
not  due  to artefactual  irradiation of  the hypophysis  as  doses  of  the  same 
order applied  to  the  hypophysis  have  no  such effect  (350).  A more  sensi-
tive sign of radiation damage  is observed within 24  hours  after irradiation, 
i.e.  the  leakage  of  thyroglobulin from  the gland.  This  effect is demonstrated 
in rat already after a  5  rads  treatment  by an  increase  in plasma PBI  (351). 
Such  a  leakage might  lead  to  the  autoimmune  response  later observed  in I 131 
treated patients  (352).  As  evaluated by .electron microscopy,  the organelle 
which  appears  to  be  the most  sensitive to radiation by moderate  doses  of 
I 131  in the  thyroid  1s  the apical plasma membrane  (353)  which may  explain 
thyroglobulin leakage. 
The  main consequence  ofnormruly encountered heavy  1n vivo  irradiation of 
the  thyroid  therefore appearsto  be  the failure of  thyroid cells  to replicate - 151  -
and  cell death.Xray irradiation iriduces  a  latent cell damage  which  is 
expressed later as  a  decreased  thyroid growth  response under goitrogenic 
stimulation.  In rat,  it reduces  the plateau level of  thyroid weight 
but not  the rate of growth  (6).  As  cell density remains  approximately 
constant  under  these  conditions, the  reduction in thyroid weight  reflects 
a  reduction in cell number.As  it is known  that goitrogenic  stimulation 
after irradiation is followed  by  increases  in cell DNA  by a  factor of  two 
or more,  the defect  appears  to  be  on  the mitotic process.  At  2000  rads 
the block is complete.  Qualitatively similar results have  been obtained 
for other  tissues  :  in the weanling  mice  for  instance,  1500  to  2000  rads 
Xray  irradiation block  compensatory renal  growth completely and  perma-
nently  (354),  -and  approximately  1800  rads  of X-rays  is regarded  as  the 
tolerance  dose  of many  normal  tissues  (439). 
If the  capacity of  the cell to undergo mitosis is  taken as  an  index 
of  cell survival,  then  survival  can be  estimated  from  the  plateau growth 
of  the  thyroid under  goitrogenic  stimulation using  a  number  of  assumptions 
(6).  Measurement  of  cell survival after irradiation in the  thyroid  is  important - 152-
fti'Pl  m.,.1y  points  ul  Vll'\-.'.  For  l'Xan.ph·,it  is  thought  to  be  one  of  lht..·  critictl 
param~ters  in  determining  the  1 inal  outcome  of  radioiodine  therapy  (6,93, 16~201 ,2 
It  is also  relevant  to  treatment  of  thyroid  carcinoma  and  to determining  whether 
or  not  the  carcinogenic  action  of  radiation  in  the  gland  can  be  expressed  (  1~7). 
llowev~r,  cell  su1·vival  me~1surements have  been difficult  to achieve  in  the 
gland,  because  this  parameter  is  usually defined  in radiobiology with  reference 
to  the  presen~e or  absence  of  c~pacity for  cell proliferation  (6 ).  Other 
indices  such  as  trypan blue  exclusion or  interphase  death  ~re not  sufficiently 
sensitive,  at  the  relevant dose  levels,to be  of  value  (213).  As  the  thyroid 
is  higl1ly  Jitferentiated  and  under  normal  circumstances  does  not  undertake 
much  cell ptoliferation i_n  vivo,  it was  difficult  to  find  a  means  of  applying 
the  concept  of  cell  survival  to it in anything  other  than qualitative  form. 
Fven  in  circumstances  where  growth  in  the  size  of  the  gland  could  be  induced 
by  goitrogenic  stimulation it was  not  clqar until  relatively recently  what 
proportion of  ~h~ growth  was  due  to  hyperplasia  (6,203-205). 
ln  1948  Skanse  reported  that  large doses  of  131r  inhibited  the  growth 
response  of  chicken  thyroid  to  goitrogenic  stimulation  (206).  This  effect  was 
widely  used  by  several  groups  to  investigate  the  radiation response  of  the 
gle1nci  in  a  number  of  species  (6 ).  Studies  performed  in  the  late  1960's  in 
the  rat  and  mouse  thyroid  indicated  the  proportion of  gland  growth  that  was 
due  to  cell  proliferation and  the  influence  of  radiation  on  this  component 
(203,204,208  ).  This  finally  allowed  a  number  of  indices  approximating 
closely  to cell survival  to  be  developed  (6,99,205-208).  In Fig.  1  results 
from  one  of  these  methods  is presented  indicating,  on  the  left side  ,  the 
radiation  induced  inhibition of  goitrogenic weight  increase.  The  same  data 
is presented  on  the  right  side,  after processing,  so  that it is representative 
of  an  index  of  cell  survival.  The  index  is not  in fact  the  one  normally  quoted 
by  radiobioloGists,  that  is  the  proportion  of  cells  capable  of  proliferating. 
Instead  the  closely related  property of  total  increase  in  the  cell  number  1n 
the  gland  is  used  (6,  99  ).  The  parameters  for  the  available  thyroid  cell 
survival  curves  obtained  using  this method  are  listed  in Table  3  ·  They 1
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-·------------------------~-------------t 
Radiation 
Type 
X-Rays 
1-Rays 
y  -Rays 
1-Rays 
X-Rays 
X-Rays 
IN  ViVO  SURVIVAL  PARAMETERS 
n 
0  Extrapolation 
(rad)  No.  "n" 
450  1.7 
540  2.0 
410  3.5 
405  2.8 
SPECIAL  IN  VIVO  SURVIVAL  PARAMETERS 
Radiation 
Type 
J) 
0  (rad) 
Extrapolation 
No.  "n" 
Ref. 
99 
209 
209 
210 
207,6 
207,6 
Ref. 
-----------------+-----------t---------~--------1--------------T 
1 31  [ 
I 'J 5 
- l 
5,500 
9,400 
1  99 
1  99 
-----------------------+-------------~---------------~--------~--~ 
IN  VlTRO  SURVIVAL  PARAMETERS. 
Radiaiton/TypB 
and  Culture  Age 
X-Ray;  3  day 
differentiated 
X-Ray;  10  day 
differentiated 
X  -Ray;  10  day 
differentiated 
D 
0  (rad) 
410 
439 
Extrapolation 
No.  "n" 
1.14 
1.18 
1.04 
Ref. 
96 
96 
96 
L-------------------~----------~----------------~------------~ 
* Values  calculated  by  author  from  data presented  for  other purposes. 
TABLE  3  :  Parameters  of  various  thyroid  cell survival  curves  using 
in vivo  and  in vitro  assay  systems. 1
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consistently demonstrate  an  extrapolation  number  ("n")  of  about  2,  which  is 
normal  for  mammalian  cells.  The  mean  lethal  dose  ("D  ")  is in the  region,of 
'  0 
400  - 550  rads.  This  value is very  high  for  mammalian  cells,  which  generally 
have  a  D 0  in the  range  80  - 200  rads.  (209  - 214),  and  consequently indicates 
that with  respect to cell survival  the  thyroid appears  radioresistant (6). 
Antithyroid  drugs  that inhibit thyroid  peroxidase  (methylthiouracil,  aminotriazole), 
but  not  perchlorate  which  inhibits iodide  uptake,  protect the  thyroid  (349). 
This  effect has  been  attributed tti  a  decrease,  by  peroxidase inhibition by 
the  drug,of  the  yield of active free  radicals.  It is not  clear how  peroxidase 
by  reducing  H2o2  could  enhance  the  radiation effects.  However,  it has  been  reported 
that  H
2o
2  decreases  radiation sensitivity in bacteria  (355). 
This  method  of  measuring  cell survival  has  been  used  to  demonstrate  that 
the  gland  has  many  conventional  radiobiological  properties.  For  example,  split 
dose  experiments  show  that  recovery  from  sublethal radiation  damage  takes 
place in the  thyroid although  the  recovery  factor is smaller in the thyroid 
than  in tissue culture cell lines and  some  in vivo  systems.  Nevertheless,  it 
can  be  estimated that  "about  4650  rads  of  X radiation,  delivered in daily fractions 
of  218  rads,  would  be  needed  to  produce  an  effect equal  to that of  a  1800  rads 
.  1  d  "  ( 209  210)  t  th  d  d  d  t  .  d  d  .  131  s1ng  e  ose  ,  •  A  e  re  uce  ose  ra es  exper1ence  ur1ng  I  or 
125I  irradiation much  less  damage  is caused.  This is illustrated in  Fig.  2 
which  demonstrates  an  approximately  10- fold  increase in the  D 0  value  for  131I 
compared  with  high  dose  rate  X-rays  (99).  The  curve  for  125I  has  an  even  larger 
D0  and  this may  be  accounted  for  by  the  fact  that dose  to  the cell nucleus is 
much  less  than  the  mean  gland  dose  with  this nuclide(Section III  )i/hile  the 
major  part  of  the  above  effects may  be  accounted  for  by  dose  rate considerations, 
it is possible that dosimetry  errors  could  be  responsible  for  a  minor  portion  (6). 
Recent  work  has  led  to  the  development  of  a  system that allows  long  term 
retention of follicular structure in cultured sheep  thyroid cells in vitro  (96, 
186,  215  - 217).  This  system  allows  conventional  radiobiological assays  to  be - 157-
applied  to  the  gland.  Cell  survival  assessed  by  cloning  in this 
system also  suggests  that  the  thyroid is highly radioresistant as 
is indicated by  the  data  in Fig.  3  and  Table  3.  Furthermore,  the 
system suggests  that in the  absence  of  induced  cell proliferation 
radiation damage  develops  very  slowly  in the gland,  and  that in 
the  short  term it is refractory  to  very  high doses  (96). _j 
_J 
w 
0 
1·0 
- 158-
THYROID 
cell  survival 
in  vitro 
• 
...___ _____  ._..,L_ _____  --L. _____  _ 
0  500 
DOSE 
1000 
(RADS) 
1500 
Fig.  3  :  Survival  of  sheep  thyroid cells assessed  in vitro.  Irradiation was 
performed  three  days after explantation. - 169-
The  late consequences of  the failure  to divide and mitotic  and  interphase 
cell death is atrophy and  hypofunction of  a  thyroid which is characterized by 
imlow response  to  administred  TSH  (356).  The  latter phenomenon  and  such 
features  as  increased  iodide content,  high T3/T4  ratio,may be  due  to 
increased  TSH  levels  in response  to  thyroid  insufficiency,  as  they are 
accompanied  by  increased  TSH  levels  and  suppressed by  thyroid  hormone 
treatment  (357).  Thyroid  irradiation is a  convenient  way  to  induce  thyro-
tropic adenomas  in rats  (358). 
A later consequence of  the  irradiation and  the TSH  response  is  the 
appearance of  cell hypertrophy,  nuclear  changes  (359)  and  of  a  striking 
focal  epithelial hyperplasia presumably  involving  the cells which  are still 
able  to  respond  to  TSH  by multiplication.  Such  foci  are probably  the 
starting points of  adenomas  and  thyroid cancers  (360,361).  The  optimal 
carcinogenic dose  of  X ray is between  1000  and  2000  rads,  i.e. at the level 
at which a  great part of  the  thyroid  is no  longer able  to respond  by  growth 
to  goitrogenic stimulation. 
In this area  there is a  general paralell between  the effects of  X-ray 
131  .  d.  .  .  h  h  .d  and  I  1rra 1at1on 1n  t  e  t  yro1  •  However,  as  pointed out  in Section 
III the different properties of  131I  and  125I  radiations  lead one  to 
expect quantitatively different results with  the  two  isotopes.  Much  of  the 
.  .  125  b  b  b  d  .  h  11  . d  d  th  .  1  soft rad1at1on from  the  I  must  e  a  sor e  1n  t  e  co  01  an  e  ap1ca 
part of  the follicular cells,  whereas  the nuclei must  receive less 
radiation from  the  luminal  131I.  Indeed  17  months  after radioiodine 
administration,  131 I  treated rats  (25 pCi)  displayed evidence  of hypothy-
roidism  (reduction of  iodine uptake  and high  TSH  plasma levels),  but  no 
such effect  could qe  detected with  125I  even with high  doses  (125 pCi)  (362). - 160-
f  1 J]  1 2 5  I  .  .  .I  l  1  h  l  . d  Very  large  doses  o  I  or  1  a' m1n1stercu  to  t  1e  norma  or  ypert 1yru1 
hum.:~n  gl..u1d  caust•  luss  of  glanJ  function  and  possible  total  ablation of  the 
tissul' (6,87,91  ,92,105  ).This  mdy  even  occur  in  foetal  glands  when  the  mother 
ingests  Lldioiodine(21R-220}~toderate doses  used  111  therapy  of  thyrotoxicosis  caut-:c 
a  reduction  in  the  gland's  function which  in  the  short  term may  or  may  not 
be  complete.  Such  doses  reduce  cell survival  so  that  in  the  long  term  the 
capacity of  the  gland  to  renew  itself is  limited.  Consequently failure  of  the 
gland,  or  radiation  induced  hypothyroidism,  is possible 
The  time  lapse  between  radiation  and  failure  is probably  a  function  ~f  the 
level  to  which  cell  survival is  reduced  and  the  humoral  pressures  on  the 
gland. 
fL>rmerly  it was  thought  that  radiation  induced  hypothyroidism did  not 
h.1ve  a  well  defined  relationship with  radiation dose.  This  impression  1s 
~tobably in part  attributable  to  the  poor  quality  of  the dosimetry  associated 
with radioiodine  therapy  (149,214).  However,  recent  work  has  demonstratecl 
that  the  incidence  of  hypothyroidism  appears  to  be  a  two  step process,  one 
of  which  is  dose  relatcd(41,93  ,219  ).  The  early  incic.lence,  two  years after 
therapy  is,  as  illustrated  in  Fig.  4  ,  a  linear  function  of  dose  for  both 
131  125 
I  and  I  (41,93,94  ).  Therefore,  the  mechanisms  underlying it must  be 
closely associated  with  the  amount  of  radiation damage  developed  in  the  gland. 
Tl1e  rate  of  incidence,that  is  the  additional  increment  of  hypothyroidism  ~er 
year,  from  two  years  onwards,is  relatively dose  independent,  indicating  it 
is  11ot  strongly associated  with  primary  radiation damage.  It is more  likely 
to  be  determined  by  a  fundamental  biological process  involving  the  gland 
itself and  may  be  initiated  by  the  radiation insult  (9~.  However,  small 
differences  in  the  rate  ()f  late  incidence  have  been  noted  and  may  be  important 
in  the  long-term  (35,94,171). H
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Tht•se  dat<J  indicall·  clearly  that,in humans,aspccts  of  thyroid  fu11<..tiou 
have  a  we) 1  defined dose-response  relationship.  However,  they  represent 
a  very  scvct·e  cnd  point,  that  is  total  loss  of  gland  function.  Study  of 
lt!SS  dramatic  (\lld  points  1s  rendered difficult  in vivo  by  the  existence 
of  intPrchangeable  body  pools  of  hormone,  and  by  the autoregulating mechanisms 
of  the  pituitary-thyroid  axis  (6,105).  The  advent  of  tissue culture methods, 
it  which differentiation and  function  can  be  preserved  for  long  periods  of 
time,  will  reduce  many  of  these  problems  (96,2H\217).Consequently  it should 
now  be  possible  to obtain  a  rPlatively clear picture of  the  radiation response 
uf  glauJ  function without  the  inevitable complications  encountered  in in vivo 
experimental  models.  This  should,  ~hen coupled with  good  dosimetry,  allow  a 
better understanding  to  be  evolved  for  the  inter-relationships between cell 
survival,  gland  function,  the  integrity  of  the  gland  as  a  whole,  response  t1> 
t 
humeral  pressures  and  carcinogenesis,which will  be  discussed  in the  next 
section. - 163-
III.  INDUCTION  OF  THYROID  CANCER  BY  RADIATION  IN  ANIMALS  AND  MAN 
Tumors  appear  spontaneously in animal  thyroids  and  their incidence, 
which  is greater in some&rains  than in othersU.e.  depends  on genetic factorsh 
increases with ageing.  The  incidence of  thyroid  tumors  may  be greatly increased 
by  any  treatment  which  leads  to  chronic  stimulation of  the gland  :  TSH 
secreting pituitary tumors,  severe  iodine deficiency,  treatment with 
goitrogens which block at one  step or another  thyroid hormone  secretion, 
partial  thyroidectomy,  intrasplenic transplantation,  etc.  Combinations 
of  these  treatments  further  enhance  the  incidence of  tumors.  Irradiation 
by  external or  internal radiation may  by itself increase  the  incidence 
of  tumors;this  effect is greatly enhanced if irradiation is followed  by 
any  type  of  chronic  stimulation.  Similarly,  chemical  carcinogenesis 
acceleratesthe formation of  tumors  in chronically stimulated glands. 
This  subject has  been reviewed  by  Christov and  Raichev  (7). 
Except  in  some  inbred  strains,  thyroid  tumors  are  infrequent  in 
mice  (0,2  % 0 ).  In rats,  spontaneous  tumors  are f.requent.  They  are 
carcinomas,  mostly of  the  lobular  type,  composed  of light parafollicular 
cells.  Their frequency varies much  from  one  strain of  inbred  animals 
to  another  (0  % to  40  % at  24  months  age)  which clearly suggests  a  genetic 
influence  (363). 
The  transplantation in mice  of  autonomous  thyrotropin producing 
tumors  of  the hypophysis  induces  ~n thyroid  transplants hyperplasia,  then 
adenomas.  · Serial passages  of  such  adenomas  result  in the progressive 
emergence  of  autonomous  carcinomas which metastasize  (364).  Subtotal 
thyroidectomy also  increases  tumor  incidence, but  to  a  much  lo'tver  extent, 
1  .  131  .  .  .  1  d  ( 365)  un  ess  treatment  w~th I  or  w~th a  gro~trogen  ~s  coup  e  • Incidence  in  percent 
100 
- 164-
o Incidence  r:J  adenomas 
•  Incidence  of carcinomas 
1131  : 30 lJ(;i 
0  0  MT  ~31  J131  xRay.;  ~~--
x  Rays  : 1100  rads 
+MT  +MT 
TUMORIGENESIS  IN  RAT  THYROIDS  15  MONTHS  AFTER 
TREATMENT  BY  IRRADIATION  FOLLOWED  BY  MElHYLTHIOURtCIL 
TREATMENT  (MT).(OATA  CALa.lATED  FRav1  DONIACH). 
Fig. 5.  :From data of Doniach  (387). - 165-
Similarly,transplantation of  thyrotd  tissue in the  spleen of  thyroidec-
tomized  animals.leads  to  thyroxine degradation  ~n the liver, marked 
stimulation of pituitary thyrotrophs,  hyperplasia  of  the  thyroid  and  the 
appearance of  adenomas  (366).  There  is therefore no  doubt  that chronic 
thyrotropin stimulation per  se may  induce  thyroid  tumOEs in experimental 
animals. 
Feeding a  very  low  iodine diet to rats or mice  causes  a  lowering of 
plasma  levels of  thyroid hormones,  increased levels of TSH,  then diffuse 
hyperplasia of  thyroid  epithelium,  followed  after  12  months  by  the 
appearance  of  adenomas  and  carcinomas  (367-370).  The  latter tumaEs show 
infiltrative growth  and  develop metastases  (367,  371).  The  appearance of 
chromosomal  abnormalities  (chromatid  deletions,  hyperdiploidy,  etc.) 
precedes  nodule  formation  (369,372).  In this  case also,  it appears  that 
chronic  stimulation per  se  is sufficient to  induce  tumorigenesis.  However, 
the  relative roles of  thyrotropin stimulation and  relief  of  iodine 
intrathyroidal inhibition have  not  been  investigated.  As  could be  expected, 
administration of  iodine at  an early stage decreases  the size of  adenomas , 
if not  their number,  but  light  parafollicular cell nodules seem strongly stimulated(368 
The  best  studied  example  of  thyroid  carcinogenesis  in chronically 
stimulated tissue is  the  induction of  tumrurs by  goitrogenic agents  in 
rats,  mice  and  hamsters  (Fig.5 ).  The  most  commonly  used  drugs  are  thiouracil, 
propylthiouracil  and  methylthiouracil.  Iodization of  thiouracil  in the 
5  position eliminates  both its goitrogenic and  carcinogenic effects, which 
suggests  that both effects are  linked.  Three  stages  can be distinguished 
in the  genesis  of  the  tumours  after the beginning of  the  treatment  :  diffuse 
hyperplasia  (until  6  to  8  months),  nodular proliferation of  epithelial 
cells with formation of  adenomas  (until  the  16th to  18th month),  malignant - 166-
tumour  growth  (afte~  18  months).  Extending  the  treatment  period  increases 
both the  number  of  animals with  tumours  and  the  number  of  tumours  per 
gland.  However,  the age at which  the  treatment  is applied does  not play. 
a  significant role.  Increasing the  dosage  of  the  goitrogen will,  above 
a  certain level,  depress  thyroid  growth.  As  in the  case of  spontaneous 
tumours,  the  incidence of  adenomas  in goitrogen treated rats varies much 
from  one  inbred strain to  another  (7,373-376).  Although  there is no 
doubt  that  tumorigenesis  by  goitrogens  lS  secondary  to  chronic  stimulation, 
a  supplementary direct role of  these agents  on thyroid  enzyme  systems 
(6,321)  and  for  instance on  the  iodine intrathyroidal autoregulatory 
mechanisms  (282)  is not  excluded.  Serial passage of goitrogen  induced 
tumours  leads  to progressive dedifferentiation and  TSH  independence  (374). 
In goitrogen treated animals  the  incidence and  the rate of  appearance of 
thyroid  tumours  are  increased by  previous administration of  chemical  car-
clnogens. 
The  functional  characteristics of  induced  thyroid  tumours  vary  from 
a  fully differentiated to  the undifferentiated stage.  Although,  there  is 
no  strict relation between structure and  function,  in general,  follicular 
variants  express  the most  differentiated functional activity.  The  main 
aspects of dedifferentiation are greatly increased  thyroglobulin secretion, 
formation of  large amounts  of  iodoproteins  (eg.  albumin)  other  than  thyro-
globulin,  impaired  iodothyronine  synthesis  and  protein iodination,  and 
loss of  response  to  thyrotropin. 
While  spontaneous  thyroid  tumours  in rats are mostly of  the parafoili-
cular cell  type,  induced  tumours  resemble much  more  human  spontaneous 
and  induced  tumours  and  thus  represent  good  experimental models.  As  in man, 
adenomas,  papillary  and  follicular  carcinomas  are  found,  although  there are 
less mixed variants  and  few  anaplastic  carcinomas.  As  in rna~ their iodine - 167-
metabolism varies  from  a  complete  cycle to  truncated  sequences  to  the 
absence of  any specific metabolism. 
In general,  experimentally induced  tumours  remain very 
dependent  on TSH.  When  serial passages  of  the  tumours 
are carried out,  the first passages must  be  in thyroidectomized  animals, 
i.e.  under  TSH  stimulation;  later passages  can be  performed  in euthyroid 
animals.  During  successive passages,  the characteristics of  normal  thyroid 
tissue  tend  to dissapear.  For  example  follicular  structure,  polarized 
secretory aspects  of  the cell, karyotype,  iodide  trapping, 
thyroglobulin synthesis,  protein iodination,  iodothyronine  synthesis 
and  secretion,  and  functional  and  growth  responses  to  TSH  are all 
reduced.  However  there is no  precise  sequence 
or  linkage between markers  in this dedifferentiation.  Thus 
different  tumour  cell lines with different characteristics may  be  evolved 
(370,372,374,377).  Such  a  pattern of  almost  random  loss of morphological 
and  biochemical  markers  is similar  to  the pattern observed in spontaneous 
and  induced  animal  and  spontaneous  human  thyroid  tumours  (378-381). 
B)  ~~i~!i~~-!~~~~~~-f~E~!~£~~~~~!~-!~-~~E~E!~~~!~!-~~i~~!~· 
Irradiation whether  by  external  X-rays or  internal  emissions  from 
various  radioisotopes  induces  thyroid  tumours.  The  similar action of 
different radiations  is in keeping with data in other  systems  and  suggests 
a  common  mechanism  (382-333). 
Administration of  radioiodine  alone  induces  the  formation of  tumours. 
In one  typical experiment  on  15  rats,  25  pCi  of  r 131  induced  9  adenomas 
and  3  carcinomas within 2  years.  Similarly administration of 
X-rays  (1000  rads)  induced  adenomas  in 54  % and  carcinomas  in 22  % of 
the  irradiated rats after 2  years while  the  incidence of alveolar  carcinomas 
did not  increase  (363)  (Fig.  5). 
Carcinomas  appear  even after administration of  a  single dose  of  1 pCi - 168-
i.e.  in cases whereno  evidence of TSH  stimulation is  found  (365,375). 
Tumours  may  even  develop  in the presence of  reduced  TSH  levels  (319). 
However,  even with  the additional  stimulus  of  a  low  iodine diet,  no 
tumoursdevelop  in hypophysectomized  animals  (384).  Of  course,  as  seen 
above,  radiation by  its late depressing  effect on  thyroid function may 
induce  TSH  secretion  (192,194).  Thus  radiation by itself without  increased 
TSH  activation induces  thyroid  tumours  but it will not  do  so  in the 
absence  of  TSH. 
The  pattern of histological development  of  these  tumours  has  been 
described by  Lindsay  (360,363).  This  pattern is very  similar  to  the 
pattern observed  in tumorigenesis  induced  by  iodine deficiency or  goitrogens 
(360). 
"The  smallest  and  earliest lesions  observed consisted of  a  group  of 
enlarged  thyroid follicles  that appeared  to  arise in a  segment  of  a 
thyroid  lobule.  The  enlarged follicles were  lined by  cuboidal  epithelium, 
and  contained pale,  vacuolated colloid.  In larger nodules,  epithelial 
hyperplasia with papillary infolding was  observed.  Further  enlargement 
seemed  to  result  from epithelial growth by follicular budding,  leading 
to  the  development  of macrofollicular or microfollicular patterns.  As  a 
rule the  smaller follicles  contained little colloid,  whereas  the macro-
follicles generally were well  filled with this  substance. 
As  the nodules  enlarged,  they  tended  to  compress  the  surrounding 
parenchyma  from which  they were  sharply demarcated by  intact fibrous 
capsules.  These  adenomas  occurred  singly,  but  in many  instances were 
multiple  in one  or both lobes.  In some  cases,  these  enlarging macrofolli-
cular nodules  had  entirely replaced  the original  thyroid parenchyma  and 
thus  caused  enlargement  and  distension of an entire lobe. - 169-
Some  macrofollicular nodules  were  desienated as  papillary adenomas. 
These were  cystic  and  encapsulated,  and  were  composed  of  large follicles 
lined by  thyroid epithelium that displayed many  delicate papillary folds 
or fronds"  (363). 
Carcinomas  were  either papillary or follicular.  This  is  the descrip-
tion of  a  nodule containing a  papillary carcinoma:  "The  neoplasm consisted 
of follicles of varying size  (normal  to microfollicular)  which were  composed 
of mildly pleomorphic,  cuboidal or flattened epithelial cells.  The  pattern 
of  this portion of  the nodule was  identical with  those of  the benign 
follicular  adenomas  observed  in many  of  the  animals.  Approximately  one-
third of  the  large nodule was  occupied  by malignant neoplastic  tissue  that 
had  a  distinctly different histologic and  cytologic pattern.  The  follicular 
and  papillary structures were  composed  of moderately pleomorphic  cells 
with pale,  vesicular opaque  nuclei,  characteristic of  those of papillary 
carcinoma.  The  cytoplasm was  sparse;  a  few  mitoses were  present.  This 
papillary and  follicular neoplastic  tissue had  infiltrated the benign 
nodule  in which it appeared  to  have  arisen and  had  penetrated  the narrow 
rim of  residual  parenchyma  to  the  thyroid capsule."  In  such carcinomas, 
often the neoplasm had  infiltrated widely  and  extended  through  the  thyroid 
capsule.  Many  extraglandular satellite nodules  were  found,  and  invasion 
between  tracheal cartilages had  occurred.  Several veins  in the peripheral 
portion of  the neoplasm were  invaded  by neoplastic  thyroid epithelium  (363). 
A typical follicular  carcinoma  is also  described by Lindsay  (363).  "The 
neoplasm had  locally infiltrated the  adjacent  parenchyma  and  had  invaded  the 
lumen  of  a  large  thyroid vein.  The  pattern of  this  tumour  was  mainly 
microfollicular,  but  a  few  larger follicles,  some  containing fresh blood, 
were  present.  Many  of  the follicles  contained pale,  vacuolated colloid. 
The  cells weremihlly  pleomorphic,  with oval  or  round vesicular nuclei  and - 170-
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Fig. 5.:  From  data of Lindsay  (363). - 171  -
abundant vacuolated  cytoplasm.  Few  mitoses were  presentJ' 
The  finding of  carcinomas  developing  in adenomas,  as well  as  the 
similarity of  the pattern (papillary and  follicular)  of  adenomas  and 
carcinomas  suggest  that malignant  cells originate from previously benign 
nodules.  Similar  induction of  thyroid neoplasms  and  carcinomas  by  I 131 
treatment  alone has  been observed  in mice,  sheep  and  dogs  (7,360,385). 
The  dose  response  for  I 131 ,·  as  well  as  for  Xray  irradiation,  clearly 
exhibits  a  maximum  (Fig. 6 ).  This  is true for  I 131  in rats  (where  the 
optimal  dose was  30JlCi)  as well  as  for  Xray  (where  the optimal  dose was 
1100  rads)  (363,386,387).  Tumour  induction by radiation obviously requires 
a  balance between  the  inductory effect and  the  lethal effects  on  thyroid 
cells  (183).  There  is  some  suggestion that in mice  the  curve of 
frequency  of  adenomas,  may  be biphasic,  the  slope being  lower  for  low doses 
(194). but  the data do  not  allow any  firm conclusion.  That  the dose 
rate is important  in carcinogenesis  is  shown  by  the  great differences 
b  db  1  f  1  d  131  .  d.  .  (  h  o  serve  etween resu ts o  comparab  e  Xray  an  I  1rra 1at1ons  more  t  an 
1  d  f  131  .  .  1  h  11  d  f  )  0.000 ra  s  o  I  g1v1ng  ess  response  t  an  00  ra  s  o  Xray  •  In the 
case of  I 131  the  irradiation is delivered  in several days  whereas  it is 
delivered  in a  few  minutes  for  the Xrays.  On  the other hand,  administration 
of  I 131  in 2  doses  separated by  4  to  6  months  did not decrease  the  incidence 
of  tumours  1n rats  (183,319).  Experimental data do  not  throw more  light 
than clinical data on  the  subject. 
Susceptibility to  cancer is clearly different  from  one  strain to 
another,  which  suggests  a  genetic  component  in susceptibility  (7).  This has 
its counterpart  in man,  with  the higher susceptibility of  Jewish patients 
(388).  Whereas  spontaneous  thyroid  cancers  (lobular and  carcinomas)  appear 
twice more  often in females  rats after irradiation,their  spontaneous  frequency 
is higher  in males  (389).  Because follicular cells are  taller in males,  it has  beer - 172-
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Fig.  7  :  !H  indicates administration of  thyroid extract (365). - 173-
suggested  that this is due  to  higher  TSH  levels or responsivity in males 
(183,319,387).  In humans  the  incidence of radiation  in~uced and  spontaneous 
tumours  is higher  in females  (87,388). 
The  types  of neoplasms  induced by  radiation in the rat are mostly  the 
follicular and  papillary carcinomas.  This is different from  the most  common 
spontaneous  tumours  in these  animals  (lobular carcinomas)  but  similar to 
human  spontaneous  and  radiation induced  tumours  (360,363).  In man  and  in 
sheep  (385),  radiation induced  and  spontaneous  carcinomas are of  similar 
type  (360).  The  data  in rat however  suggest  that radiation induces  a 
certain number  of  tumours  rather  than increasing their  spontaneous  incidence. 
As  with  tumours  induced  by  chronic  stimulation alone,  radiation induced 
thyroid  tumours  are often initially TSH  dependent,  but  subsequently loose 
~his dependence  (384).  The  latency of  induced  cancers is long  compared 
to  the life span of  the  species  :  8  months  in the rat,  10  years  in sheep 
(385),  and  10  to  20  years  in man  which is of  the  same  order as  for various 
types  of  leukaemias  (390). 
TSH  as  well  as  any  treatment  stimulating  the  gland  (e.g.  goitrogens) 
greatly enhances  the  frequency  of  radiation induced  cancers  and  combination 
of  these  treatments  further multiply this  frequency  (321,360,386)  (Fig.  5,7). 
The  converse effect is obtained by  thyroid hormone  administration  (Fig.7). 
Among  such goitrogens,  some  are  chemicals  used  for various  purposes 
(e.g.  aminotriazole as  an herbicide)  (376).  Goitrogens also  reduce  the 
delay between irradiation and  the  appearance of  tumours  (to 5-6 months 
from  24  months). - 174-
Even  though  the  formation of  tumours  is greatly accelerated by  TSH,  in 
the presence of  goitrogens  thyroid extract in small  quantities may  poten-
tiate goitrogenesis  and  the  appearance  of  adenomas  and  carcinomas.  Thus 
tumorigenesis  and  goitrogenesis  are  favored  by  the presence of  a  minimum 
of  thyroid  hormone.  It is probable  that this  is due  to  the fact  that 
such a  minimum  is required  to maintain the level of  growth  factors,  such 
as  growth  hormone  (373,375).  It has  also been reported  that stress by 
faradization  increases  the  frequency  and  decreased  the  latency of  thyroid 
·  d  '  h  13 I  d  1  h.  . 1  ( 39  2)  cancers  1n rats treate  w1t  I  an  methy  t  1ourac1  • 
In the  induction of  thyroid  tumours,  the proliferation state of  the 
thyroid at the  time of  irradiation is crucial.  300  rads  of Xrays  given to 
a  non proliferating rat thyroid gland  induced  tumour  growth  in 25  % of  the 
' 
animals  18  months  after irradiation.  The  same  dose,  applied  to  a  prelife-
rating thyroid of  a  goitrogen treated animal  increased  the  tumour  incidence 
to  30  % when  administered  in the  lag phase,  to  75  % wh~n administered at 
the  peak of  the proliferating phase,  and  to  62,5  % when  given at the 
plateau phase.  Moreover,  most malignant  tumours  appear  in the  animals 
irradiated at  the  top  of  the proliferative wave.  Similarly,  when  animals 
are  treated with  a  carcinogen AAF  (2  acetylaminofluorene)  instead of 
irradiation,  during  the different phases  of  the  thyroid proliferating wave, 
most  tumours  appear when  the carcinogen is given at  the  top  of  the proli-
ferating wave  (321).  A similar phenomenon  has  been observed  for  liver and 
kidney. - 175-
C.  Radiation induced  carcinogenesis in man  and  its relation to 
present dose limits. 
The  known  carcinogenic  action of  ionizing  radiations  has  led  to  concern 
that  ·their widespread  use  in  the  thyroid ,may  lead  to development  of  unwanted 
and  potentially dangerous  neoplasia  (41,80, 187, 18f)Section II) .The criteria by 
wl1ich  j  relationship  can  be  established  between  irradiation and  subsequent 
neoplastic  Jevelopment  in human  subjects are  demanding  and  have  been outlined 
by  Saenger  and  co-workers  ( 188).  In particular  the  hypothesis  claiming  to 
establish an  association must  be  formulated  in  a  fashion  that  it could  b~ 
proven  to  be  untrue.  Thus  selection of  appropriate  control  groups  wl1en 
surveys  on  radiation  induced  disease  are  being  conducted  1s  particularly 
important.  For  example,comparison  of  the  radiated  group with  the  public  at 
large will  frequently  not  provide  an  adequate  control.  This  is because 
tddiation will  often have  been  administered  as  a  medical  procedure  for  a 
L·<Judi Lion  that  may  predispose  the  subject  to acquire  the  disease  being 
investigated  (  18~.  Therefore,  finding  valid  control  groups  is difficult, 
,dthough  in  the  case  of  the  thyr<Jid  it has  been  achieved  (41,178,188  ).  Once 
acceptable  controls  have  been established;it is also desirable  to demonstrate 
a  dose-effect  relationship when  an association between radiation and  disease 
1s  being  evaluated. 
Some  reports  associating  head  and  neck.irradiation during  childhood  with - 176-
thyroid neoplasia in later life did not have controls satisfying the above 
criteria (61).  The  uncertainty resulting  from  this position has  been 
resolved,  and  the epidemiological  evidence  linking neoplastic development  in 
the  gland with childhood irradiation is now  indisputable  (41,178,188).  It 
is based  on a  wide variety of experience  including irradiation consequent  on 
nuclear explosions  as well  as  diagnostic  and  therapeutic medical  procedures 
(6,41,61,72,87,178,183,184,188,189)  (see Section II).  Furthermore,  the data 
demonstrate  a  dose-effect relationship  that is continuous  down  to 6.5  rads. 
Data on  induction of  cancer  in the  thyroid were critically reviewed  by  the 
BEIR  Committee  and more  recently have  been  summarized  by  Conard  (87,178). 
Additional  data  (above  and  beyond  those discussed  in these reports)  is 
available,  and  has  been  subject  to  some  analytical  comment  (41,72,80,176,189,212). 
The  risk estimates for malignant  and  benign neoplastic developments  from  these 
reports are  summarized  in Table  4.  For calculation purposes  a  value  of 
3  x  10-6  per man-rad  per year will be  taken for  induction of malignancies. 
The  rate at which benign adenomas  occur is greater,  but more  uncertain and 
appears  to  range  from  twice  to fifty times  the rate for  carcinomas.  However, 
for calculation purposes it is not unreasonable  to use a  value of  5  (41,87,187). 
The  epidemiological  investigations cited above  have  been 
performed  to  a  large extent  in children and  are  supported by  the  extensive 
experimental work  in animals  noted  in V,III,B.  These  investigations 
confirm the  sensitivity of  the  thyroid  to  low doses  (190),  and  clearly identify 
irradiation as  a  significant factor  in the  tumour  induction  process  (80,183,187, 
191-193).  This  process  requires  that  some  time after irradiation the  thyroid  is 
subjected  to  a  stress  such as  TSH  stimulation,  which will lead to cell division. 
The  fact  that  the gland  comes  under  such pressures naturally during adolescence 
is thought  to  explain the high  tumour  incidence  in young  adults whose  thyroids 
were  irradiated while  they were  children.  It is also likely that  similar mecha-
nisms  operate  in adults whose  thyroid is supject  to 
horconal  pressures arising naturally for  example  from - 177-
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pregnancy,  through disease or  through dietary factors.  Consequently 
while  these riskestimates are for  a  great part based on  the results 
from  populations  irradiated during childhood,  they may  not  be  ignored 
for  the adult population.  This  is supported by  the fact  that radiation 
inducedneoplasia have  been noted  in adult  populations  in studies of both 
animals  and man  (87,177,184,192,194,434)  and  a  recent investigation noted  a 
similar cancer  incidence in those  irradiated as  children or adults  (41). 
Furthermore,  the risk of death from  a  thyroid  cancer  induced after adult 
irradiation may  be greater,  since  thyroid cancers  in older  people  tend  to 
follow a  more  malignant  course  (178).  This may  be associated with  a  more 
prolonged  period of  stress arising from  abnormal  thyroid status,  than  the 
limited  time  scale of  stress during adolesence. 
Table  5  lists the consequences  of  these risk estimates  for workers 
receiving various  annual  doses  during  a  40  year working life with an average 
follow up  period of  30  years.  These  figures  suggest  that  the risk of 
malignancy  for  a  worker  receiving 50  rads/year  to  the  thyroid would  be  18  % 
and  that of a  benign adenoma  would  be  90  %.  The  adenoma  risk appears  somewhat 
high compared  with  some  values  quoted  in the literature but is in keeping with 
recent estimates  (Table  5)  (41,178,195).  The  risks of fatality in Table  5 
are calculated from  estimates  in the  recent  recommendations  of  ICRP  (181). 
While  the risks  quoted  above  do  not  imply  a  fatal  outcome,  except  those 
of  ICRP,  they are relatively high when  considered in relation to  the maximum 
permissible  thyroid  dose  levels allowed  by various  agencies  (180,181).  Because 
of  the high ratio of  thyroid  to·whole  body  dose when  nuclides of  iodine are 
ingested,  the maximum  permissible dose  to  the gland  is quite large if it is 
calculated according  to  the  new  ICRP  weighting factor  system  (181).  In many - 179-
----------------------------
Risk  ~H·r  10°  lll.:lll  rads  ~~~r  year  Reference 
l;IJiguant  Benign 
---------
1.6 - 9.3  75%  of  those  receiving  178 
1000  rads 
3.4+  49 
+  87 
-'tApprox  10  - 72,189 
4.2  12.3  ld 
-
+  Mean  values  from  10  groups 
* Approximate  value 
IAHLE  5  :  Risk  of  benign  and  malignant  neoplasia  in 
thyroid  after  irradiation.  Adapted  from 
Malone,  1978  (168) - 180-
c.!ses il is  so  high  that  it  i!i  coustraineJ  by  th~  SO  rad  limit whose  main 
purpose  is  to prevent  non  stochastic effects  ( 168, 181).  Thcrl~fore, within 
the  present  dos~ limits it may  be  possible  for  subgroups  of  the population 
to  be  J.t  substantial risk of  nonfatal  harm  from  thyroid  irradiation.  It 
could  be  wortl1  further 1constraining dose  limits or  introducing  new  forms  of 
medical  surveillance  to  reduce  these  risks  pending  a  clearer evaluation of 
the  above  data,  and  an  assessment  of  the  acceptability of  nonfatal  harm  to 
radiation workers  ( 168,434,435). 
At  higher  dose  levels,  for  example  after radioiodine  therapy  of  hypcrthyroidis 
it has  been established  that  there  is no  excess  of  thyroid  carcinoma  in 
radiation  treated  patients when  they  are  compared  with a  surgically treated 
control  group  (39 ).  This  is  thought  to  be  a  consequence of  radiation 
sterilization of  the  cells which  renders  them  refractory  to  TSH  pressure  to 
undertake  mitosis,  and  thereby  makes  tumour  formation difficult.  Strong 
support  for  this  view  is available  from  experimental  work in animals  noted  in 
B above  (~,41,196,212).  The  data  on  incidence  of  thyroid  cancer  after 
radioiodine  therc.1py  has  been  obtained  from  studying  groups  who,by  todays 
standards,received  relatively high  doses.  With  low  dose  therapy  and  thP  ttst 
f  125  1  •  •  .  •  •  o  I  t1ere  1s  a  poss1b1l1ty  that  the  cells  1n  the  gland  may  not  be  as 
effectively sterilized  as  with  larger doses.  Hence  the  question  of  radiation 
induced  neoplasia must  be  reexamined  for  patients who  have  been  treated  in 
this  manner  ( 6, 184  ) • 
Similar  surveys  have  established  that  there  is  no  excess  of  leukaemia 
after  radioiodine  therapy  for  hyperthyroidism  ~97 ), although  there may  be 
in  those  given very  large doses  for  thyroid  carcinoma  (190  ) •  Th-e  likelihood 
of  abnormalities  in reproductive history after  these  forms  of  treatment  is 
regarded  small  provided  sufficient  time  is allowed  to  lapse between 
therapy  and  concept  ion  ( b, 199, 200 , 220) • - 181  -
IV.  PRESENT  CONCEPTS  IN  TUMORIGENESIS  AS  APPLIED  TO  RADIATIOrl  INDUCED 
THYROID  CANCERS 
Our  present concepts  on  the  induction of  tumours  are derived  from 
the now  classical induction ofskinneoplasia by  the  successive application 
of benzopyrene  and  croton oil  (393).  The  induction of  a  tumour  would 
result from  2  independent actions  referred to  as  "initiation''and"promotion" 
(II,  393 -395).  The  former  would  be  a  fast irreversible process  acting on a 
normal  cell  and  conferring upon it tumorous  characteristics;  the  induced 
cell might  remain  indefinitely in adormant  state without further division. 
When  followed  by  the  slowly acting process of promotion,  initiation would 
result in tumour  growth. 
Initiators are compounds  which usually behave as mutagens  and  can be 
given under  conditions where  no  tumours  form.  Promoters,  which are not 
mutagens,  and  do  not by  themselves  cause  tumours,  can cause  the expression 
of  tumours  in animals  pretreated with initiators.  In contrast  to  the one 
hit effect of initiators,  promoters must  be  continuously applied  to first 
cause  tumours  such as  papillomas;  these disappear when  promoter  is  removed; 
only after prolonged application of  promoters  do  tumours  appear  (396).  The 
actions of  i,nitiation and  promotion are  thus  resolvai in time but also  in 
quality.  The  final yields of  tumours  is generally a  function of  the initia-
tors dose,  while  the rate of appearance  depends  upon  the  time  of action and 
dose of  the  promoter.  It is considered  in general  (11)  that radiation is a 
very special  carcinogenic agent,  shares  the properties of initiator and  pro-
motor  and  cannot  be  considered as  a  pure  initiator or  promoter. 
Initiation and  promotion may  involve several discrete steps.  A model 
which apparently accounts  for  existing data has  been proposed  for  the  induc-
tion of  osteosarcomas  by  internal emitters;  it involves  3  successive  stages, - 182-
2  of  initiation followed  by  one  of promotion  (390).  With human  carcinomas, 
a  log-log plot of  incidence versus  age gives a straight line of  slope  4-6 
which  suggests  4  to  6  stages  in the progression of  normal  to  cancer cell 
(396,397).  In inherited medullary  thyroid  carcinomas,  the  presence  in 
the  same  individuals  of different monoclonal  tumours  suggests  that  the 
inherited defect  is an initial mutation producing multiple clones  of defec-
tive cells;  each  tumour  would  then arise as  a  final mutation in one  clone 
of  these cells  (398). 
In the  systems  studied  so  far,  there has  been  a  relation between 
promotion and  enhancement  of cellular proliferation;  the latter is clearly 
necessary for  tumour  progression.  However,  so  far,  there is no  unequivocal 
evidence  that  the  induction of proliferation in cells is a  key  event  in 
radiation carcinogenesis  (11).  Most  promoters  stimulate cell division 
but many  non promoting  chemicals  also  stimulate cell proliferation. 
It is widely believed  that  initiation involves  an alteration in the 
cell's DNA.  This  is supported  by  the  fact  that  a  single  low  dose  of 
initiator is sufficient  to  produce  permanent  changes.  Tumours  develop  in 
the mouse  skin,  for  example,  even if a  year is allowed  to  elapse between 
application of  the  initiator and  treatment with the  promoter.  The  cells 
appear  to  have  a  memory  for  the  initiator,  a  result  implying  that initiation 
involves  a  genetic  change  that  can be  passed  from  one  generation of  cells 
to  the next.  The  fact  that initiating agents  are  or  can be  converted  to 
compounds  that attack DNA  also  supports  this  concept  (399). 
The  most  prevalent  concept  about  the nature of  initiator attack is 
that  they  induce  somatic mutations.  The  proposal  that  the  induction of 
malignancy  1s  associated with  somatic mutation has  been  and  still is  supported 
by many  arguments  including ' 
183  -
I) Most  chemical  carcinogens  1n  eukaryotic cells are mutagens  in 
bacteria ,  provided  the  chemicals  are  treated with  liver endoplasmic 
reticulum,  as  an in vitro substitute of  in vivo metabolic  transformations. 
There  is  a  rough  parallelism between  the  two  properties  (400,401).  Indeed, 
a  test of  the mutagenic  capacity of  environmental  chemicals  is now  used 
to  predict potential carcinogenic actions. 
2)  A  connnon  feature of very different  chemical  carcinogens  and  a  variety 
of  radiations  which  are also carcinogenic,is  that all damage  DNA  (383,400,402). 
3)  Metabolic  defects  of  DNA  repair mechanisms  (eg.  in xeroderma  pigmen-
tosum ataxia  telangiectasia,  Fanconi' s  anaemia)  are  accompanied  by  a  high 
incidence of malignant  lesions  and  high  susceptibility to  UV  induced 
lesions  (403-405).  Although  for  each disease,  some  strains of cells have 
been  shown  to  be  repair deficient for  ionizing radiation damage  (405,406), 
we  know  of  no. study on  the possible X ray  induction of malignant  neoplasms 
in such patients. 
4)  The  elegant cell hybridization experiments  of Harris  have  shown 
that hybrid cells  formed  by  fusing malignant  and  non malignant  mouse  cells 
are  in general  non malignant.  The  hybrids  become  malignant  when  some 
defin1te  chromosomes  are lost.  This  clearly suggests  that  the  factor 
which  controls  the  expression of malignancy  behaves  as  recessive genetic 
character  (407). 
5)  The  simulation of  equations  describing a  model  in which  transfor-
mations  would  be  caused by  a  specific DNA  alteration,according to Harris 
model, reproduces  experimental  transformation  versus  dose  curves  (408). 
There  is  therefore now  strong  support  for  the  concept  that  in a  cell 
carrying the recessive malignant  genotype,  the expression of malignancy 
could result  from  a  mutation or aberration  removing  the  suppressive action 
of  a  specific gene(400). , 
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Initiation may  require cell proliferation.  This  concept  is  supported 
by  the fact  that  several  carcinogens  are  carcinogenic in liver if injected 
after partial hepatectomy,  but  not  in intact animals  (409).  Recently, 
in a  more  precise analysis,  Cayama  et al.  (410)  have  shown  that foci  of 
phenotypically altered hepatocytes  (the precursors of  tumours)  only appear 
if the carcinogen is given after hepatectomy at a  time  of rapid cell 
proliferation.  Several  carcinogens,  which  induce  foci of altered hepatocytes 
without  exogenously  induced  cell proliferation  (eg.  by  hepatectomy)  are 
necrogenic  and  induce per se  co~pensatory liver cell proliferation. 
Although  the mechanism of this effect is not known,  it clearly suggests 
that replication of  carcinogen damaged  DNA  before repair would  fix this 
damage  by  increasing  the  chances  of altered nucleotide  sequences  in the 
newly made  DNA.  Indeed  such  carcinogen damaged  DNA  replicates  in vivo. 
Transformation of cell cultures with DNA  viruses  and  Xrays  also requires 
at least one  cycle of cell proliferation  (411)  • 
Recent  observations  on  the action of  promoters -reveal  important facts. 
Phorbol  esters  induce  in cultured cells changes (eg.  in  cell morphology, 
increase in plasminogen activator synthesis,  in deoxyglucose  uptake, and  loss 
of  large external  transformation sensitive proteins,  etc.), which  resemble 
those  seen on  transformation by  chemical  carcinogens or  tumour viruses, 
and  further  enhance  the expression of  these transformations'specific pheno-
typic  features  in already  transformed cells.  These effects are not entirely 
a  consequence of  growth stimulation since  they occur  in chicken fibroblasts 
under  conditions where  growth  stimulation does  not  occur  (412).  The  second 
important  action of  phorbol  esters on cell biology is to  inhibit  terminal 
differentiation.  Such  an effect has  been demonstrated  in several  systems. 
This  has  an  important  consequence  in systems  where  tissue growth is sustained 
by  a  stable pool  of  stem cells achieving asymmetric division,  i.e. with one - 185-
daughter cell remaining  a  stem cell, while  the other is terminally committed 
to differentiate and  to  stop dividing.  Both of  these phorbol  esters•actions 
enhance  cell multiplication and  may  favour  the multiplication of  initiated 
cells.  However,  such hypotheses  are still highly speculative  (412). 
The  biochemical  changes  induced  by  promoters  have  been intensively 
investigated.  Two  such changes  are  the  increases  in the  enzymes  ornithine 
decarboxylase  (ODC)  and  plasminogen activator.  ODC  is greatly increased 
within 2  hours  after exposure of mouse  skin or cultured cells  to  the most 
effective promoter  TPA  (12-0-tetradecanoylphorbol-13 acetate)  and,for 
various derivatives,  there is a  close correlation between  the  degree  of 
promotion and  increased  ODC  activity.  Thus  far,  all promoters  tested 
have  been found  to  increase  ODC  activity,  but  some  non  promoters  also  do  so. 
The  enzyme  ODC  is needed  for  the  synthesis of polyamines  which are  involved 
in cell multiplication.  Thus  enhanced  production of  ODC  could  lead  to 
greater cell proliferation.  Promoters  transitorily induce  ODC  production 
in normal  cells,butminitiated cells  high production of  the  enzyme 
eventually becomes  permanent.  This  has  suggested  to  Boutwell  et al.  (413) 
that initiation would  involve  the loss of  a  gene  that would  normally control 
induction of  ODC.  A number  of  agents which  inhibit  ODC  induction by  promoters 
also  inhibit promotion  (eg.putrescine,  retinoids,  inhibitors of  prostaglandin 
synthesis,  etc  ••• ).  Thus,there is strong  support  for  the hypothesis  that 
ODC  activity is  a  prerequisite for  tumour  promotion  (413). 
In cultured cells,  a  specific protease,  plasminogen activator is also 
increased by  treatment with phorbol  esters  (412,414).  It has  been proposed 
that this protease would  turn on genes  by destroying  the proteins  that 
normally block their expression.  Although,  this hypothesis  looks attractive 
many  promoters  unrelated to  the phorbol  compounds  have  no  effect on  the 
production of  plasminogen activator. 186-
There  is  some  evidence that promotion  involves  a  series of  steps. 
In the mouse  skin the first  tumours  formed  are benign papillomas.  Host  of 
these regress  if exposure  to  the promoter ceases,  but  some  of  them  grow 
autonomously.  Carcinomas  develop more  frequently  in such papillomas. 
Moreover,  papillomas  appear much  more  rapidly in skin in which papillomas 
had  formed  and  regressed  than in normal  skin.  Thus,  cells previously 
submitted  to promoters  retain some  permanent  characteristics.  This  concept 
of  ~ultistep promotion suggests  that by  removing  a  promoting agent or by 
using inhibitors of  promotion one might  stop  the progression  towards 
cancer  (394).  This  would  be  even more  so  in cases  in which  the various 
steps would  not be  irreversible and  redifferentiation could  take place  (395). 
The  concept  of multistep progression from  the  normal  to  the fully 
invasive  cancer cell  (397)  also  appears  to  apply  to  the  formation of 
metastasizing cells.  Indeed,  clones  derived  in vitro from parent cultures 
of malignant melanoma  cells vary greatly in their ability to  produce metas-
tatic colonies.  This  suggests  that  the parent  tumour  is heterogeneous with 
regard  to  this property and  that highly metastatic  tumour  cell variants 
I 
preexist  in the parental population,  i.e.  that  the acquisition of  this 
property is  ano~her discrete genetic step  in the process  of  transformation(415). 
It is perhaps  in the  framework  of  the  concept of  tumour  promotion that 
the very challenging hypothesis  of  tumour  production of ectopic  growth 
factors  and  their autostimulation by  these  factors  should be  introduced. 
It is well  known  that many  types  of  tumours  secrete proteins,  such as 
hormones  or  growth  factors  that  the normal  parental cells do  not  synthesize 
(eg.  somatomedins,  ACTH,  etc.).  These  factors  are necessary for  the  growth 
of  some  normal  cells.  It is also well  known  that  tumour  cells may  have 
receptors  for  hormones  other  than the  hormone  controlling the  normal  parental 
cells.  Secreting factors  which would  interact with  them  and  stimulate their - 187-
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Fig. 8 •  :  Present working  hypotheses  on  the mechanism of  thyroid cancer 
induction by  irradiation. - 188-
own  growth would  therefore confer  a  great advantage  to  tumour  cells. 
Although  the evidence  that  such a  scheme  would  apply  is  tenuous,  it would 
• 
give  a  role  to  two  until now  puzzling phenomena  :  ectopic  protein synthesis 
and  ectopic receptor  appearance  (416).  Prostaglandins which are  secreted 
in greater-amounts  by  some  tumours  and  act as  promoters  in skin epithelium 
(417)  may  be  another  example  of  such  a  mechanism. 
The  parallels  between  the  generation of  thyroid  tumours  and  the 
concepts  developed  above,  with  irradiation as  the initiator and  TSH 
or  growth  stimulation as  promoter,  as  proposed by Doniach and  Christov 
(7, 183)are  striking  (Fig. 8).  There  are several  arguments  suggesting that 
irradiation fulfills  the criteria for  an  initiator  : 
1)  Radiation is considered as  an initiator in other  systems. 
2)  Tumours  appear when  irradiation precedes  stimulation. 
3)  One  hit irradiation is sufficient. 
4)  The  frequency  of  experimental tumours is a function of the radiation dose. 
5)  The  carcinogenic effect of radiation in rat reflects an  induction 
of  new  cancers rather  than an  increase in spontaneous  incidence. 
6)  Irradiation  is a  more  effective carcinogenic  agent with proliferative 
thyroid  cells,  just as  irradiation, viral transformation and  other 
carcinogens  are  in other cells  (411). 
The  known  mutagenic action of  irradiation,  the  appearance of  chromosomal 
abnormalities  in thyroid  irradiated at carcinogenetic  levels  and  the fact 
that  long lasting irradiation  (by  internal  radioisotopes)  induces  less 
tumours  than equal  radiation applied  in a  short  time,  i.e.  that repair 
phenomena  take place,  are  compatible with  the  concept  that initiation is 
caused by  a  somatic mutation.  Moreover,  a  very  good  argument  in favor  of 
the  application of  this  theory would  be  the  demonstration of  a  clonal 
origin of  the  tumour  cells.  The  inactivation of  one  X chromosome  in each - 189-
somatic  cell of mammalian  females,  with  the  expression'of  one  allele 
for  any  X linked  enzyme  in each cell,gives the meansto  test this 
hypothesis.  Fialkov et al.  (418)  have  shown  that,  in  thyroid  tumours 
of women,  only  one  allele of  the X linked glucose  6  phosphate  dehydrogenase 
is expressed.  However,  such a  compelling evidence has,  as yet,  not been 
looked  for  in irradiation caused  thyroid  tumours  wheth~er human  or experi-
mental. 
The  concept  that  TSH  acts as  a  promoter  in irradiation induced 
thyroid  tumours  is  suggested by  the fact  that all experimental  procedures 
which  increase  TSH  stimulation increase  the  frequency of  tumours  and/or 
decrease their latency.  Horeover  suppression of  the  continuous  stimulation 
by  TSH  leads  to  a  decrease or suppression of  tumour  appearance.  That 
promotion may  also be  achieved by alteration of  intracellular  iodine metabo-
lism is  suggested by  the fact  that goitrogens,  i.e.,  inhibitors of  iodide 
oxidation,  are  the most efficient promoters,  while  iodide decreases  tumour 
frequency in irradiated glands.  However,  this  concept  is still debatable. 
It is therefore clear that  the  concept  of radiation as  initiator and 
TSH  as  promoter  of  thyroid  tumour  formation  is compatible with most  of  the 
existing data.  However,  this concept  should  be  refined.  Radiation alone, 
with no  increased  TSH  stimulation but not  in the absenee  of TSH,  can  induce 
tumours.  In this  case,  normal  thyroid  growth alone  could act  as  the  promoter. 
On  the  other hand,  prolonged  thyroid  stimulation alone also  leads  to 
tumour  formation.  TSH  could  th~s promote  spontaneously initiated cells. 
It is obvious  that  the action of  TSH  should be  related  to its growth 
promoting rather  than  to its function activating effects.  This  is supported 
by  the parallel  between  the  goitrogenic  and  carcinogenic properties of 
antithyroid drugs  and  in keeping with  the possible role of cellular prolife-
ration in the promotion of  tumours.  The  precise mechanism of  promotion by - 190-
TSH  is unknown,  but it is interesting to note  that TSH  like other promoters 
in other  systems  activates  the  synthesis of ornithine decarboxylase  and 
that human  tumours  contain increased amounts  of  polyamines  (419).  Nothing 
is known  about  the  synthesis of  plasminogen activator by  normal  or  tumour 
thyroid cells. 
Prostaglandins which  like TSH  enhance  the  ~ccumulation of  cyclic AJW 
and  the  consequent  ornithine decarboxylase  induction in thyroid cells act 
as  typical promoters  on  skin epithelial  (417)  and  thyroid cells.  In the 
skin the effect of promoters  on  the  induction of ornithine decarboxylase 
is blocked by  inhibitors of prostaglandin synthesis  such as  indomethacin, 
but  relieved by prostaglandins of theE  type  (413,420).  The  role of 
prostaglandin like compounds  in TSH  promotion action or as  an  independent 
promoter certainly deserves  further  study. 
The  long  latency period of  induced  thyroid  tumours  can be explained in 
part by  the  time  ~equired for  a  transformed cell  to multiply  into a  clone 
of  detectable size.  However,  experimental  evidence  implies  that  the 
evolution of many  neoplasms  involves  a  series of qualitative changes  that 
give rise to  successive populations of  increasingly autonomous  cells. 
There  is good  evidence  that  this concept  applies  to  radiation induced 
thyroid cancers 
I)  In experimental  tumour  induction,  hyperplasia,  adenoma,  carcinoma, 
follow a  clear  sequence.  Generation of  carcinomas  requires  stronger  tumori-
genic  stimuli. 
2)  In any  given animal,carcinom$ are of  the  same  type  as  the  adenomas 
(papillary vs.  follicular). 
3)  There are  good  demonstrations  of  carcinoiD$ developing  in previously 
existing adenomas. 
4)  The  loss of biochemical markers  of  differentiation and  of follicula·r - 191  -
characteristics is independent,  stepwise  and  progressive.  This  is also 
true for  the appearance of  TSH  independance  in human  carcinomas  as  ~n 
serially transplanted experimental  tumours.  However,  the demonstrated 
discrepancies between  incidence of  radiation induced  thyroid adenomas  and 
carcinomas  (eg.  rats treated with  I 131  alone,  greater  incidence of nodules 
but not  carcinomas  in female  patients,  etc.)  suggest  that  the  sequence 
between  the observed discrete changes  may  not  be  straightforward. 
V.  REGULATORY  SYSTEUS  IN  IRRADIATION  INDUCED  THYROID  CANCERS 
The  biochemistry of  spontaneous  and  induced  thyroid  tumours,  though 
not  specially of irradiation induced  tumours,  has  been much  studied with 
regard  to  iodine and  specialized metabolism  (379).  To  summarize  shortly 
this  important  literature,  isolated or combined  defec~of all the metabolic 
steps  in thyroid hormone  synthesis or secretion have  been described  :  defects 
in iodide  trapping,  in protein iodination at the level of  H
2o
2 
generation 
or peroxidase,  defective synthesis or sialidation of  thyroglobulin,  prefe-
rential accumulation of  iodalbumin  in the colloid lumen,  defective 
coupling of  iodotyrosyls  in iodothyronines,  abnormal  secretion of  thyroglo-
bulin or of  iodoalbumin,  etc.  (374,379).  There  seems  to be  no  clear-cut 
relationship between  the histological  appearance of cancers  and  their 
specialized metabolism.  When  they are irreversible,  such defects  have  a 
great  importance  in therapy as  the most  efficient treatment  for  irradiation 
of  thyroid  tumours  and  their metastases  is their destruction by administered 
131  and  sequestrated  I  • 
From  the  therapeutic  v~ew point  the most  interesting area in the 
biochemistry of  normal  and  tumour  thyroid is  the regulation of  growth  and 
differentiation.  lVhich  are  the  intracellular signals  involved  and  how  are 
they controlled ?  Could  their modulation in tumours  stop  growth  and  induce 
redifferentiation ? - 192  -
Pastan and  his  group  (421)  have  shown  that cyclic A}W  and  its derivatives 
inhibit  the  growth of  normal  and  transformed  fibroblasts.  The  cells lost 
most  of  their transformation characteristics and  appeared  to redifferentiate. 
Moreover,  in such cells an  inverse correlation was  demonstrated  between 
cyclic AJW  levels  and  rate of growth,  transformed cells containing less 
cyclic  JU~ than  the parent  strain from  which  they were  derived.  The  cause 
of  the decrease was  related  to  decreased  adenylate  cyclase or  to  increased 
cyclic nucleotide phosphodiesterase activity.  Based  on  such data,  Pastan 
et al.  proposed  the general hypothesis  that cyclic AMP  is  a  negative  signal 
of  grovlth  and  a  positive signal  for differentiation and  that  this  signal 
1s  the regulator of  the  expression of  transformation,  vs  differentiation 
(421).  However,  later studies  in other cells  (314,422,423)  showed  that 
cyclic  GMP  analogs  stimulated  them  to initiate DNA  synthesis  and  increase 
in cyclic  Gl~ occurred when  they were  stimulated  to divide  (238,314).  Thus 
there  is  some  evidence  that  cyclic  G~W could be  a  positive signal  for 
growth.  Rates  of  cell multiplication in culture have also been related  to 
the ratio cyclic GMP/cyclic  AMP  (423).  Berridge has  made  a  strong case 
++  in favor  of  the hypothesis  that  Ca  could  be  the positive signal  for 
growth  and  cell multiplication  (275).  In his  scheme,  cyclic nucleotides 
would mostly be  involved  in the  regulation of  calcium levels.  Despite  the 
apparent  contradictions between  these  theories,  a  unifying  scheme  is  slowly 
emerging.  First of all,_although the  intracellular signals may  modulate  the 
rate of  growth  and  cell multiplication,  they do  not  appear  to  be  required 
for  any  fundamental  aspect  of  these processes.  For  example,  cells devoid 
of  cyclic AMP  or mutants  lacking responsive  cyclic AMP  dependent  protein 
kinase  grow  and  divide normally.  Second,  it 1s more  and more  apparent  that 
different  types  of cells respond differently to  the  same  intracellular 
signal.  Cyclic  AMP  may  be  an  inhibitor  of  fibroblasts  growth,  but it - 193  -
enhances  the proliferation of  follicular  thyroid cells  (Section IV). 
Although  there may  be  a  final  common  mechanism or  trigg~ of  cell multipli-
cation in various  types  of cells,  this mechanism may  be modulated differently 
by  intracellular signals or by  general metabolism depending  on  the 
cell  type  (423). 
Within this  framework,  it would  be  of  great  interest to  define  the 
alterations of  the various control mechanisms  and  actions of  extracellular 
and  intracellular signals at  the various  stages of  thyroid  tumour  induction. 
According  to Pastan's hypothesis,  cyclic AJW  concentration or action should 
be  depressed  in thyroid  tumours.  No  data are available on  human  or animal 
radiation induced  thyroid  tumours.  Some  information may  however  be  obtained 
from  other radiation induced  tumours  or non  radiation induced  thyroid  tumours. 
X irradiation induced rat small  bowel  adenocarcinoma  contains  significantly 
reduced  intracellular quantities of  cyclic AMP  compared  to  normal  intestinal 
tissue.  This  decrease has  been related to ~vated cyclic nucleotide phospho-
diesterases activities  (424).  Radiation induced  thyroid  tumours  in animals 
are  similar  to  other experimentally  induced  tumours  (  V,  III,B  )  and  there 
is no  apparent  difference between  spontaneous  and  radiation induced  thyroid 
tumours  in man  (Section!!).  Evidence  on animal  experimental  tumours  and 
human  spontaneous  cancers will  therefore be  examined.  Cyclic  AMP  levels 
are higher  in incubated human  carcinomatous  tissue than  in the adjacent 
normal  thyroid  tissue.  Similarly,  basal adenylate cyclase activity is 
higher  in the  carcinomatous  tissue  (425).  Orgiazzi et al.  have  shown  that 
the latter conclusion only applies  to differentiated carcinomas  (426). 
Stimulation of  adenylate  cyclase by  TSH  is on  the  average  normal  in differen-
tiated but abolished  in anaplastic carcinomas  (425-427).  However,  this 
apparent  similarity reflects  the existence of  some  higly responsive  and many 
poorly responsive  carcinomas.  In slices,  the  enhancement  of  cyclic AJW - 194-
accumulation by  TSH  is much  reduced.  Generally  similar results have  been 
obtained  in rat experimentally  induced  tumours  (379,428).  In  such  tumours, 
the decreased  response  to  TSH  is  accompanied  by  a  reduction of  TSH  binding 
to  plasma membranes  (428).  Thus,  the general  pattern seems  clear in the 
differentiated  thyroid  tumours.  Cyclic AMP  levels  and  adenylate  cyclase 
activity are high while  the response  of  the  tumour  to TSH  is decreased 
. by  an alteration at  the  level of  the  TSH  receptor.  Such  a  conclusion is 
in keeping with findings  in other  types  of epithelial  tumours  (422).  It 
clearly suggests  that  in thyroid  tumours  cyclic AMP  is no  more  the negative 
signal of  transformation and  the positive signal  of differentiation than it 
is the negative  signal  of  growth  in normal  thyroid cells. 
Nothing  is known  about  a  final  common  pathway  for  induction of  growth 
and  dedifferentiation.  Tantalizing clues  about  such a  mechanism exist and 
suggest  a  role of ornithine decarboxylase  and  the polyamines  synthesized 
by  this pathway.  TSH  through  a  cyclic ~W dependent mechanism greatly 
enhances  ornithine decarboxylase  synthesis  and  accumulation  (Section IV). 
Ornithine decarboxylase  synthesis precedes  growth  in all vertebrate tissues. 
The  role for  this  enzyme  in tumour  promotion has  been discussed  above. 
Human  thyroid adenocarcinomas  contain much  higher  levels of  polyamines 
(mostly putrescine)than the normal  tissue  (419).  It is obviously  impossible 
at this  stage  to  propose mechanisms, but  on  the basis of  this  evidence 
further  investigations  are certainly warranted. 
Work  realized under  contract "230-76-1  BIO  B"  of  the  Radiobiology 
Program of  Euratom. - 195  -
CONCLUSION 
The  relation between  irradiation and  thyroid disease,  particularly 
cancer is well  demonstrated  in humans  (Section II)  as  well  as  in experimental 
animals  (Section V).  With  the  use  of  human  epidemiological  and  clinical 
data  (Section II),  of  animal  experiments,  and  of  the  huge  information provided 
by  studies  on experimental  carcinogenesis  in other  systems  (Section V)  a 
fairly clear picture of  the pathogenesis of  this  cancer  can now  be  proposed. 
The  implications with regard  to  prevention and  treatment  are generally 
accepted  (Section II).  However,  as  has  been  shown  all  through this book, 
many  questions  remain  open  and  as  conclusion we  should  like to point out 
the most  obvious. 
From  the clinical and  epidemiological  point of view,  the most  vexing 
question remains,  in the  thyroid  as  in other organs,  the dose  effect rela-
tionship particularly in  the  range of clinical interest.  In  the  thyroid 
this problem has  a  number  of  unusual  aspects,  in that  the  doses  received 
accidentally and  in diagnostic medical work,  have  frequently been  large,  i.e. 
in the  range of  several  rads  to  several hundred  rads,  compared with  those 
received by  other organs.  Notwithstanding  these  large doses it has still 
been difficult  to define  dose  effect relationships because  the  dosimetry  in 
most  cases has  not  been exact  and  the  dose  rates  involved have  generally 
been  low.  In defining dose-effect relationships  the possible existence of 
tresholds  is  always  of  interest as  is the  level at which  they  occur.  While 
no  treshold is known  to  exist for  carcinogenesis  the  investigation of  the 
low  dose  region must  remain  important.  On  the other hand,  at much  higher 
doses  where  hypothyroidism is  induced,  the existence of  a  treshold is possible 
on  theoretical  grounds.  If such  a  treshold exists it would  be  of  interest to 
characterize it with respect  to  dose  and  the  dependence,  if any,  of  the  dose 
on  the  age  and  clinical standing of  subjects. - 196-
Fruitful epidemiological  studies  could perhaps  be  performed  on  the  numerous 
131  patients who  in the early days  of  I  use  received diagnostic doses  of  up 
to  200 pCi,  although  the  exact  rad  dose  to  the  thyroid of  such subjects 
would  be difficult to  determine  retrospectively.  An  advantage  of  studying 
such  a  population is the fact  that their clinical and  biochemical  status 
would  probably be very well  defined.  Patients who  were  hypothyroid at the 
time of  investigation,  i.e.  whose  thyroid was  under  intense  stimulation, 
would  presumably have  been particularly sensitive to  carcinogenesis,  if 
131  their glands  have not  subsequently been ablated by  large doses  of  I. 
Epidemiological  investigations might  also be profitably be  unde~taken on 
populations  of areas with high natural radioactivity  such as  Kerala  in 
India,  Gabon,  Shaba,  etc.  Within this context it would  be valuable  to  check 
if the human  thyroid  concentrates  radium as has  been  suggested  for  cattle 
(429).  In these  studies  and  in contemporary accidental exposures it is 
worth  attempting  to obtain more  exact dosimetric  information.  This  should 
be facilitated  in many  cases by  the  thermoluminescent  technique which 
should  render it more  practical to determine  the  cumulated activity in many 
circumstances. 
An  index allowing prediction of  the likelihood that an  individual 
patient will develop  nodules  or cancer when  due  account  has  been  taken of 
the clinical,  biochemical  and  dose  considerations  involved,  would  clearly 
be  useful  in the clinical cace  of  irradiated patients.  In this regard 
the  systematic use  of  serum  thyroglobulin measurements  in the  follow up  of 
irradiated subjects  could yield valuable results.  Obviously,  the  dose  level 
at which it is appropriate  to  '!?egin  to  follow up  patients needs  consideration, 
since it is not practical to  follow up,  for  example,  every patient receiving 
99  m  h  ·d  1  h  h  ·  b  h  ·1  · d  ·  ·  1  ·  h  a  Tc  t  yro1  scan,  a  t  oug  1t may  e  wort  w1  e  cons1  er1ng  1nc  ud1ng  t  ose 
who  receive more  than,  for  example,  100JUCi  of  131I.  Likewise  in the case - 197-
of occupational  exposure it is obviously not  necessary or desirable  to  follow 
up  every minor  incident.  Ilowever,  the  ICRP  Maximum  Permissable Doses  are set 
so  high  that  to  use  them as  guidelines  to acceptable  levels of  exposure 
would  be misleading  and  would  probably misinterpret  the  significance 
that  ICRP  attaches  to  the dose  limits.  In view of  the data in Section V 
even  those  receiving  a  fraction of  the maximum  permissible dose  annually 
should be  followed  up.  In this context it is worth noting  that  the  level 
of  non fatal harm consequent  on  thyroid  irradiation is high and  in this 
respect it may  be  unusual. 
Apart  from  the fact  that  they  should be  protected from  any 
irradiation, medical  or otherwise,  patients with genetic defects either 
in DNA  repair  (Fanconi's  anemia,  Xeroderma  pigmentosum,  Ataxia 
telengiectasia)  or in o2  metabolism  (acatalasemia,  glucose  6  phosphate 
dehydrogenase  deficiency,  chronic  granulomatous  disease,  etc  ••• ) 
could  provide cells or tissue  samples  of great interest for  radiobiolo-
gical  studies.  The  possibility of  identifying heterozygotes  (430) 
could also  allow epidemiological  studies. 
With  regard  to  the biochemistry of  human  thyroid cancers,  spontaneous 
Gr  radiation induced,  we  have  seen that little is definitely known  but - 198-
much  could be  learned by available methodology.  Their monoclonal 
character,  their  synthesis of  and  sensitivity to  other hormones  than 
thyroxin and  thyrotropin,  including prostaglandins,  the possibility 
to  redifferentiate  the~ by  pharmacological  agents  as  well  as  their 
intracellular control mechanisms  (cyclic nucleotides)  should be 
assessed. 
The  carcinogenetic process  itself would  be much  better understood 
if more  was  known  about  the cellular physiology  and  the radiobiology 
of  the  thyroid cell itself.  It is striking that we  know  so little of 
oxygen metabolism in the follicular cell  and  how  the  enzymes  involved 
in this metabolism may  influence its sensitivity to radiation.  Th~re 
are  indications  that  the  thyroid cell may  be more  radioresistant  than 
other  tissues  (Section V),  and  this could  be  studied now,  in vitro, 
using  new  systems  of growing  thyroid cells cultures,  with relatively 
exact dosimetry  and  uncomplicated biological  end  points.  In 
vivo  studies  in similar areas  could also  now  be undertaken with more 
confidence  in vue  of  the more  reliable dosimetric methods 
available.  The  comparison of effects of  UV  vs  X-ray  irradiation of 
the  cultured cells could  have  a  very general  impact  on  the understanding 
of  the  above  problems. - 199-
Finally, an insight in two  very  fundamental  problems  could have  very 
direct clinical implications.  First,we do  not  know  with certainty if human 
differentiated thyroid follicular cells have  a  finite life span, i.e., 
can only susnina limited number  of divisions,  or even,if after maturity, 
they  normally divide all.  The  answer  to  this question would 
bear directly on  the  problem of carcinogenesis  and  on  the  use  of 
radioiodine  therapy.  Second,  we  know  little of  the  control  of cell 
growth  and  differentiation in thyroid,both at  the  intercellular level 
(interaction between follicular,  endothelial  cells and  fibroblasts), 
and  at the  intracellular level  (role of  cyclic nucleotides,  of  polyamines, 
of  prostaglandins,  of  iodine,  etc.)  although  such knowledge  could 
provide  the  tools  to modify  tumor  promotion at several  stages  and  thus 
to  treat our patients. 
Thus,  as  stated at the  beginning of  this  section,in the field of 
irradiation and  thyroid  cancer,  although  the general  picture is beginning 
to  appear,  much  of  the precise knowledge  which allows  to  predict,  to 
prevent  and  to  treat,is still lacking.  We  cannot yet provide many 
answers  but  we  can now  begin  to  ask very  good  questions. -200-
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